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Abstract
An important aspect of cancer research is the development of better prognostic
tools for clinicians. These tools aim at predicting the survival time outcome of
patients. Such tools are crucial as they assist clinicians in the choice of the best
treatment strategy for each patient. An accurate prognostic model could help to
save patients from unnecessary treatments. This thesis is centred around the
development of prognostic models in their three key aspects. These three aspects
are the selection of relevant markers, the learning of the prognosis model itself
and its validation. We proposed the Coxlogit model for feature selection from
survival and classification data. Classification and survival prediction are two
common tasks in cancer research. With the Coxlogit model, we propose to model
together these two tasks to improve the prediction and the feature selection. The
Coxlogit model can be seen as a regularized mixture of a Cox and logistic models.
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Abstract
An important aspect of cancer research is the development of better
prognostic tools for clinicians. These tools aim at predicting the sur-
vival time outcome of patients. Such tools are crucial as they assist
clinicians in the choice of the best treatment strategy for each patient.
An accurate prognostic model could help to save patients from unnec-
essary treatments.
This thesis is centred around the development of prognostic models in
their three key aspects. These three aspects are the selection of relevant
markers, the learning of the prognosis model itself and its validation.
We proposed the Coxlogit model for feature selection from survival
and classiﬁcation data. Classiﬁcation and survival prediction are two
common tasks in cancer research. With the Coxlogit model, we propose
to model together these two tasks to improve the prediction and the fea-
ture selection. The Coxlogit model can be seen as a regularized mixture
of a Cox and logistic models.
The relevance of a prognostic model is typically assessed with a haz-
ard ratio between the predicted risk groups. We identiﬁed some limita-
tions of the hazard ratio in this particular context. More precisely, it
appears to be very sensitive to the choice of discretization of the risk
scores and has extreme values with unbalanced risk groups. We inves-
tigate the eﬀect of the discretization in risk groups for the hazard ratio
and other related metrics. A new metric, the balanced hazard ratio, is
also proposed to solve those issues.
The biomedical part of this thesis investigates the use of hypoxia
related gene signatures as potential prognostic markers. In controlled
experiments, cell lines were submitted to normoxia, hypoxia and cycling
hypoxia and then used to deduce molecular signatures. Promising prog-
nosis results were found on real breast cancer data. Moreover, these
hypoxia related gene signatures turn out to be an added value to the
standard clinical prognostic models.
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Chapter 1
Introduction
Cancer is a major cause of death in the world. In Europe only, the num-
ber of new cases was estimated to more than 3 millions for 2012 [46]. The
most common ones are the female breast, the colorectal, prostate and
lung cancer. An important aspect of cancer research is the development
of better prognostic tools for clinicians [63, 106, 127, 64]. These tools
aim at predicting the survival time outcome of patients [3], computing
their risk to develop metastasis after surgery. Such tools are crucial as
they assist clinicians in the choice of the best treatment strategy for
each patient. For instance, one might decide according to the estimated
risk whether a patient needs an adjuvant chemotherapy, a radiother-
apy or both. An accurate prognostic model could help to save patients
from unnecessary treatments. Treatments that have both high costs and
adverse side eﬀects.
The traditional prognostic models are based on clinicopathological
criteria including, for example, the tumor size, histological grade, nodal
status, age, etc. Usually, a small number of them are combined together
to form a prognostic model. This combination in a model outputs a
score representing the risk of each patient, the risk score. The higher
is the risk score, the greater are the chances of relapse. An example of
traditional prognostic models is the Nottingham prognostic index (NPI)
for breast cancer [54]. The NPI model computes the risk as a linear
combination of the tumor size, the histological grade and nodal status.
In the last 20 years, new technologies were developed, like the mi-
croarray and next-generation sequencing (NGS). In one experiment, they
are able to measure the expression levels of thousands of genes. The ex-
pression level measure the transcription rate of a gene, which can be
seen as its activity. Those technologies oﬀer us a ’view’ of the tumor at
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a molecular level. This view gives precious information about the cancer
biology and could help to improve the traditional prognostic tools. This
improvement comes through the identiﬁcation of new prognostic mark-
ers based on gene expression. Not limited any more to the small set of
clinically measured variables, new prognostic models bring the hope of
better and personalized treatment strategies.
This thesis is centred around the development of prognostic models
in its three key aspects. These three aspects are the selection of relevant
markers, the learning of the prognosis model itself and its validation.
They all falls within the general framework of survival analysis. Survival
analysis is thus introduce here and is followed by a brief description of the
thesis contributions. These contributions concern both methodological
aspects and biomedical ﬁndings. As a machine learning thesis more
emphasis shall be put on the methodological part.
1.1 Survival analysis
Survival analysis is the class of statistical methods used to study the
occurrence and timing of event. It is used in many domains like en-
gineering, sociology, economics, etc. Some examples are the study of
the time to industrial component failure, criminal recidivism, divorce
or school graduation. In cancer research, survival analysis studies the
time from the diagnosis or treatment to the occurrence of some event.
This event of interest, also called the end-point, can be for instance the
relapse, the death, or the appearance of distant metastasis.
A speciﬁc feature of such data is the censoring. A patient is censored
if the particular event of interest has not been observed for him/her.
Hopefully in cancer with good prognosis, most patients do not have
metastasis and do not die before the end of the follow-up. Those patients
are thus censored. The only available information for those patients is
a lower bound of their survival time. Other reasons can explain such
a censoring. Some patients move away or do not want to be in the
study anymore. They could also die from other unrelated causes known
as competing risks. This speciﬁcity of survival data makes the use of
standard regression techniques inappropriate. Inappropriate in the sense
that they can not make a proper use of censored patients.
There are two central functions used to describe survival data: the
survivor function and the hazard function. These functions are so im-
portant that their standard estimation methods are the two most cited
statistical papers of all time [140]. The survivor function models the
probability of a patient to survive longer than some time t. This function
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is the standard way to represent the survival of patients, the well-known
survival curves. The hazard function, on the other hand, is used to ex-
press and model the risk of patients. The hazard function computes the
risk of a patient to experience the event at some time t knowing that he
has not experienced the event so far.
The Cox proportional hazard model is the most common way to
model hazard functions. It allows us to compute the relationship be-
tween variables and the survival of patients through their hazard. The
success of this method comes from the possibility to model the relative
risk of patients without actually estimating full hazard functions. In
practice, the Cox proportional hazard model is the method of choice
for both the learning and the validation of prognostic models. The Cox
model is thus central in the context of this thesis and will be covered in
detail, in chapters 2 and 3.
1.2 Contributions
The methodological and biomedical contributions, summarized here, are
described in detail respectively in Part II and Part III of this thesis.
Often, the methodological contributions were triggered by problems and
needs of real biomedical applications, especially in cancer research. They
will be mostly presented in this context. However, those contributions
aim at a broader applicability even outside the biomedical domains.
1. Coxlogit model: feature selection from survival and clas-
siﬁcation data. A common task in cancer research consists in
showing and understanding the links between some patient condi-
tions and their survival. One way is to ﬁnd biomarkers that are
predictive of both the patient condition and survival. The feature
selection for the prediction of classes/conditions or survival are
two common tasks in cancer research. However, they are gener-
ally tackled independently. The Coxlogit model is an embedded
feature selection to select markers jointly predictive for both tasks
seen as a multi-objective optimization. The Coxlogit model can
be seen as a regularized mixture of a Cox and logistic models. The
approach is detailed in the Chapter 6.
2. Random non-linear projections for survival analysis. The
Cox proportional hazard model cannot account directly for non-
linearity eﬀects in patient variables. Several approaches relying on
the use of kernels or neural networks have been proposed to tackle
this issue. We proposed to use the cox model with non-linear
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random projections as used in extreme learning. The simplicity
and eﬃciency of this approach spares the additional complexity of
deﬁning an appropriate non-linear kernel or of training complex
neural networks. Moreover the results of the model are still inter-
pretable in terms of hazard. The random non-linear projections
for survival analysis are presented in Chapter 7.
3. Balanced hazard ratio for risk group evaluation from sur-
vival data. The classiﬁcation of patients in risk groups is needed
since clinicians are routinely required to decide whether a speciﬁc
treatment should be considered for a given patient. Such decision
is precisely based on the assignment of this patient to a particu-
lar risk group. Besides, the deﬁnition of risk groups also comes
from the stratiﬁcation of patients according to discrete categories
(e.g. smoker/non-smoker, gender, . . . ). The relevance of such risk
groups is typically assessed by their diﬀerence in survival com-
puted with a hazard ratio. We identiﬁed some limitations of the
hazard ratio in this particular context. More precisely, it appears
to be very sensitive to the choice of discretization of the risk scores
and has extreme values with unbalanced risk groups. The hazard
ratio can also be inconsistent with other metrics like the logrank
test. In Chapter 8, we investigate the eﬀect of the discretization in
risk groups for the hazard ratio and other related metrics. A new
metric, the balanced hazard ratio, is also proposed to solve those
issues.
4. Hypoxia signatures for cancer prognosis. Hypoxia, the lack
of oxygen, is a common characteristic of tumors. The tumor re-
sponses to this lack of O2 are well known: tumor angiogenesis and
glycolytic metabolism. These two mechanisms induce a local and
temporal O2 ﬂuctuation, known as cycling hypoxia. The extent of
cycling hypoxia reﬂects the tumor plasticity and capacity to sur-
vive and proliferate. Cycling hypoxia can thus be an important
prognostic biomarker of cancer progression. However, technolo-
gies to measure these ﬂuctuations are not easily available on real
tissues for clinicians.
Part III of this thesis investigates the use of hypoxia related gene
signatures as potential prognostic markers. In controlled experi-
ments, cell lines were submitted to normoxia, hypoxia and cycling
hypoxia and then used to deduce molecular signatures. Promising
prognosis results were found on real breast cancer data. Moreover,
these hypoxia related gene signatures turn out to be an added value
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to the standard clinical prognostic models.
Those contributions are the object of some publications and patent:
• Branders, S. and Dupont, P. (2015). A balanced hazard ratio for
risk group evaluation from survival data. Statistics in Medicine,
34(17)
• Branders, S., Fre´nay, B., and Dupont, P. (2015b). Survival Analy-
sis with Cox Regression and Random Non-linear Projections. Pro-
ceedings of the 23th European Symposium on Artiﬁcial Neural Net-
works , pages 119–124
• Branders, S., D’Ambrosio, R., and Dupont, P. (2014). The Coxlogit
model: Feature selection from survival and classiﬁcation data. In
2014 IEEE Symposium on Computational Intelligence in Multi-
Criteria Decision-Making (MCDM), pages 137–143
• Branders, S., D’Ambrosio, R., and Dupont, P. (2015a). A mixture
Cox-Logistic model for feature selection from survival and classi-
ﬁcation data. arXiv:1502.01493 [stat.ML] , pages 1–6
• Boidot, R., Branders, S., Helleputte, T., Rubio, L. I., Dupont, P.,
and Feron, O. (2014). A generic cycling hypoxia-derived prognostic
gene signature: application to breast cancer proﬁling. Oncotarget ,
5(16)
• Grandjean, M., Sermeus, A., Branders, S., Defresne, F., Dieu, M.,
Dupont, P., Raes, M., De Ridder, M., and Feron, O. (2013). Hy-
poxia Integration in the Serological Proteome Analysis Unmasks
Tumor Antigens and Fosters the Identiﬁcation of Anti-Phospho-
eEF2 Antibodies as Potential Cancer Biomarkers. PloS one, 8(10),
e76508
• Seront, E., Rottey, S., Sautois, B., Kerger, J., D’Hondt, L. a.,
Verschaeve, V., Canon, J.-L., Dopchie, C., Vandenbulcke, J. M.,
Whenham, N., Goeminne, J. C., Clausse, M., Verhoeven, D., Glo-
rieux, P., Branders, S., Dupont, P., Schoonjans, J., Feron, O., and
Machiels, J.-P. (2012). Phase II study of everolimus in patients
with locally advanced or metastatic transitional cell carcinoma
of the urothelial tract: clinical activity, molecular response, and
biomarkers. Annals of oncology : oﬃcial journal of the European
Society for Medical Oncology / ESMO , 23(10), 2663—-2670
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• Feron, O., Boidot, R., Branders, S., Dupont, P., and Helleputte,
T. (2015). Signature of cycling hypoxia and use thereof for the
prognosis of cancer. WO Patent App. PCT/EP2014/066,643
Part I
Background

Chapter 2
Survival Analysis
Survival analysis is the class of statistical methods used to study the
occurrence and timing of events. It is used in many domains like engi-
neering, sociology, economics and medicine. In cancer research, survival
analysis studies the time from the diagnosis or treatment to the occur-
rence of some event [28]. This event of interest, also called the end-point,
is usually relapse, cancer related death, or appearance of distant metas-
tasis. For the sake of simplicity, the term survival is used here even with
non-lethal end-points.
Survival analysis is used to answer many questions: What is the
survival probability of patients at 10 years? What are the diﬀerences in
survival between patients treated with diﬀerent medications? What are
the risk factors explaining early recurrences?
The medical context of this thesis allows us to make some assump-
tions on the survival data encountered. Those assumptions are very
common and ﬁt in the classical survival analysis framework. They nat-
urally guide the choices of the statistical methods that are used and
presented here.
Many possible kinds of events exist, but an event is always assumed
to be a switch from one state to another at a precise location in time.
Even if it can be relevant in some other situations, we assume here that
an event can only appears once for each patient/sample.
In some study, multiple end-points are recorded such as death from
cancer and death from heart attack. Such mutually exclusive events are
known as competing risks. Speciﬁc survival techniques are designed to
deal with such data. However, competing risks are rarely recorded in
practice. We decide not to consider them in this chapter.
One may ask why there is a need for speciﬁc survival methods? The
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time of event is a continuous variable and could thus be studied by
classical regression techniques. The speciﬁcity of the survival data comes
from the censoring. A patient is censored if the particular event of
interest has not been observed for him/her. There are diﬀerent kinds
of censoring and many reasons to explain it. This chapter starts with
more detailed explanations on censored data, in section 2.1.
The survival time of patients can be regarded as a random variable.
A random variable which is commonly described using its probability
density, survivor and hazard functions. Section 2.2 presents those key
functions/distributions on which are based the diﬀerent survival meth-
ods and models. Two of them, the Kaplan-Meier method and Cox
proportional hazard model, are introduced respectively in section 2.3
and 2.4. More advanced survival regression techniques are detailed in
the chapter 3.
2.1 Censored data
In survival data, there are many patients with no observed event. There
are many possible reasons for such a situation. The patient may not
experience the event before the end of the study. He could also die from
another unrelated cause or simply have moved away. Those patients lost
to follow-up are called censored patients.
Three kinds of censoring can be distinguished. The previous exam-
ples correspond to right censored patients. The only available informa-
tion for those patients is a lower bound of their survival time.
Sometimes, a patient could experience the event before the ﬁrst ex-
amination after the treatment/diagnosis. In such a case, the only avail-
able information is an upper bound on the survival time. Those patients
are called left censored patients. This censoring is not very common and
is not considered here.
The third kind is the interval censoring. It happens when the patient
experiences the event between two examinations. This is often the case
for non-lethal end-points like recurrence or appearance of distant metas-
tasis. When the time between two examinations is suﬃciently small, it
may not require a speciﬁc processing. The time of the event is simply
set at the end of the interval.
An important assumption on the censoring is made by most survival
methods. It is assumed to be random and noninformative. As an ex-
ample, let’s consider a patient with a poor prognosis who needs some
aggressive medications. This patient dies from a heart attack induced
by their side eﬀects and is censored. In this example, the censoring is in-
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formative and non-random. The poor prognosis patient are more likely
to be censored. Such situation should be avoided as much as possible.
These considerations are important. In retrospective data, however,
they are diﬃcult to control for the statistician. Like most survival meth-
ods, this thesis is focused on the standard survival analysis framework
with non-informative right censored data.
2.2 Probabilistic view
The survival time t of a patient can be viewed as a realisation of a random
variable T . The random variable T has an underlying probability density
function f(t) and cumulative distribution function F (t).
f(t) = lim
Δt→0
P (t ≤ T < t+Δt)
Δt
(2.1)
F (t) = P (T ≤ t) =
� t
0
f(u) du (2.2)
F (t) is the probability to have the event before time t. In survival
analysis, it is often more convenient to work with S(t) the survivor
function. The survivor or survival function S(t) is the probability of a
patient to have a survival time greater than some value t. In cancer
studies with distant metastasis as end-point, S(t) is the probability of a
patient to live free of metastasis until time t.
S(t) = P (T ≥ t) = 1− F (t) (2.3)
2.2.1 Hazard function
Another very often used function is the hazard function h(t). The hazard
function is used to represent the risk or hazard of having the event at
time t. The hazard function h(t) is deﬁned as:
h(t) = lim
Δt→0
P (t ≤ T < t+Δt|T ≥ t)
Δt
(2.4)
It computes the probability density of a patient to experience the
event between t and t+Δt, conditioned to his survival until time t. The
hazard function is expressed in number of events per time unit and is
not a probability. The hazard function can be expressed in terms of the
probability density function and the survivor function:
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h(t) =
f(t)
S(t)
(2.5)
From the previous equations (2.5), (2.3) and (2.2), we can derive
that
h(t) = − d
dt
logS(t) (2.6)
The probability density function f(t) and the survival function S(t)
can also be expressed in terms of h(t)
S(t) = exp
�
−
� t
0
h(u) du
�
(2.7)
f(t) = h(t) exp
�
−
� t
0
h(u) du
�
(2.8)
With equation (2.8), the probability density function f(t) can be
computed from h(t). In the special case where the hazard function is a
constant h(t) = 1/λ, f(t) follows an exponential distribution.
f(t) =
1
λ
exp
�
− t
λ
�
(2.9)
where λ ∈ [0,∞] is also known as the scale parameter of the exponential
distribution. λ is also the mean of the distribution and thus the aver-
age survival time. The exponential distribution is a special case of the
Weibull distribution which is often used as a simple model for survival
data. The Weibull distribution is deﬁned by two parameters: the scale
λ and the shape k.
f(t) =
k
λ
�
t
λ
�k−1
exp
�
−( t
λ
)k
�
(2.10)
The corresponding hazard function is computed as:
h(t) =
k
λ
�
t
λ
�k−1
(2.11)
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The shape parameter k is used to deﬁne increasing or decreasing
hazard function, resp. with k > 1 and 0 < k < 1. When k equals 1
the Weibull distribution is an exponential distribution with a constant
hazard function. This simple model is often used to generate survival
data. The censoring is generated independently by another distribution,
typically another Weibull.
2.3 Kaplan-Meier survival curve
A Kaplan-Meier survival curve is the representation of the Kaplan-Meier
estimate of a survival function [77]. The Kaplan-Meier estimate is a
nonparametric maximum likelihood estimator and the most widely used
estimator of the survival function.
To understand how the estimation is made, let us consider a partic-
ular time point tj where at least a patient experienced the event. The
probability to survive through this time point tj can be estimated from
the number of patients at risk just before tj and the number of patients
who die at tj , respectively nj and dj . A patient is at risk if he has not yet
experienced the event and is not yet censored. The patient probability
of surviving until tj+Δt, knowing that he survived until tj , is estimated
by
Pˆ (T > tj +Δt|T ≥ tj) = (nj − dj)
nj
(2.12)
Assuming all events to be independent, the survival function S(tj +
Δt) or the probability to survive until tj +Δt can be expressed as
S(tj +Δt) = P (T > tj +Δt|T ≥ tj)P (T ≥ tj) (2.13)
Sˆ(tj +Δt) =
(nj − dj)
nj
S(tj) (2.14)
As a nonparametric estimator, no assumption is made on the un-
derlying event distribution and hazard. The estimated probability to
survive through a time interval without any observed event is then 1.
Sˆ(t) is thus constant between any pair (tj , tj+1) of consecutive time
points with occurring events.
Sˆ(tj+1) = Sˆ(tj +Δt) (2.15)
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From equations (2.14) and (2.15) , we can derive a general formu-
lation for Sˆ(t) which includes all time points with an event prior to
t.
Sˆ(t) =
�
j|tj≤t
�
(nj − dj)
nj
�
(2.16)
From t = 0 to the ﬁrst event, Sˆ(t) equals 1. As censored patients
are at risk until their censoring, they are included in all nj prior to their
censoring and thus contribute to the estimation. If there is no censoring,
(nj − dj) will be equal to nj+1 for two consecutive time points tj and
tj+1. The estimate of the survival function S(t) becomes simply the
number of patients alive at t divided by the total number of patients.
A Kaplan-Meier survival curve is represented as a step function.
Each step corresponds to the occurrence of at least an event. Tradition-
ally, the censoring is marked with a small cross on the curve. Figure 2.1
is an example of Kaplan-Meier survival curve.
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Figure 2.1: An example of Kaplan-Meier survival curve
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2.4 Cox proportional hazards model
The Cox model is a regression model mainly used to estimate and pre-
dict the relative risk/hazard of patients. We consider each patient
i ∈ {1, . . . , n} as being characterized by a 3-tuple (ti, δi,xi), where ti
is the time of an event whenever δi equals 1 and the censoring time
whenever δi equals 0. The vector xi includes p covariates for the pa-
tient i. The covariates are variables that are possibly predictive of the
survival, e.g. age, clinical factors, gene expression values, . . .
The main idea behind the Cox model [30] is to express the hazard
hi(t) of a patient i as the product of a baseline hazard h0(t) and a
positive function of the covariates xi:
hi(t) = h0(t) exp(β
�xi) (2.17)
The baseline hazard is shared among all patients. ri = β
�xi repre-
sents the patient relative risk, his risk score. The higher the risk score,
the higher is the hazard hi(t) and the chances of experiencing an early
event.
Modelling the hazard in this way makes the hazards hi(t) and hj(t)
of any pair of samples (i, j) proportional. Their ratio hi(t)/hj(t) is
constant over time and do not depend on h0(t).
hi(t)
hj(t)
=
exp(β�xi)
exp(β�xj)
(2.18)
The name of the model derives from this assumption of proportion-
ality of the hazards. Its strength comes from the possibility to estimate
the parameters β independently and without any further assumptions
on h0(t). The Cox proportional hazards model is thus often referred to
as a semi-parametric model. In practice, the relative risk of patients
ri = β
�xi is more interesting than the actual hazard function hi(t).
These risks can help clinicians to identify patients with poor prognosis
who may need more attention or a particular treatment.
2.4.1 Partial likelihood
Along with the proportional hazard model, Cox proposed a way to ﬁt
the parameters β which is known as the partial likelihood maximiza-
tion [30]. Except from the proportionality assumption, the method does
not require the selection of a particular survival time distribution.
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Let us now consider a particular time ti where the patient i experi-
enced the event. Conditioned on R(ti), the set of patients at risk at ti,
the probability that the event occurs for patient i as observed is given
by
P (ti|R(ti)) = hi(ti)�
k∈R(ti) hk(ti)
(2.19)
Pβ(ti|R(ti)) = h0(ti) exp(β
�xi)�
k∈R(ti) h0(ti) exp(β
�xk)
(2.20)
Pβ(ti|R(ti)) = exp(β
�xi)�
k∈R(ti) exp(β
�xk)
(2.21)
where R(ti) = {k|tk ≥ ti} is the set of patients still at risk right before
time ti (still without event nor censoring). The likelihood Li(β) of the
parameters for this event is given by Pβ(ti|R(ti)) and does not depend
on the baseline hazard h0(t). The method relies only on the ranking
of the survival times to compute R(ti) and is thus insensitive to any
monotonic transformation of the time values. Assuming independence
between events, the likelihood of β over all events is given by
L(β) =
�
i|δi=1
exp(β�xi)�
k∈R(ti) exp(β
�xk)
(2.22)
L(β) =
n�
i=1
�
exp(β�xi)�
k∈R(ti) exp(β
�xk)
�δi
(2.23)
It is worth noting that this likelihood is only exact when there is no
ties in the event times. In such a case the conditional probabilities (2.19)
of tied events should not be considered independently. However when
there is not too many tied events, this simpliﬁcation is a good approx-
imation known as the Breslow approximation [21], which is used by
default in many survival software.
This likelihood (2.23) is known as the partial likelihood. Partial
in opposition to a full likelihood which takes into account the baseline
hazard function not considered here. The maximization of this partial
likelihood gives estimates of the parameters β. Cox shows that these
maximum partial likelihood estimates are consistent and asymptotically
normal [31]. With an increasing number of patients, the estimates con-
verge and are asymptotically unbiased. In many realistic situations,
these estimators are also asymptotically fully eﬃcient [40]. This means
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that with a suﬃcient number of patients, the variances of the estimates
will not be much larger than if we were using the full likelihood. Stan-
dard MLE inference methods can thus be used on the maximum partial
likelihood estimators of the Cox model [31].
In chapter 3, more details are given on the methods used to maximize
the partial likelihood. In particular when the number p of covariates is
much larger than the number of patients n. In such a case, additional
constraints are needed on the β to obtain good estimates.

Chapter 3
Modelisation and Prediction
An important aspect of cancer research is the development of better
prognostic tools/models for clinicians. This chapter presents one of the
key aspects of such tools: how they can be used to model and predict
the possible outcomes of a disease.
The model predictions are based on a vector xi with the p covariates
of the patient i ∈ {1, . . . , n}. In this thesis, those p variables are mostly
gene expression data from microarrays. For simplicity, we assume that
each variable xj represents the level of expression of a diﬀerent gene
j ∈ {1, . . . , p}. The number of genes is usually many times larger than
the number of patients, p� n.
In cancer, the classical outcome of interest is the survival: the time
to relapse, distant metastasis or death. As presented in section 2.2, the
survival probabilities can be described through the hazard function. The
objective of prognostic models is then to model and predict the hazard
of patients, or at least their relative hazards/risks.
This relative risk can be continuous or discrete. The variable ri
represents a continuous risk, called the risk score, of a patient i. A
patient with a higher risk score is more likely to have an early event
than a patient with a lower risk score.
When the relative risk is discrete, it deﬁnes groups of patients with
a similar outcome. These groups are called risk groups. In this thesis,
we mainly use two risk groups deﬁning the high and low risk patients.
The predicted risk group gi is either 1 or −1, respectively for the high
and low risk groups.
This discretization in two (sometimes more) risk groups is a common
practice in the medical literature. The risk groups are justiﬁed by the
need of clinicians to make decisions i.e. whether or not a speciﬁc (and
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sometimes aggressive) treatment should be given to a patient. Such de-
cision is precisely based on the assignment of this patient to a particular
risk group.
However, this discretization should only be applied to risk scores
and not to continuous predictor variables. The variable dichotomization
may indeed introduce problems such as loss of information, reduction
in power, uncertainty in deﬁning the cutpoint [110]. In this thesis, we
only descretize risk scores at the very end of the model-building process.
Moreover, the prognostic model and the discretization cut-oﬀ are always
assessed on external validation data to avoid any optimistic bias.
In this thesis, we use two kinds of risk prediction methods using
either survival or classiﬁcation models. Their main diﬀerence is the
nature of their supervisions, that is the external information available
on the survival of patients or its true risk group. Unlike the covariates,
this information is used to learn a model but is not available for the
predictions on new patients.
The supervision used with survival models is the survival data, (ti, δi)
for each patient i. ti is the time of an event whenever δi equals 1 and the
censoring time whenever δi equals 0. With survival models, we assume
that the true risk scores and risk groups of patients are unknown.
On the contrary, classiﬁcation models are used precisely when the
true risk groups are known. Here, the supervision is not some survival
data but a variable yi coding for the true risk group of a patient i. The
deﬁnition of these group labels yi is external and represents the decisions
(or predictions) of clinicians. We diﬀerentiate gi and yi, predicted and
true group labels, to make explicit when true labels are available at
training time.
In this thesis, we mainly focus on (generalized) linear prognostic
models for their relative simplicity and interpretability. This chapter
starts with a general description of linear models, section 3.1, and moti-
vates this speciﬁc choice of prognosis models. A particular focus is made
on their use with high dimensional data such as microarrays. Section 3.2
presents two classiﬁcation models namely the logistic regression and sup-
port vector machines. Section 3.3 revisits the Cox model presented in
section 2.4 and shows its links with the logistic model. An extension of
the Cox model using support vector machine is also presented.
3.1 Linear models
Linear models assume that the variable of interest Y can be described
as a function f of a linear combination of the input variables (or covari-
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ates) x.
Y = f(β�x) (3.1)
The linear combination of the variables, r = β�x, is named here the
score of the model. The function f is used to link the score and the
prediction. This function can be non-linear but it is ﬁxed, not trained.
The weights of the linear combination β are the model parameters. The
challenge with linear prognostic models is to ﬁnd the best parameters
to have good prediction performances on new data.
The key advantage of linear models is their relative simplicity. What-
ever method is used to ﬁt the parameters β, the model can be summa-
rized as a weighted sum of the patients variables x. The advantages of
this simplicity are two folds.
First, the linear relation between the model parameters and the vari-
ables is easy to interpret. The absolute value of the parameter βj ,
β = [ . . . βj . . . ]
�, can be interpreted as the importance of the variable
xj in the prognostic model. With the models presented in this chap-
ter, the sign of a parameter further shows if a variable is positively or
negatively correlated with the prognosis. Those parameters can thus be
interpreted by clinicians and give them some insights on important risk
factors. These risk factors can in turn be used to better understand the
biological processes involved in the recurrence or metastatisation. The
simplicity and interpretability make the linear models understandable
by clinicians. It is particularly important, if we want them to trust and
use prognostic models.
The second advantage comes from the data used in this thesis: mi-
croarrays. The microarrays are used here to measure the expression lev-
els of thousands of genes which are used as potential prognostic markers.
Due to their price, these microarrays data are not available in quantity.
The number of genes is usually many times larger than the number of
patients, p � n. In such a setting, ﬁnding a good set of model pa-
rameters β becomes very diﬃcult. This problem is known as the curse
of dimensionality. Allowing more complex models with non-linear rela-
tionships in the variables will increase even more the diﬃculties. These
complex model are then very often outperformed by simpler linear ones.
3.1.1 Fitting the parameters
Fitting the parameters of the model can be viewed as an optimization
problem. The solution of this optimization problem is a set of parameters
βˆ minimizing a particular function of the parameters.
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βˆ = argmin
β
L(β) + λR(β) (3.2)
where L is known as the loss of the model andR is a regularization term.
λ is a meta-parameter controlling the relative importance between loss
and regularization. This pattern loss + regularization is very common
with linear model for high dimensional data such as microarrays. In
particular, the pattern ﬁts with all models presented here.
Loss function
The loss function L(β) deﬁnes the ﬁt of the model to the observed data.
The better the ﬁt, the lower the loss. The loss measures in particular
how far are the observations (survival times, group labels, etc) from
the model predictions. This “distance” between observations and pre-
dictions changes with the assumptions of each model, leading to many
diﬀerent losses. In this chapter, the models are thus presented and com-
pared through their loss functions.
Regularization
When the number of patients n is smaller than the number of variables
p, there are many solutions βˆ minimizing the loss function. In such a
setting with p � n, the problem is then how to choose a good one.
Following the Occam’s razor principle, among these apparently equal
solutions the simplest one is the better.
If the loss function L(β) deﬁnes how a model ﬁts the data, the regu-
larization R(β) computes how complex the model is. Adding a regular-
ization R(β) in the optimization problem (3.2) is thus a way to penalize
complex models and favour the simplest ones.
The two most common regularization are known as the L1 and L2
regularizations. The L2 regularization, or ridge penalty [65], is the
square of the Euclidean (L2) norm of β. The L1 regularization, or
lasso [132], is the Manhattan (L1) norm.
L2 =
1
2
p�
j=1
β2j =
1
2
�β�22 (3.3)
L1 =
p�
j=1
|βj | = �β�1 (3.4)
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In a probabilistic setting, the regularization can be viewed as a prior
(an assumption) on the distribution of the parameters [53]. Minimizing
the pattern loss + regularization will then ﬁnd the parameters β that
maximize the likelihood of both the observations and the parameters.
The L1 and L2 regularizations respectively correspond to a Laplace and
a Gaussian prior. The meta-parameter λ can be interpreted as a way to
deﬁne the variance of the parameters distribution. The higher is λ, the
lower is the variance of the prior distribution.
The L1 norm is a sparsity inducing norm. This regularization is
particularly eﬃcient when there are only few relevant variables [132].
However, it can sometimes lead to overly sparse models. In particu-
lar, the L2 regularization outperforms the lasso when there is a high
correlation between the variables.
Zou and Hastie [147] introduce the elastic-net penalty to combine
the strength of these two regularizations. The elastic-net penalty is a
combination of the L1 and L2 penalty.
Le = α�β�1 + (1− α)1
2
�β�22 (3.5)
=
α p�
j=1
|βj |+ (1− α)1
2
p�
j=1
β2j
 (3.6)
where α ∈ [0−1] is a meta-parameter of the regularization. The elastic-
net regularization is reduced to the lasso (respectively to ridge penalty)
whenever α = 1 (respectively α = 0).
The lasso and elastic-net regularizations can be seen as some form
of soft-thresholding of the parameters Zou and Hastie [147], Tibshirani
[132]. Using these regularizations will then shrink many parameters
to 0. These penalties are thus a way to select relevant variables and to
improve the interpretability of prognostic models. This property of some
regularizations is discussed in the chapter 5 with other feature/variable
selection techniques.
3.2 Classiﬁcation models
Classiﬁcation models are used to model and predict risk groups. In
this section, we assume that the true risk groups are known at training
time and can be used when estimating the model. The deﬁnition of
these group labels yi is external and represents the decision process of
clinicians. This decision can be based on the observed survival times,
risk factors or cancer subtypes.
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As an example, the low risk patients yi = −1 can be deﬁned as
the patients without events or that live longer than a particular time
threshold. In both cases, we have problems with early censoring. Those
early censored patients cannot be safely assumed as neither at high nor
at low risk. Another problem is how to choose a good time threshold.
In practice, this approach is not very common to learn a classiﬁcation
model such as a logistic regression or a SVM. A survival model using
the full survival data is preferred in this thesis when risk groups are not
directly available.
The classiﬁcation models are more useful when risk groups are truly
observed, for example with cancer subtypes or risk factors. We then have
a real classiﬁcation problem where the groups have diﬀerences in their
survival. An example of such classiﬁcation problem is the prediction
of the histologic grade of the tumor which is highly correlated with
the survival. A good classiﬁcation model can improve the histological
grading (or replace it) and help survival prediction.
We present in sections 3.2.1 and 3.2.2 logistic regression and sup-
port vector machines. They are two very common classiﬁcation models
and have a strong connection with the two survival models presented in
section 3.3. The classiﬁcation schemes for multi-class problems are not
covered here, but extensions exist along the same lines [12].
3.2.1 Logistic regression
The logistic model is a binary classiﬁcation model. It assumes the risk
group of a patient i to be computed as the sign of an unknown risk score,
r∗i . This unknown risk score r
∗
i can be written as a linear combination
of the patients covariates xi in addition to a random error term �.
yi = sign(r
∗
i ) (3.7)
= sign(β�xi + �) (3.8)
where � is distributed according to a standard logistic distribution. The
high risk patients are the patients with a positive risk score r∗i = β
�xi+�.
The probability of a patient i to be in the high risk group (the positive
class) is given by
P (Yi = 1|xi) = P (r∗i > 0) (3.9)
= P (β�xi + � > 0) (3.10)
= P (−� < β�xi) (3.11)
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The logistic distribution is symmetric. The −� can be replaced by
�. This probability can be computed from the cumulative distribution
function of a logistic random variable.
P (Yi = 1|xi) = P (� < β�xi) (3.12)
=
1
1 + exp(−β�xi) (3.13)
The probability of patient i to be in the negative class can be com-
puted from the previous equation.
P (Yi = −1|xi) = 1− P (Yi = 1|xi) (3.14)
= 1− 1
1 + exp(−β�xi) (3.15)
=
exp(−β�xi)
1 + exp(−β�xi) (3.16)
=
1
1 + exp(β�xi)
(3.17)
The probability of a patient i to be in his observed class/group can
be computed as follow:
P (Yi = yi|xi) = 1
1 + exp(−yiβ�xi) (3.18)
The likelihood of the parameters β is computed as the product of
the probability of the observed labels in the training set.
L(β) =
n�
i=1
1
1 + exp(−yiβ�xi) (3.19)
The optimal model parameters are learned by maximizing this like-
lihood. Equivalently, we can minimize minus its logarithm, the loss
function of the logistic model.
L(β) =
n�
i=1
log(1 + exp(−yiβ�xi)) (3.20)
In the logistic model, the score ri = β
�xi can be used to compute
and to predict risk group probabilities. Assigning new patients to their
most likely risk group gives us the following decision function:
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gi = sign(β
�xi) (3.21)
In high-dimension, the logistic model needs some regularization: L1,
L2 or elastic-net. Eﬃcient algorithms exist to solve the optimization
problem of the regularized logistic model. They often relies on an iter-
atively reweighted least squares methods such as the method proposed
by Friedman et al. [52].
3.2.2 Support vector machines
Support vector machines, or SVM, are binary classiﬁcation models. Sim-
ilarly to the logistic model, the decision function of an SVM is deﬁned
as:
gi = sign(β
�xi) (3.22)
but the estimation procedure for the β diﬀers. The parameters β can
be viewed as the deﬁnition of a hyperplane. A hyperplane is the gen-
eralization of a 3D plane for an arbitrary number of dimensions. Here,
we have a plane in a p-dimensional space deﬁned by the p covariate of
the patients. The hyperplane is deﬁned as the set of points for which
β�x = 0. The decision function of both an SVM and a logistic regres-
sion can be interpreted as looking on which side of the hyperplane are
the samples/patients.
The deﬁnition of an SVM comes from the question: what is a good
hyperplane to classify new unseen samples? One reasonable solution is
to choose the hyperplane achieving the largest separation between the
two classes/groups. In other words, the hyperplane that maximize the
distance with the closest points of both sides. This distance is called the
margin. These closest points are deﬁned as the samples xi such that
|β�xi| = 1 (3.23)
The size of the margin can be computed as 1/�β�2. Finding the best
hyperplane becomes a minimization problem:
argmin
β
1
2
�β�22 (3.24)
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under the constraints that every sample is outside the margin and on
the correct side of the hyperplane. These constraints are written:
yiβ
�xi ≥ 1 ∀i ∈ 1, . . . , n (3.25)
With nonlinearly separable data, the margin constraints are too
strong. A soft-margin version of SVMs was introduced by Cortes and
Vapnik [29] to solve this issue. The problem becomes the minimization
of both �β�22 and the violation of the margin constraints.
argmin
β
1
2
�β�22 + C
n�
i=1
�
1− yiβ�xi
�
+
(3.26)
where the function [x]+ is deﬁned as
[x]+ =
�
x if x > 0
0 if x ≤ 0 (3.27)
A sample contribute in the SVM minimization only if he violates the
constraint, that is when yiβ
�xi ≤ 1. Those contributing samples are
called the support vectors. Usually, the number of support vectors is
small. The SVM is thus robust to small changes of the data set that
keep the support vectors untouched.
Deﬁning C as 1/(2λ), this formulation of the soft-margin SVM per-
fectly ﬁt in the loss + regularization pattern. The SVM loss is known
as the hinge loss and is close to the logistic loss, as shown in ﬁgure 3.1.
The SVM is thus very similar to a L2 regularized logistic regression but
does not oﬀer a probabilistic interpretation of its output. Rosset et al.
[107] even prove that under some conditions the logistic regression and
SVM converge to the same solution.
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Figure 3.1: Comparison between hinge and logistic losses
3.3 Survival models
The objective of linear survival models presented in this section is to
model and predict the survival of patients through their risk scores.
ri = β
�xi (3.28)
Unlike the classiﬁcation models, survival models do not have as-
sumption or information on the risk groups. The model parameters β
are learned using only the survival data (ti, δi). The risk score of the
survival model cannot be directly used to compute the risk group. An
additional cutoﬀ θ should be provided to deﬁne the decision function:
gi = sign(β
�xi − θ) (3.29)
gi =
�
1 if ri > θ
−1 if ri ≤ θ (3.30)
There are many possible choices for the parameter θ. It can be
deﬁned to ﬁt the expected proportion of risk groups or to maximize
some criteria on the quality of those groups. Such criteria are presented
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in the chapter 4. The eﬀect of the speciﬁc choice of parameter θ on the
risk groups is discussed in chapter 8.
The most common survival model is the Cox proportional hazards
model presented in section 2.4. Section 3.3.1 presents how it can be
used with high dimensional data and its links to the logistic model.
Section presents an extension of the Cox model using SVMs, which have
the advantage of being sparse in the number of observations used.
In this thesis, we focus mainly on linear models but other kinds of
survival models exist such as the random survival forests [71], the partial
logistic artiﬁcial neural networks [11], etc.
3.3.1 Cox regression
As presented in details in section 2.4, the Cox model [30] assumes that
the hazard hi(t) of a patient i is the product of a baseline hazard h0(t)
and a positive function of the covariates xi:
hi(t) = h0(t) exp(β
�xi) (3.31)
The estimation of the parameters β can be done by maximizing a
partial likelihood.
L(β) =
n�
i=1
�
exp(β�xi)�
k∈R(ti) exp(β
�xk)
�δi
(3.32)
where R(ti) = {k|tk ≥ ti} is the set of patients still at risk right before
time ti (still without event nor censoring). To ﬁt in the loss + regular-
ization pattern, the likelihood can be turned into a loss function deﬁned
as minus its logarithm.
L(β) =
n�
i=1
δi
−β�xi + log �
k∈R(ti)
exp(β�xk)
 (3.33)
An additional regularization term can be added to the minimization
process to avoid overﬁtting. Like the logistic regression, the cox model is
a generalized linear model. The same eﬃcient algorithms can be used to
solve both the Cox and Logistic regularized minimization problems [52,
117].
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Cox model and logistic regression
Section 2.4 presents the classical interpretation of the Cox model leading
to the partial likelihood. We present here an alternative interpretation
of the Cox model using the conditional logistic model [27, 28]. The links
between conditional logistic model and Cox model is not always well
known but is described in [24], which is the source of inspiration for this
section. This interpretation is used later in section 3.3.2 and chapter 6.
As a consequence of the proportional hazard assumption, no informa-
tion can be used from the time intervals between consecutive events [30].
The parameters β of the cox model are thus learned by looking at all
time points with events. Each time point is characterized by a set of
observed events among patients at risk, which can thus be viewed as
a binary classiﬁcation problem. The positive class contains the events.
The negative class contains the patients censored or surviving further.
The conditional logistic model allows us to compute the probabilities of
these particular classes:
P (Yi = 1|xi) = exp(β
�xi)
1 + exp(β�xi)
(3.34)
P (Yi = −1|xi) = 1
1 + exp(β�xi)
(3.35)
Those probabilities can be used at a particular time point ti where
patient i experienced the event. The conditional probability of this event
knowing that exactly one event occurs and the set of patients at risk is
given by:
P (ti|R(ti),xi) =
P (Yi = 1|xi)
�
j∈R(ti)\{i} P (Yj = −1|xj)�
k∈R(ti) P (Yk = 1|xk)
�
j∈R(ti)\{k} P (Yj = −1|xj)
(3.36)
The numerator in equation (3.36) is decomposed as the probability
of patient i having the event P (Yi = 1|xi) and all the others patients,
among those still at risk at time ti (i.e. in R(ti)), not experiencing this
event (P (Yj = −1|xj)). As a conditional probability, the denominator is
the normalization factor representing the probability of having exactly
one event, not speciﬁcally for patient i, among the set R(ti) of patients
at risk at time ti. This expression is thus similar to the numerator but
with a summation and a running index k over the set of patients still at
risk.
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Such a conditional logistic regression is also used in matched case-
control studies [27] where speciﬁc patients of interest are distinguished
from control patients in a classiﬁcation context. Here, in a survival
context, we consider in equation (3.36) a single patient of interest (the
one experiencing the event at time ti) and all other patients as control
cases. In other words, equation 3.36 can be considered analogous to
a 1:M matched case-control study with one case and M controls (see
equation (B.6) of appendix B.2 from [27]).
Combining equation (3.36) with the class probabilities (3.34) and (3.35)
leads to:
P (ti|R(ti),xi) =
exp(β�xi)
1+exp(β�xi)
�
j∈R(ti)\{i}
1
1+exp(β�xj)�
k∈R(ti)
exp(β�xk)
1+exp(β�xk)
�
j∈R(ti)\{k}
1
1+exp(β�xj)
(3.37)
=
exp (β�xi)�
k∈R(ti) exp (β
�xk)
(3.38)
Equation (3.38) is exactly the partial likelihood of the event as de-
ﬁned previously. It is worth noticing that the solution is invariant by
translation, as opposed to a logistic regression solution. If we replace
β�xi by β�xi−θ, the likelihood is unchanged as any additional θ will be
cancelled out in equation (3.38). Without a θ, the risk scores ri = β
�xi
may not be well centered and cannot be interpreted in class probabilities
through equations (3.34) and (3.35).
The Cox model can thus be seen as a set of classiﬁcation models,
one for each time with at least an event, sharing the same parameters
β but with diﬀerent decision functions.
3.3.2 Survival-SVM
Survival-SVMs form a natural extension of Cox models proposed in Van
Belle et al. [136], Evers and Messow [44]. Survival-SVMs are based
on the interpretation of a Cox model as a set of classiﬁcation models.
The conditional logistic models are replaced here by SVMs sharing the
same parameters β. Using SVMs has the advantage of producing sparse
models in the observation space.
Survival-SVM minimizes �β�22 under a set of constraints deﬁning the
margin, similarly to the standard SVM. For each classiﬁcation problem,
the margin is deﬁned as the space between the patients experiencing the
event and the patients who survive further. Those constraints can be
written in terms of diﬀerences between pairs of patients.
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β�xi − β�xk > 1 (3.39)
β�(xi − xk) > 1 (3.40)
for all pairs i, k such that i experienced the event at time ti and k
survived at ti. A soft-margin version of a survival-SVM is obtained by
relaxing those constraints. The minimization problem becomes:
argmin
β
�
i|δi=1
�
k∈R(t+i )
�
1− β�(xi − xk)
�
+
+
λ
2
�β�22 (3.41)
where R(t+i ) = {k|tk > ti} is the set of patients surviving longer than
patient i. The loss of a survival-SVM is a convex approximation to the
concordance index [62] presented in chapter 4. The concordance index
is a popular metric to assess the performance of a survival model. The
concordance index computes the probability of patients to experience
the event before patients with a lower risk.
Unlike with a Cox model, a survival-SVM risk score cannot be inter-
preted in terms of hazard and is given by:
ri = β
�xi (3.42)
By using the same parameters β for all time points, a survival-SVM
makes implicitly the proportional hazards assumption. Without this
assumption, the relative risks of patients could change over time which
is not the case here. All risk scores ri are constant over time.
Evers and Messow [44] make an interesting comparison between the
unregularized loss functions of a survival-SVM and a Cox model. They
consider a particular situation with three patients: patient 1 experienced
the event, patients 2 and 3 are censored later. With the risk scores
ri = β
�xi, ∀i ∈ {1, 2, 3}, the loss of a survival-SVM becomes:
[1− (r1 − r2)]+ + [1− (r1 − r3)]+ (3.43)
Similarly to a survival-SVM, the loss of a Cox model can be expressed
in terms of diﬀerences between the risk score of patients. From equation
(3.33), the loss of a Cox model becomes:
log(1 + exp(−(r1 − r2)) + exp(−(r1 − r3))) (3.44)
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Figure 3.2: Losses of a Cox and a Survival-SVM in an example with
three patients.
Both losses tend to 0 when r1−r2 and r1−r3 are going to +∞. When
r1−r2 is suﬃciently large, the losses are the logistic and SVM losses with
respect to r1 − r3. Figure 3.2 illustrate the two losses while changing
the diﬀerences between the three risk scores. The similarities between a
survival-SVM and a regularized Cox model explain their similar results
as reported in [136, 44, 138, 137].

Chapter 4
Performance Assessment
This chapter deﬁnes diﬀerent metrics used to assess the performances of
the prognostic models presented in chapter 3. The performance metrics
are divided in two categories: the metrics to assess the classiﬁcation
performances (section 4.1) and those to assess the survival prediction
(section 4.2). These metrics describe how well the model predictions
ﬁt the observed true risk groups or times of events, respectively for the
classiﬁcation and survival prediction.
The prediction tasks in this thesis are mostly binary: high versus
low risk groups. The metrics are thus presented in this context. Most
of them are however easily extended to multi-group settings.
4.1 Classiﬁcation performances
The classiﬁcation models assume the risk groups are known at train-
ing time. The risk groups represent the decision of clinicians, deﬁning
patients either at high or low risk. In this section, we present metrics
to assess how good are the model predictions with respect to clinician
decisions.
The classiﬁcation results can be summarized in a confusion matrix,
such as table 4.1 for a binary classiﬁcation problem. A confusion matrix
contains a row and a column for each possible risk group. Each column,
resp. row, represents a true, resp. predicted, class/group label. A table
cell contains the number of patients with a particular combination of
true and predicted risk groups.
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Risk groups True
High Low
Predicted
High TP FP
Low FN TN
Table 4.1: Confusion matrix
4.1.1 Accuracy
The accuracy is the proportion of patients predicted with the correct
label. Classiﬁcation accuracy is one of the most commonly used metrics
to summarize the confusion matrix presented in table 4.1:
Accuracy =
TP + TN
TP + TN + FP + FN
(4.1)
In a multi-classes setting, the accuracy can be generalized as the sum
of the diagonal of the confusion matrix divided by the total number of
samples. A major problem of this metric appears with unbalanced data
set. An unbalanced data set is a data set where the samples are not dis-
tributed equally in all classes. One or several classes are overrepresented.
In this context, the importance of a class in the accuracy is proportional
to its size. If 90% of the samples are in one class, the prediction per-
formance in this class account for 90% of the global accuracy. A naive
classiﬁer giving to every samples the label of this majority class will
have 90% of accuracy. This problem is addressed by the BCR deﬁned
in section 4.1.3.
4.1.2 Sensitivity and speciﬁcity
In some cases, the cost of a classiﬁcation error is not equal for each class.
Failing to identify a high risk patient can have very bad consequences, as
he may need some particular treatments. The opposite, wrong labelling
of a low risk patient may be discovered with further tests. In the medi-
cal domain, the model accuracies in each class are thus often reported.
For a binary classiﬁcation problem, they are called the sensitivity and
speciﬁcity.
Sensitivity, or true positive rate, is the proportion of patients at high
risk correctly identiﬁed as such. It answers the question: are we able to
ﬁnd the high risk patients?
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SE =
TP
TP + FN
(4.2)
Speciﬁcity, or true negative rate, is the proportion of samples in the
negative class (low risk) identiﬁed as such.
SP =
TN
TN + FP
(4.3)
A classiﬁcation model generally oﬀers a particular trade-oﬀ between
those two aspects. The sensitivity can generally be increased at the cost
of a poor speciﬁcity. They are thus not informative alone and should be
reported together.
4.1.3 Balanced classiﬁcation rate
The balanced classiﬁcation rate (BCR) is the arithmetic average of the
accuracy per class label. With two classes, it is the mean between sen-
sitivity and speciﬁcity.
BCR =
1
2
�
TP
TP + FN
+
TN
TN + FP
�
(4.4)
When the classes are of the same size, the BCR is equivalent to
the Accuracy (4.1.1). The BCR overcomes the problem of unbalanced
data accuracy. A naive classiﬁer which gives the same label to every
samples always has a BCR of 50% regardless of the class sizes. Unlike
the accuracy, the expected BCR of a random classiﬁer is always 50% for
any true and predicted class priors.
4.1.4 Area under the ROC curves
The area under the ROC curves diﬀers from the previous classiﬁcation
metrics. It assess the performance of the score (the continuous output)
of a classiﬁer without considering its decision threshold.
The ROC curve depicts the trade-oﬀs between sensitivity and speci-
ﬁcity while changing the decision threshold. The ROC curve is plotted in
the 2-dimensional ROC space deﬁned by the sensitivity and 1-speciﬁcity.
Each possible decision threshold deﬁnes a particular classiﬁcation with a
speciﬁcity and sensitivity and is a point of the ROC curve. An example
of ROC curve is presented in ﬁgure 4.1.
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Figure 4.1: An example of ROC curve
The ROC space is a unit square as the sensitivity and the speciﬁcity
are deﬁned over [0 − 1]. The top-left corner equals to a speciﬁcity and
sensitivity of 1 and thus a BCR of 1. At the opposite, the bottom-
right corner corresponds to a classiﬁer with a BCR of 0. The diagonal
between the two last corners is an isoline corresponding to a BCR of
0.5. All parallels to this diagonal are also isolines of BCR. A good ROC
curves should thus be as far as possible from the diagonal.
The AUC, Area Under the ROC Curve, is used to summarize the
ROC curve in a single number. The AUC can be viewed as a probability.
For a random pair of samples from each class, the AUC is the probability
of the continuous output (risk score) of the classiﬁer to have a higher
value for the sample of the positive class (at high risk). An AUC of 1
means that the classiﬁer achieves a perfect ranking of the patients. 0.5
is the AUC expected from a random model.
4.2 Survival prediction performances
The metrics, presented in this section, compute how well the survival
model predictions ﬁt the observed times of events. As presented in
chapter 3, survival models predictions are of two kinds: risk score ri
(continuous) or risk group gi (discrete). With the survival model used
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in this thesis, the risk score is deﬁned as a linear combination of the
patient variables:
ri = β
�xi (4.5)
The predicted risk groups are deﬁned from the risk scores as:
gi =
�
1 if ri > θ
−1 if ri ≤ θ (4.6)
The risk group gi of a patient i is 1 for the high risk group and −1
for the low risk group. The discretization in two (sometimes more) risk
groups is a common practice in the medical literature. The groups are
used to make decisions on the treatments given to a patient. A proper
assessment of the risk groups is then particularly important. The per-
formance metrics for survival are presented here in this context of binary
risk group prediction. However, most of them can be easily extend to
assess risk scores or multiple risk groups.
4.2.1 Hazard ratio
The group hazard ratio (HR) evaluates the diﬀerence between survival
curves computed by a Cox proportional hazards model (see section 2.4).
It represents the increase in the risk of event between the low and high
risk groups. When used to evaluate risk groups, the hazard ratio is
computed with a Cox model using the binary group variable gi as single
covariate. Usually, the two risk groups are deﬁned with 0 and 1. To
have the same hazard ratio deﬁnition using −1 and 1, we divide gi by
two in the Cox model. The hazard function hi(t) for a patient i is then
written as:
hi(t) = h0(t) exp
�
βgi
2
�
(4.7)
Since gi equals −1 or 1 for the patients in respectively the low risk
or high risk group, the hazard of each risk group is given by:
hHigh(t) = h0(t) exp (β/2) (4.8)
hLow(t) = h0(t) exp (−β/2) (4.9)
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The hazard ratio HR is the ratio between the hazard of the two risk
groups.
HR =
hHigh(t)
hLow(t)
(4.10)
=
h0(t) exp (β/2)
h0(t) exp (−β/2) = exp (β) (4.11)
With the proportional hazard assumptions [30], h0(t) vanishes in
the estimation of the hazard ratio. The HR, exp (β), is then constant
over time and represents the increased risk of being at high risk with
respect to the low risk patients. The higher the hazard ratio, the higher
the diﬀerence between the two hazard functions and thus between the
survival curves.
The hazard ratio is computed as the solution of ﬁtting a Cox model
with only one covariate gi and one parameter β. The log-hazard ratio
β maximizes the partial likelihood and has most of the good properties
of maximum likelihood estimator (see section 2.4.1). With only one
variable to compute the hazard ratio, the parameter of the Cox model
is written β and not β. In this thesis, we will use β when a hazard ratio
is computed and β for multivariate prognostic models.
The hazard ratio can also be computed for more groups or a contin-
uous risk score. In the continuous case, gi is replaced by the risk score
ri in the equations.
4.2.2 Concordance index
The concordance index (C-index) measures to which extent the risk
groups are concordant with the time to event, that is whether the pa-
tients in the high risk group actually experience the event before the
patients in the low risk group [62].
The C-index speciﬁcally relies on the notion of comparable pairs. A
pair of patients {i, k} is comparable if patient i experiences the event
while the patient k is still at risk (not censored and not having experi-
enced the event) at time ti. Such comparable pair is concordant if the
patient i, experiencing the event earlier, belongs to the high risk group
and patient k in the low risk group, gi > gk. The C-index lies between 0
and 1 as it estimates the probability for a comparable pair of patients to
be concordant. This estimate is the number of concordant comparable
pairs divided by the number of comparable pairs:
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C-Index =
�
i,k∈ΩConc(gi, gk)
|Ω| (4.12)
with
Conc(gi, gk) =
�
1 if gi > gk
0.5 if gi = gk
(4.13)
Ω = {(i, k)|δi = 1, ti < tk} (4.14)
Ω is the set with all comparable pairs of patients. For the pairs of
patients in the same groups, 12 rather than 1 is added to the count of
concordant pairs. The C-index can be directly used in the continuous
case by replacing the groups gi by ri the risk score. Furthermore, it is
not limited to survival data as the notion of comparable pairs can be
extended to other response variables.
Links to classiﬁcation metrics
In a classiﬁcation setting, the set of comparable pairs is deﬁned as the
set of patient pairs (i, k) such that i and k are respectively in the high
and low true risk groups.
Ω = {(i, k)|yi = 1, yk = −1} (4.15)
With this deﬁnition, computing the C-index with the risk scores
of a classiﬁer gives the AUC (section 4.1.4) as they estimate the same
probability. Furthermore in this context, the C-index of the predicted
risk groups gi is the BCR presented in section 4.1.3. This last result can
be easily found from equation (4.12) and using the confusion matrix in
table 4.1.
4.2.3 Logrank test
The logrank is the statistics of a test to assess whether there is a signif-
icant survival diﬀerence between risk groups [88]. For each time point
ti where at least one patient has the event, the numbers of patients in
each group and having the event can be summarized in a table:
Risk Groups Number of Number surviving Number at risk
events at ti beyond ti just before ti
I (High) d1i n1i − d1i n1i
II (Low) d2i n2i − d2i n2i
Total di ni − di ni
Table 4.2: Number of events for the two groups
42 Chapter 4. Performance Assessment
Assuming the numbers of patients in each group (n1i and n2i) and
having the event di as ﬁxed, table 4.2 can be solely determined by d1i.
Under the null hypothesis that there is no survival diﬀerence across
groups, d1i follows an hypergeometric distribution. The expected value
of d1i under this null hypothesis, e1i, is the mean of this hypergeometric
distribution which can be computed as:
e1i =
din1i
ni
(4.16)
The logrank statistic measures diﬀerences during the follow-up in
number of events between what is observed d1i in a group and what is
expected under the null hypothesis e1i. It is computed over all time ti
with an observed event.
U =
�
i
(d1i − e1i) (4.17)
A high logrank implies that there is a higher than expected rate of
events in the high risk group and more evidence against the null hypoth-
esis. The logrank statistics is a sum of hypergeometric random variables
(one variable for each time step ti with an event) which approximately
follows a normal distribution, from which a p-value can be easily com-
puted.
4.2.4 SEP
The SEP metric compares the risk of each risk group with the risk of the
entire population. SEP is a weighted geometric mean of the absolute
relative risks between the risk groups and the global population [112].
SEP = exp
�
nHigh|βHigh|+ nLow|βLow|
n
�
(4.18)
nHigh and nLow are the number of patients in respectively the high
and low risk groups. βHigh and βLow are the log hazard ratios between
each group and the whole population. SEP is not designed to handle
continuous risk scores but can be easily extended to many risk groups.
SEP = exp
��
k
nk
n
|βk|
�
(4.19)
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where nk is the number of patients in the k
th risk group, and βk is the log
hazard ratio between the kth risk group and the whole population. The
SEP metric is designed to be interpretable in a similar way as the hazard
ratio. It computes the average multiplicative factor between the hazard
of a risk group and the global hazard of the population. To be clinically
useful, a risk group needs to be well separated but also to incorporate a
substantial part of the patients [112]. This particular point is assessed
while introducing an average weighted by the risk group sizes. If one
particular risk group contains nearly all patients, its hazard should be
close to the global hazard and the corresponding βk close to 0. The SEP
metrics will then be close to 1 which is the minimal value of the metric.
Royston and Sauerbrei [108] proposed an extension of the SEP metric
the D-index. The D-index behaves very similarly to a hazard ratio with
a small correction for unbalanced risk groups. Unlike SEP, it can be
used for the assessment of risk scores and risk groups.
4.2.5 Sensitivity and speciﬁcity
In some cases, it is useful to investigate the survival at a particular
time threshold. For instance, in the context of breast cancer progno-
sis, 5 years after treatment is commonly accepted as a critical value
from a clinical viewpoint. Deﬁning such a time threshold transforms the
survival prediction in a classiﬁcation problem. The goal is to predict
the patients who will experienced the event before this threshold or live
longer. The risk group predictions can be assessed with the classiﬁcation
metrics presented in section 4.1, in particular the Sensitivity, speciﬁcity
and BCR. These metrics are now deﬁned for a speciﬁc time t, the time
threshold at which the survival is computed.
The sensitivity/speciﬁcity is the proportion of high/low risk patients
identiﬁed as such by a model. In the survival context, the sensitivity
SE(t) at time t is the proportion of high risk patients, i.e. classiﬁed
in the high risk group, among those patients experiencing the event
before time t. The speciﬁcity SP (t) at time t is the proportion of low
risk patients among those patients still at risk just after time t. The
balanced classiﬁcation rate BCR(t) is the arithmetic average between
sensitivity and speciﬁcity.
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SE(t) =
�
i|ti≤t,δi=1 I(gi = 1)�
i|ti≤t,δi=1 1
(4.20)
SP (t) =
�
i|ti>t I(gi = −1)�
i|ti>t 1
(4.21)
BCR(t) =
SE(t) + SP (t)
2
(4.22)
BCR(t) values lies between 0 and 1. A perfect prognostic index
would have a BCR(t) of 1. Uniform random guessing between risk
groups has an expected BCR(t) of 0.5 while a lower BCR(t) would
correspond to an even worse prognosis (e.g. inverting risk groups). It
is worth noting that the patients censored before the time threshold
are not assigned to any class. They are ignored in the BCR and the
sensitivity.
4.2.6 Discussion
The general topic of model performance assessment is very broad
and extensively discussed in the statistics and machine learning liter-
ature. It covers many aspects including several deﬁnitions of model
performance scores or metrics, evaluation protocols (e.g. variants of
cross-validation or bootstrap resampling), dedicated statistical tests to
assess the signiﬁcance of observed diﬀerences, to name just a few. The
interested reader may consult, for example, a whole monograph on those
issues, and many related ones, especially in a classiﬁcation context [72].
For the sake of conciseness, our discussion in this section is much
more focused. We are describing various performance metrics that are
speciﬁc or adapted to survival data. Besides, while those metrics could
in general be computed on the same (= training) data used to estimate a
survival model, our interest is towards their use on independent valida-
tion data (either explicitly or through cross-validation or resampling).
In other words, we are focusing throughout this work on predictive
performances rather than goodness-of-ﬁt measures. This is moti-
vated, at least, by a pragmatic choice to report results, eventually to
clinicians, that would be representative of what should be expected for
new but similar patients1
Finally, we discuss here quality metrics that can be used to measure
to which extent patients are assigned to a correct risk group. This
1Technically, this is related to an i.i.d. assumption between training and validation
samples. This assumption is very common but could be questioned. Recent works on
transfer learning [99] precisely aim at relaxing this assumption.
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discretization corresponds to a decision support setting: “such decisions
are typically binary and require the deﬁnition of clinically relevant de-
cision thresholds” [128]. Considering a low versus a high risk group also
simpliﬁes the mathematical presentation of these notions. Yet, as men-
tioned below and in chapter 8, we also consider the cases with more than
two risk groups.
While the classiﬁcation metrics are mainly variations around the
confusion matrix (table 4.1), the survival metrics are much more diverse.
We cover here a non-exhaustive list of such metrics. The hazard ratio
and C-index can assess both continuous risk scores and discrete risk
groups. Others are designed solely for risk group assessment like the
logrank, SEP and BCR. Our central question is: what should we use to
assess the quality of the prediction into speciﬁc risk groups?
If we want to assess prediction into risk groups at a particular time
threshold, the metrics of choice are the time dependent balanced clas-
siﬁcation rate, sensitivity and speciﬁcity. But these metrics are limited
to a particular time threshold. They are unable to assess properly the
survival through the complete follow-up.
In general, it is better to use the hazard ratio, C-index, logrank, SEP
or D-index. To compare them, we use the set of desirable properties pro-
posed by Royston and Sauerbrei [108] to deﬁne what is a good survival
metric. Some of those properties are:
• Interpretability: The metric should have a simple and intuitive
meaning.
• Directness: If the risk group ordering changes, the metric should
change in the appropriate direction.
• Unbiasedness: The estimated metrics should also be an unbiased
estimate of the true value. In particular, the metric should be
close to a known value when the risk groups have on average no
relationship with the survival times.
The logrank and SEP do not have the directness property, they are
insensitive to the group ordering [28, 112]. For instance, in the special
case of a high versus a low risk group, the two metrics are unable to de-
tect when the groups are switched, for example by assigning all high risk
patients to the low risk group. Moreover, these metrics do not penalize
a situation where two out of k groups have exactly the same hazard.
They cannot detect if there are more groups than what is needed. The
logrank and SEP can only assess if there is a diﬀerence between the
survival of some risk groups.
46 Chapter 4. Performance Assessment
The C-index and hazard ratio have the directness property and are
thus useful to quantify the diﬀerence between group survival [59]. But,
this diﬀerence is useful and informative only if all groups incorporate a
substantial part of the patients [108]. As they do not take into account
the sizes of the groups, the C-index and hazard ratio can estimate the
survival diﬀerence but not the relevance of risk groups. They are some-
how biased as they do not tend to their minimal values when all patients
tend to be in one group. The D-index also has the directness property
and somehow takes into account the sizes of the groups. While being
better than the C-index and hazard ratio, the D-index does not tend to
its minimal value when all patients are in one group (see appendix C).
In chapter 8, we further investigate the diﬀerences between these
survival metrics: hazard ratio, C-index, logrank, SEP and time depen-
dent BCR. We also propose the balanced hazard ratio which have most
desired properties of a good survival metric.
To sum up, we present and discuss in this chapter several perfor-
mance metrics in the particular context of binary classiﬁcation and
survival risk group assessment. We limit our discussion essentially to
predictive performance metrics for a discrimination purpose. The
discrimination refers here to the capacity of a model to classify or to
rank the patients in the right way. However, calibration is another as-
pect of prediction accuracy, which can be assessed separately [128, 75].
In particular, calibration measures the agreement between predictions
and observed outcomes, e.g. if the estimated risk of a patient ﬁts the
observations and is neither overestimated nor underestimated. For ex-
ample, the Hosmer-Lemeshow goodness-of-ﬁt test [66] for the logistic
model compares the predicted probabilities of event for each decile with
the observed event rates. The calibration is particularly important for
patients who are more concerned with their actual chances of survival
rather than their relative risks. Another important aspect, which we do
not further detail in this manuscript, is the estimation of the real impact
of the predictive models on the patient care [104]. Indeed, the goal of
predictive models is often to help physicians and to improve the clinical
decision making. The impact of such decisions and whether they are
ultimately beneﬁcial or harmful to the patients should also be assessed.
Chapter 5
Feature Selection
A critical aspect of learning new prognostic models is the feature se-
lection. Feature selection refers to the set of methods used to select a
subset of relevant covariates/features, that can be used in a (prognostic)
model. The feature selection can improved prognostic models in three
key points: performance, interpretability and usability.
By selecting the relevant covariates, a good feature selection is ex-
pected to reduced the number of noisy ones. Eliminating these noisy
variables can improve the prediction performance on unseen data. Fea-
ture selection can also be viewed as a form of regularization. It favours
simpler models that are more likely to have better generalization per-
formances. This increase in performance is not always observed, espe-
cially with drastic feature selection. An example is microarray where
the number of features is sometimes divided by 1000, from 55000 to 50
genes/covariates. However, small losses in prediction performances are
mitigated by the others advantages of the selection.
A major advantage of feature selection is interpretability. In mi-
croarray, by selecting a small number of relevant features, we have good
chances to selected genes that are related to the disease under study.
They can give us a better understanding of the biological processes in-
volved. They can even be sometimes the target of new treatments.
By reducing the number of needed variables, we can also reduce the
cost of a new prognostic model. The expression levels of the selected
genes can be measured with some cheaper technologies than microarray.
Technologies that might not measure thousands of genes but can be used
to make small prognostic kits. Feature selection may make a prognostic
model usable in clinics.
Classically, the feature selection schemes are divided in three cat-
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egories [58]: ﬁlter, wrapper and embedded method. The ﬁlters are
sometimes viewed as a preprocessing step. The selection is made sepa-
rately of any prognostic model used later. They do not try to optimize
directly the performance of the predictive model.
With the wrappers, the features are selected to maximize the pre-
dictive performance of the model. They often rely on iterative methods
adding or removing features to search for the best ones. The models are
here used as a black box to measure the quality of a set of variables. To
avoid overﬁtting, the performances of these models should be estimated
in cross-validation [58, 78]. This selection scheme requires the learning
of a large number of models and is thus very time-consuming.
The feature selection in an embedded method is performed while
learning the model. There is no separation between the feature selection
and training. Many linear models can be turned in an embedded fea-
ture selection method by using some sparsity inducing regularization.
An example of such regularization is the LASSO [132, 133] or elastic
net [147].
In this thesis, we used ﬁlters and embedded methods. Filters are used
for their computational eﬃciency. They are also less prone to overﬁtting
and more stable [97, 58]. Stable in the sense that the selected features
do not change much under small perturbations of the data. Two uni-
variate ﬁlters are presented in the sections 5.1.1 and 5.1.2, respectively
for classiﬁcation and survival prediction.
The prognostic models used in this thesis are mainly linear ones such
as the Cox and the logistic regression (see chapter 3). Such linear models
are often regularized in high dimensions with an L1 penalty and can be
considered as embedded methods. The feature selection with L1 type
regularization is discussed in section 5.2.
In the context of gene expression data, such as microarray data, these
sets of features/genes are deﬁning gene signatures. They are called gene
signatures as their combined expression pattern should be characteris-
tic of a particular biological phenotype or medical condition. Section 5.3
presents some ways to assess the relevance of such gene signatures.
5.1 Univariate ﬁlters
Feature selection with ﬁlters is often associated with feature ranking.
This ranking of the features is often done by computing their association
with a response variable (group labels, survival times, etc).
We choose to present here two univariate ﬁlters (sections 5.1.1 and
5.1.2). They both rely on hypothesis testing to compute the association
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between each feature and the response. They oﬀer a ranking of the
features and p-values associated to the tests.
To perform feature selection, there are two common choices:
• If the number d of features required is known, select the d ﬁrst
features with the smallest p-values.
• Otherwise, select the features with a p-value smaller than some
threshold (often 0.05).
The second option requires the p-values to be corrected for the mul-
tiplicity of the test and e.g. to control the false discovery rate. In this
thesis, we use the FDR procedure proposed by Benjamini and Hochberg
[8].
5.1.1 T-test
The t-test is often used as a univariate ﬁlter for classiﬁcation problems.
For each feature, the t-test compare the mean values of the two risk
groups.
t =
|µHigh − µHigh|�
σ2High/nHigh + σ
2
Low/nLow
(5.1)
µHigh and µLow are the means of the feature in respectively the high
and low risk groups. Those means are compared to the group variances
and sizes, respectively: σ2High, σ
2
Low, nHigh and nLow. Under the null
hypothesis that there is no diﬀerence between the groups, the statistic
(5.1) follows a Student’s t distribution from which we can compute a
p-value.
5.1.2 Hazard ratio
Similarly as in section 4.2.1, an hazard ratio can be used to test the
association between each feature and the survival. We replace here the
risk scores and risk groups by a single covariate.
The hazard ratio of two patients i and k with respect to the feature
j can be written:
hi(t)
hk(t)
=
h0(t) exp (βxij)
h0(t) exp (βxkj)
(5.2)
=
exp (βxij)
exp (βxkj)
= exp (β(xij − xkj)) (5.3)
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The value exp (β) represents the hazard ratio between i and k, two
patients with a unit diﬀerence xij − xkj = 1 in feature j. As the gene
expression is often expressed in log2, exp (β) is then the multiplicative
increase of the hazard when the gene expression level is doubled. A p-
value can be computed to test if β is signiﬁcantly diﬀerent from 0 using
standard MLE inference (see section 2.4.1).
5.2 L1 regularized embedded methods
Embedded feature selection methods diﬀer from ﬁlter as the selection
is performed while learning the model and not as a preprocessing step.
The selected features are simply the feature that are used in model.
Other features may be used during the learning but are not part of the
ﬁnal predictive model.
The L1 regularization (or lasso) is a sparsity enforcing regulariza-
tion [132] which is very often used in combination with (generalized)
linear models such as the Cox or logistic regression. The lasso regular-
ization can be viewed as some form of soft-thresholding of the model
parameters. For instance, a L1 regularized Cox model will tend to have
its smallest parameters shrinked to zero. A parameter shrinked to zero
means that the corresponding feature is not used in the model. The L1
regularization can thus be used as multivariate feature selection.
The lasso regularization can however be too sparse, especially with
correlated features [132, 147]. The lasso will tend to select one and
discard all other correlated covariates. The elastic net regularization
was introduced by Zou and Hastie [147] to solve this issue. It combines
the lasso and the ridge (or L2) penalties.
Le = α�β�1 + (1− α)1
2
�β�22 (5.4)
=
α p�
j=1
|βj |+ (1− α)1
2
p�
j=1
β2j
 (5.5)
where α ∈ [0−1] is a meta-parameter of the elastic-net regularization. It
combines the advantage of both regularization. The elastic-net is sparse
and can be used as feature selection. It also encourages the grouping
eﬀect. Highly correlated features tend to be in or out of the model
together [147].
5.3. Gene signature validation 51
5.3 Gene signature validation
Assessing the relevance of gene signatures is most of the time an unsu-
pervised problem. Excepted with artiﬁcial experiments, the best set of
features is unknown. There are two common indirect ways to assess the
relevance of a gene signature.
The ﬁrst possibility is to assess its predictive performance, especially
when the selected features are used to build a prognostic model. The
validation of a gene signature will then depend on the choice of model
and performance metric (chapters 3 and 4). This assessment must be
done on independent data, not used for the feature selection, to avoid
any optimistic bias.
The obtained performances could be compared with other prognostic
models or gene signatures on the same data. In particular, the gene
signature could be compared to random gene signatures. This approach
was proposed by Venet et al. [142] and is described in section 5.3.1.
The second possibility comes from the idea that a good feature selec-
tion should select genes related to the disease under study. In particular,
the signature is expected to have links with other known signatures. For
instance, signatures of metabolic or signaling pathways that are related
to the predictive task. Rediscovering those links can be seen as a vali-
dation of the biological soundness of the signature.
Many tools are available to compare gene signatures [67]. Those
tools, known as singular enrichment analysis, commonly relies on an hy-
pergeometric or Fisher’s exact test. Section 5.3.2 presents the principles
of this enrichment analysis.
The feature selection can often be seen as the selection of a cutoﬀ
on a particular ranking of the features (see section 5.1). Subramanian
et al. [129] proposed to compare directly this ranking to other reference
gene signature to avoid any cutoﬀ eﬀect. This method known as gene
set enrichment analysis (GSEA) is presented in section 5.3.3.
A third possibility, out of the scope of this thesis, is a true biological
validation of the genes in a lab.
5.3.1 Predictive performance of random gene signatures
Venet et al. [142] show that most random gene signatures are signiﬁ-
cantly associated with breast cancer outcome. They report more than
90% of the signatures with > 100 genes tested as signiﬁcant.
Since there are many genes associated with cancer progression, even
random signatures can contain useful genes. As a practical example,
assuming that there are only 1000 probesets associated with cancer
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progression on a total of 22283 probesets in an Aﬀymetrix HGU133a
microarray, the probability of a random signature of 100 probesets to
contain at least one of them is 0.99.
To validate the interest of a signature, this signature should be sig-
niﬁcantly better at the predictive task than random signatures of the
same size. In particular the signature should be better than 95% of the
random signatures (using the statistical standard of p-values < 0.05).
This methodology was used to validated the prognostic performances
of the CycHyp and ContHyp signatures on breast cancer data (presented
in section 10). Using the same experimental protocol, we compare the
logrank p-values (see section 4.2.3) of the CycHyp and ContHyp signa-
tures with random signature of the same sizes (resp. 87 and 123 probe
sets). Figure 5.1 shows the distribution of the p-values (logrank test
in log 10) for 1000 randomly generated signatures together with the
p-values of the CycHyp and ContHyp signatures represented with the
two red dots. The discrimination between risk groups was here signiﬁ-
cantly higher (p-value < 0.001) with the CycHyp signature as compared
to each of the random signatures whereas the ContHyp signature was
not signiﬁcantly better (vs. random ones; p-value=0.141). The green
line in ﬁgure 5.1 represent the 0.05 threshold for the p-values. We can
observe that logrank p-values of most random gene signatures are below
this threshold and are thus signiﬁcant.
5.3.2 Singular enrichment analysis
The traditional strategy of singular enrichment analysis is to compare
the gene signature with a set of reference signatures/genesets. An ex-
ample of application is TFactS [43]. In TFactS, the gene signature is
compared to genesets containing target genes of transcription factors.
This tool can thus test the association between a particular signature
and the regulation of transcription factors.
To assess the links between a signature and a reference geneset, tools
like TFacts compare their number of genes in common with respect to
what is expected from a random selection. The comparison between two
signatures can be summarized in a table:
Gene Signature
Present Absent Total
Reference
Present k l − k l
Absent d− k p+ k − l − d p− l
Total d p− d p
Table 5.1: Comparison between gene signatures
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Figure 5.1: Graph represents the power of discrimination in high vs. low
risk groups (expressed as the logarithm of the p-values of the logrank)
of the ContHyp and CycHyp signatures (see red dots) versus 1,000 ran-
domly generated signatures (yellow shapes depicting their distribution).
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where d is the number of genes selected in the signature on a total of p
genes available, l is the number of genes in the reference signature, k is
the number of genes in common between the two signatures.
Under the null hypothesis that there is no link between the two
signatures, k follows a hypergeometric distribution. The probability to
observe k or more genes in common under this null hypothesis gives the
p-values of the enrichment.
Singular enrichment analysis has the problem of being sensitive to
the number of genes selected in the signature. If this number is too
small, the analysis may miss some important genesets. At the opposite,
selecting too many genes may reduce the signiﬁcance of the test.
5.3.3 Gene set enrichment analysis
Mootha et al. [96] introduce the gene set enrichment analysis to avoid
the cutoﬀ eﬀect of the traditional singular enrichment analysis. The
principle of gene set enrichment analysis is to test if there is an associ-
ation between a ranking of the feature, as proposed for example with a
ﬁlter (see section 5.1), and reference gene signatures. In particular, we
test if the genes of a reference signature are randomly distributed in the
ranking of the features.
For example, we could have ranked the genes according to an uni-
variate hazard-ratio. A gene set associated with the survival of patients
should have its genes at the top or at the bottom of list. Genes at the
top (resp. bottom) are correlated with shorter (resp. longer) survival.
For a gene signature of size l, the enrichment score (ES) as proposed
by Mootha et al. [96] can be computed from a ranked list of all the p
genes. Walking down this list, we increase or decrease a running-sum
statistic by some value wj for each gene j encountered.
wj =

�
(p−l)
l if j is in the signature
−
�
l
(p−l) otherwise
(5.6)
In particular, the running-sum statistic is deﬁne as 0 at the beginning
and the end of the list:
0�
j=1
wj = 0 (5.7)
p�
j=1
wj =
�
(p− l)
l
l −
�
l
(p− l)(p− l) = 0 (5.8)
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When a geneset is randomly distributed in a ranked list of genes,
the positive and negative wj compensate each others and the running-
sum should stay close to zero. Its maximum, the enrichment score, is
computed as:
ES = max
1≤k≤p
k�
j=1
wj (5.9)
The enrichment score (ES) is reported and can be compared with a
null distribution. The null distribution is estimated while computing the
enrichment score on permutations of the class labels or survival times.
As an example, we compute the enrichment score (ES) of two sig-
natures on breast cancer data. The ranking of the features is based
on their correlation with the tumor grade. The ﬁrst signature is the
GGI signature [124] which was designed precisely to be predictive of the
histological grade. The second signature is the Gene76 signature [143]
and is predictive of the breast cancer outcome. Figure 5.2 presents the
values of the running-sum statistic (black curves). The red dots repre-
sent the positions of the signatures (one for each gene) in the ranking.
The dashed red lines represent the position of the running-sum statistic
maximums (where the enrichment score is computed). The GGI signa-
ture, in constrast with Gene76, is mostly enriched at the beginning of
the ranking and has a higher enrichment score, as expected.
5.3.4 Discussion
The validation of a gene signature is a very complicated process where
a particular care should be taken to avoid any optimistic bias. This
bias can come from the protocol used for the feature selection and the
validation [4]. It can also come from the data, indeed it is quite common
to have patients shared between diﬀerent datasets. This validation also
requires a proper performance assessment with the right metrics (see
chapters 4 and 8).
The validation of a signature with enrichment analysis is not perfect
either. First, we depend on the set of published gene signatures that are
assumed complete and well annotated. Finding signiﬁcantly enriched
related genesets can be used as a biological validation of the signature.
But, ﬁnding no signiﬁcantly enriched genesets is diﬃcult to interpret and
cannot be used to reject a signature. Another question is the overlap
between these genesets and their interactions, enrichment analysis are
still essentially univariate [67].
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Figure 5.2: Enrichment score of the GGI [124] and Gene76 [143] signa-
tures. The ranking of the probesets is based on the correlation with the
tumor grades on a breast cancer dataset.
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Moreover, singular enrichment analysis (section 5.3.2) is sensitive to
the size of the signature. If this number is too small, the analysis may
miss some important genesets. At the opposite, selecting too many genes
may reduce the signiﬁcance of the test. Gene set enrichment analysis
(section 5.3.3) try to solve this issue while assessing a ranking and not
the true signature. GSEA can thus be problematic for feature selections
without ranking such as the embedded methods presented in section 5.2.

Part II
Methodological
Contributions

Chapter 6
Coxlogit Model
6.1 Introduction
As discussed in chapter 3, predicting risk groups can be seen as a clas-
siﬁcation or a survival prediction problem. The diﬀerence between the
two approaches is the kind of supervision available. The Cox model, pre-
sented in section 2.4 and 3.3.1, is the most commonly used with survival
data (ti, δi). When the risk groups yi ∈ {−1, 1} are known, classiﬁcation
models such as SVMs or logistic models are preferred (see section 3.2).
Sometimes, these two kinds of supervision are available together for
the same data. In breast cancer for example, risk groups can be deﬁned
from the tumor grades or from the survival data. A logistic model
predicting the grades might be very close to a Cox model predicting
the survival as both tasks are highly correlated. The originality of this
contribution is to tackle both problems jointly.
We consider in particular generalized linear models as they oﬀer a
direct interpretation in terms of individual feature relevances. The pro-
posed Coxlogit model is a natural extension to logistic regression for
which we assume that the survival times and class labels are random
variables conditioned by a common risk. We show that the partial like-
lihood of such model, to ﬁt the ordering of observed survival times, is
directly related to the logistic class probabilities. Learning can then
be expressed as maximizing the joint probability of class labels and the
ordering of survival events, conditioned to a common weight vector.
Embedded feature selection follows naturally when ﬁtting such a
model with a LASSO or elastic net penalty. Such penalties prevent
overﬁtting while enforcing a common sparse support. Learning is also
a convex problem that can be eﬃciently solved through a coordinate
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descent algorithm.
• Branders, S., D’Ambrosio, R., and Dupont, P. (2014). The
Coxlogit model: Feature selection from survival and classiﬁcation
data. In 2014 IEEE Symposium on Computational Intelligence
in Multi-Criteria Decision-Making (MCDM), pages 137–143
• Branders, S., D’Ambrosio, R., and Dupont, P. (2015a). A mix-
ture Cox-Logistic model for feature selection from survival and
classiﬁcation data. arXiv:1502.01493 [stat.ML] , pages 1–6
6.2 The Coxlogit approach
One considers a survival analysis framework made of a collection of
samples and their associated survival times, which are possibly censored.
One further assumes that each training sample is labeled into a speciﬁc
risk group. Formally, each sample i ∈ {1, . . . , n} is then characterized
by a 4-tuple (ti, δi, yi,xi) with the survival data, the binary class label
and the patient covariates.
The survival data and the class label of patient i are seen here as
two observations of random variables conditioned by a common risk of
event, ri. This risk is simply modeled as a linear combination of the
sample covariates (xi ∈ Rp) : ri = β�xi but the ﬁt of the parameters β
should consider both types of supervision.
Starting from the classiﬁcation viewpoint, a logistic regression pre-
dicts from the vector xi the probability of patient i to be in a speciﬁc
group:
P (Yi = 1|xi) = exp(β
�xi)
1 + exp(β�xi)
(6.1)
P (Yi = −1|xi) = 1
1 + exp(β�xi)
(6.2)
= 1− P (Yi = 1|xi) (6.3)
The risk score of a patient, ri = β
�xi, can be interpreted through
the logistic model as class probabilities: high risk patients are more
likely to be in the high risk group +1 and a zero risk score corresponds
to an equal probability to be in either risk groups. The likelihood of the
parameters β with respect to the observed labels yi is given by:
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L(β) =
n�
i=1
P (Yi = yi|xi) (6.4)
=
n�
i=1
1
1 + exp(−yi(β�xi)) (6.5)
Looking now at the survival times and knowing that an event occurs
at time ti, one typically computes the probability of patient i having the
event over the set of patients still at risk just before time ti : R(ti) =
{k|tk ≥ ti}.
Since high risk patients tend to have the event before low risk ones,
the likelihood of this observed event can be modelled as the conditional
probability of patient i being the only high risk patient, knowing that
exactly one patient is in the high risk group. The conditional probability
is computed as the probability of patient i being in the high risk group
and all others (R(ti)\{i}) being in the low risk group divided by the
probability of having only one patient in the high risk group. This
likelihood can be expressed in terms of the logistic class probabilities
P (Yi = 1|xi) and P (Yi = −1|xi):
Li(β) =
P (Yi = 1|xi)
�
j∈R(ti)\{i} P (Yj = −1|xj)�
k∈R(ti) P (Yk = 1|xk)
�
j∈R(ti)\{k} P (Yj = −1|xj)
(6.6)
=
exp(β�xi)
1+exp(β�xi)
�
j∈R(ti)\{i}
1
1+exp(β�xj)�
k∈R(ti)
exp(β�xk)
1+exp(β�xk)
�
j∈R(ti)\{k}
1
1+exp(β�xj)
(6.7)
=
exp (β�xi)�
k∈R(ti) exp (β
�xk)
(6.8)
Expression (6.8), aggregated over all events, boils down to the partial
likelihood (section 2.4.1) of a Cox model for survival data. The relation
between the conditional logistic model [27, 28] and the cox model is used
here in the Coxlogit model to link the class probabilities and survival
times.
The likelihood of the Coxlogit model is now deﬁned as the joint
probability of the observed events and risk group labels knowing the
parameters β. Assuming the labels and the times to event to be con-
ditionally independent given those parameters, this likelihood can be
computed as:
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L(β) =
n�
i=1
1
1 + exp(−yi(β�xi))
�
exp (β�xi)�
k∈R(ti) exp (β
�xk)
�δi
(6.9)
The loss of L(β) of the Coxlogit model is thus naturally formulated
as a mixture of a Cox and logistic losses:
L(β) = Lcox(β) + Llogi(β) (6.10)
In the derivation of the Coxlogit model, we use a similar interpreta-
tion of the Cox model as the one presented in section 3.3.1. Compared
with the Cox model, the Coxlogit model can take into account the prior
knowledge available on the risk groups, i.e. the risk group labels yi.
These labels combined with the logistic loss allow us to interpret the
risk scores ri = β
�xi in terms of risk group probabilities. Unlike the
Cox model, the Coxlogit risk scores can directly be used in a decision
function:
gi =
�
1 if P (Yi = 1|xi) > 0.5
−1 if P (Yi = −1|xi) > 0.5 (6.11)
= sign(β�xi) (6.12)
From equation (6.8), we can observed that the Cox partial likelihood
is invariant by translation, i.e. β�xi is equivalent to β�xi + θ. This is
not the case of the logistic likelihood, equation (6.5). In the Coxlogit
model, the risk scores are thus learned from both the labels and the
survival times but the decision function is mainly based on the class
labels.
6.2.1 The Coxlogit mixed model
In equation (6.10), we deﬁne the Coxlogit loss as the sum of the Cox
and logistic losses. For a better control on the model, we can further
deﬁne the Coxlogit model as a mixture of both models:
L(β) = (1− γ) Lcox(β) + γ Llogi(β) (6.13)
The meta-parameter γ ∈ [0 − 1] controls the contribution of either
losses in the model, with γ = 0 (respectively γ = 1) corresponding to a
pure Cox model (respectively a pure logistic regression). When γ is not
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explicitly speciﬁed, the Coxlogit model refers to the model presented in
section 6.2, or equivalently to a Coxlogit model with a γ of 0.5.
We use this deﬁnition (6.13) of the Coxlogit model with γ to have a
better understanding of the roles of each loss in the model.
6.2.2 Feature selection with the Coxlogit model
An embedded feature selection is performed by regularizing the objective
function of the Coxlogit model (6.10):
argmin
β
L(β) + λR(β) (6.14)
where R(β) is a sparsity enforcing regularization such as LASSO [132,
133] or elastic net [147], and λ > 0 a regularization constant. A coor-
dinate descent algorithm, adapted from [52, 117], is used here to solve
this convex problem. It starts from a trivial solution (β = 0) for a large
λ, and follows the regularization path when λ is gradually decreased
till the model includes a desired number of features (= non-zero weight
values). The algorithm we implemented is described in more details in
appendix B.
6.3 Experiments
In order to validate the proposed Coxlogit model in prediction and
feature selection tasks, we perform experiments on synthetic and real
datasets. The performances in classiﬁcation and survival prediction are
assessed according to the classiﬁcation accuracy (see section 4.1.1) and
the risk group concordance index (see section 4.12), respectively.
In this chapter, the results are reported in accuracy as all classiﬁ-
cation problems are almost perfectly balanced. In such cases, the clas-
siﬁcation accuracy is equivalent to the balanced classiﬁcation rate (see
section 4.1.3).
The global performance, while takling both tasks, is computed as
the harmonic average between classiﬁcation accuracy and C-index:
Hmean =
�
Accuracy−1 +C-Index−1
2
�−1
(6.15)
We use the harmonic average to favor solutions with both a high
accuracy and a high C-index. The signiﬁcance of diﬀerences between
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models is computed according to a Friedman test with a Nemenyi post-
hoc test [34].
The ﬁrst experiments reported on a synthetic dataset (section 6.3.1)
illustrate that the Coxlogit model is able to select features that are
jointly informative for survival and subgroup classiﬁcation. Even with-
out a perfect correlation between the two tasks, the Coxlogit approach
oﬀers competitive classiﬁcation and survival prediction results. Those
results are conﬁrmed on real breast cancer prognosis studies (section 6.3.3).
6.3.1 Synthetic data
The synthetic dataset is designed to have both supervisions in terms of
survival times and subgroup classiﬁcation. The dataset is designed with
four groups of features. The ﬁrst 3 groups of features are predictive of
respectively
• both the survival and the class label.
• the survival only.
• the class label only.
while the remaining features are purely random and supposed to repre-
sent noise.
One would like to assess to which extent the Coxlogit approach is able
to predict both the class label and survival, as compared to a regularized
Cox or logistic model alone. One could also compare the features selected
by the three models. The data matrix X ∈ Rn×p is drawn from a
N (0, 1) distribution to represent covariates that have been centered and
normalized to unit variance, a common practice in our context.
The class assignments and hazards are generated from distinct lin-
ear combinations of the features. The weights of those predictors, βj ,
are drawn from a uniform distribution over [−1,−0.5] ∪ [0.5, 1]. Class
labels y ∈ {−1, 1}n are generated from the ﬁrst and third groups in the
following way:
βclass =
�
βj 0 . . . 0 βj 0 . . . 0
�
yi = sign (β
�
classxi)
The survival data (ti, δi) are generated from two Weibull distribu-
tions, for the time to event and the censoring respectively. The Weibull
distribution for the time to event is parametrized such that the hazard
6.3. Experiments 67
hi(t) depends on the features from the ﬁrst and second groups :
βsurv =
�
βj βj 0 . . . 0 0 . . . 0
�
hi(t) ∝ exp(β�survxi)
The class labels and survival times are correlated as βclass and βsurv
have the same weights on the ﬁrst groups of features. To increase or
decrease the correlation between the two supervision, we change the
sizes of the second and third groups containing features respectively
predictive of the survival or the classiﬁcation. The smaller is their size,
the higher is the correlation between class labels and survival times.
In practice, we consider a dataset of n = 300 patients and p = 100
features. 100 samples are used for training and 200 independent samples
serve as validation. The number of features in the ﬁrst group, predictive
of both the survival and the class label, is ﬁxed to 10. The sizes of the
second and third groups change from k = 2 to k = 10.
6.3.2 Results on synthetic data
This section reports the results using the Coxlogit model on the synthetic
data described above, as compared to a regularized Cox model (γ = 0)
or a logistic regression (γ = 1). For each experiment, the regularization
path is followed till the model contains exactly 10 features. The absolute
weight value assigned to each feature can be easily interpreted as the
relevance of the features estimated by the model.
Figure 6.1 reports the model weights obtained while varying γ in [0, 1].
The data are generated here with 10 features in each of the three groups.
Figure 6.1 shows a smooth transition between the features selected by
the method while varying the value of γ. The Cox model only selects
features that contains some survival informations (in green and red).
Similarly, the regularized logistic model only selects features associated
to class assignments (in green and blue), plus one random feature in this
particular run. In contrast, the Coxlogit model (typically for γ = 0.5),
tends to select only those features (in green) that are informative for
both tasks.
Figure 6.2 reports the sum of the absolute weight values in each group
while repeating the above experiment 100 times and averaging those
absolute values over the 100 runs. While the Cox model, respectively
the logistic regression, always selects features related to the survival,
respectively the classiﬁcation in subgroups, the Coxlogit model clearly
favors the selection of common features.
Figures 6.3, 6.4 and 6.5 report the predictive results, respectively in
terms of classiﬁcation accuracy, C-index and harmonic average between
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Figure 6.1: Model weights obtained while varying γ from 0 (Cox model)
to 1 (Logistic model). The absolute value of the weights represent the
importance assigned by the model to each feature. Only 10 out of the
100 weights have a non-zero value as a consequence of the chosen working
condition along the regularization path.
them, obtained using the features selected by the Coxlogit model and
averaged over 100 runs.
The results presented in ﬁgure 6.3 show that the best classiﬁcation
accuracy is obtained for a logistic regression or a Coxlogit model with
γ ≥ 0.75. Logically, a model ﬁtted to maximize only a regularized Cox
log-likelihood (γ = 0) performs poorly according to this metric.
Similarly, as reported in ﬁgure 6.4, the best C-index is obtained for
a Cox model or a Coxlogit model with γ ≤ 0.25 while a model ﬁtted
to maximize only a regularized logistic log-likelihood (γ = 1) is poor at
predicting survival times.
According to a Friedman test with a Nemenyi post-hoc test [34], the
Coxlogit model (γ = 0.5) is not signiﬁcantly diﬀerent from the best per-
formances in classiﬁcation (accuracy) or survival prediction (C-index).
This result is conﬁrmed in ﬁgure 6.5 reporting the harmonic average be-
tween C-index and classiﬁcation accuracy. The best results are obtained
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Figure 6.2: Mean absolute weight values in each group of features
(Common, Survival, Classiﬁcation, Random) computed while varying
γ within [0, 1].
with the Coxlogit model (γ = 0.5) which is here signiﬁcantly better than
either a Cox or a logistic regression model.
These results are obtained on data generated with 10 relevant fea-
tures in each of the three groups. The two supervisions, class labels and
survival data, are thus not exactly two diﬀerent supervisions of unique
problem. The class labels and survival data are generated here from two
diﬀerent true risk scores: β�classxi and β
�
survxi. To estimate how close are
the classiﬁcation and survival prediction tasks, we compute the Pearson
correlation coeﬃcient between these true risk scores. In this experiment,
the correlation is on average equal to 0.5. The Coxlogit model will then
have to ﬁnd a compromise and cannot be perfect. However, the Coxlogit
model is able here to perform comparably at both tasks as compared to
a Cox or a logistic model.
To strengthen the links between the class labels and survival times,
we generate data with 10 common, 2 survival and 2 classiﬁcation fea-
tures. The Pearson correlation coeﬃcient between β�classxi and β
�
survxi
is on average equal to 0.83 in this setting. Figure 6.6 reports the pre-
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Figure 6.3: Forest plot of the average classiﬁcation accuracy obtained
while varying γ from 0 (Cox model) to 1 (Logistic model). These re-
sults are averaged on 100 repeated experiments with synthetic datasets
generated with 10 common, 10 survival and 10 classiﬁcation features.
diction results on these new data. The Coxlogit model (γ = 0.5) is
signiﬁcantly better in C-index and harmonic mean than a logistic re-
gression or a Cox model. The Coxlogit model makes here a better use
of both surpervisions to improve the performances in classiﬁcation and
survival prediction.
Those results can be explain by thinking of each supervision as an
additional regularization. The Cox part of the Coxlogit model prevents
an overﬁtting on the class labels, and vice versa.
The improvement can also be explain by a better feature selection.
Figure 6.7 reports the average number of relevant features selected by
the models. The relevant features are deﬁned as the features used to
generate the class labels or the survival data, i.e. the 10 common, the
2 survival and the 2 classiﬁcation features. On average, the Coxlogit
model (γ = 0.5) ﬁnds more than 8 relevant features on the 10 selected
which is signiﬁcantly more than either a Cox or a logistic regression
model.
To further test the feature selection, we generate datasets with
p = 1000 features: 10 common, 0 survival, 0 classiﬁcation and 990
random features. With no survival or classiﬁcation features, β�classxi
becomes equal to β�survxi. The survival data and the class labels are thus
generated from the same features and same risk scores, which allows us
to have a fair comparison between the diﬀerent models.
Figure 6.8 reports the average number of relevant features selected.
The feature selection of Coxlogit model (γ = 0.5) is signiﬁcantly better
than either a Cox or a logistic regression model.
These results in feature selection are conﬁrmed by the predictive
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Figure 6.4: Forest plot of the average C-index obtained while varying γ
from 0 (Cox model) to 1 (Logistic model). These results are averaged
on 100 repeated experiments with synthetic datasets generated with 10
common, 10 survival and 10 classiﬁcation features.
performances in ﬁgure 6.9. The Coxlogit model is signiﬁcantly better in
terms of classiﬁcation accuracy, C-index and harmonic average between
them.
The previous results show that the Coxlogit model is better when
the two tasks are strongly connected. To assess the behaviour of the
model when there is no link between the tasks, we generate datasets
with p = 100 features: 0 common, 10 survival, 10 classiﬁcation and 80
random features. Figure 6.10 reports the predictive performances of the
models on these data sets. The best model for the classiﬁcation (resp.
survival prediction) is the logistic model (resp. Cox model). These
two models are also the worst when looking at the other task (Cox in
classiﬁcation and logistic model in survival prediction). The Coxlogit
model is a trade-oﬀ between the two with average results. With no
link between the tasks, the Coxlogit model has no beneﬁt of using both
supervisions. However looking at their harmonic average, the Coxlogit
model (γ = 0.5) is still signiﬁcantly better than the Cox and logistic
model.
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Figure 6.5: Forest plot with the harmonic average between classiﬁcation
accuracy and C-index obtained while varying γ from 0 (Cox model) to
1 (Logistic model). These results are averaged on 100 repeated exper-
iments with synthetic datasets generated with 10 common, 10 survival
and 10 classiﬁcation features.
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Figure 6.6: Forest plot with the results in accuracy, C-index and their
harmonic average obtained while varying γ from 0 (Cox model) to 1 (Lo-
gistic model). These results are averaged on 100 repeated experiments
with synthetic datasets generated with a high correlation between class
labels and survival times: 10 common, 2 survival and 2 classiﬁcation
features.
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Figure 6.7: Forest plot with the average number of relevant features
amongst the 10 selected in each model. Each results is an average on
100 repeated experiments with synthetic datasets generated with a high
correlation between class labels and survival times: 10 common, 2 sur-
vival and 2 classiﬁcation features.
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Figure 6.8: Forest plot with the average number of relevant features
amongst the 10 selected in each model. Each results is an average on 100
repeated experiments with synthetic datasets. The data are generated
with a perfect correlation between class labels and survival times (with
no survival nor classiﬁcation features).
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Figure 6.9: Forest plot with the results in accuracy, C-index and their
harmonic average obtained while varying γ from 0 (Cox model) to 1 (Lo-
gistic model). Each results is an average on 100 repeated experiments
with synthetic datasets. The data are generated with a perfect cor-
relation between class labels and survival times (with no survival nor
classiﬁcation features).
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Figure 6.10: Forest plot with the results in accuracy, C-index and their
harmonic average obtained while varying γ from 0 (Cox model) to 1 (Lo-
gistic model). Each results is an average on 100 repeated experiments
with synthetic datasets. The data are generated with no links between
class labels and survival times (with no common features).
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6.3.3 Results on breast cancer data
We further assess the Coxlogit approach on 4 breast cancer studies
(GSE2034, GSE5327, GSE7390, GSE2990) from the GEO repository.
Those samples are gene expression values measured on the Aﬀymetrix
HGU133a microarray platform and distant metastasis is used as survival
end point. All samples are gathered in a common dataset including 554
patients and 1115 features, after keeping only the dimensions with the
largest variances. The objective is to predict both the grade of the
tumor [54], discretized into low versus high grade with roughly equal
priors, and the survival probability of the patients.
The 98 and 173 patients with respectively a tumor grade of 1 (well
diﬀerentiated) and 2 (moderately diﬀerentiated) are grouped in the low
risk groups, yi = −1. The 283 patients with grade 3 (poorly diﬀeren-
tiated) are the high risk patients, yi = 1. To measure the diﬀerences
between these two tasks, we compute the C-index of the class labels
which is equal to 0.7. This conﬁrms that the tumor grade is associated
with the survival of patients.
Results are reported below over 100 resamplings without replacement
(also known as subsampling), the training set size varies from 20 to
400 patients, the test set contains the 154 other patients. In the ﬁrst
experiment, 10 genes are selected by the three methods. Figure 6.11
present the results in accuracy, C-index and the harmonic mean between
both.
The logistic and Coxlogit model have comparable results in accuracy
and are signiﬁcantly better than the cox model. In survival prediction,
logistic and Coxlogit model are better than the Cox model for the train-
ing sets with less than 200 patients. As expected, the maximum C-index
of the logistic model is 0.7 which is the C-index of the patient tumor
grades on these data. Using both supervision, the Coxlogit model is able
here to improve the survival prediction of the logistic and cox model.
Figures 6.12 and 6.13 present similar results with 2, 20 and 50 genes
selected.
6.4 Conclusion and perspectives
Classiﬁcation and survival prediction are two common tasks in cancer
research. These two tasks are often two diﬀerent views of a unique
problem of predicting risk groups. With the Coxlogit model, we propose
to model together these two supervisions: class labels yi and survival
data (ti, δi).
Using both supervisions introduces more constraints in the Coxlogit
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model than in the Cox and logistic model alone. These additional con-
straints can help in prediction and feature selection. While being better
at both tasks together, the Coxlogit model can also improve the Cox and
logistic model in their respective tasks. This improvement is observed in
particular when the predictions are diﬃcult, that is when the number of
training samples is limited or with a drastic feature selection. In those
cases, the advantage of having more supervisions overcomes the problem
of optimizing two objectives not perfectly correlated.
Even when it does not improve the predictive performances, the
Coxlogit model is useful in feature selection. As an embedded method,
the feature selection is multivariate and favors features that are good
in classiﬁcation and survival prediction. Moreover, having one unique
model enforce a selection of features that are consistent between the
two tasks. The Coxlogit model will not selected features that are pos-
itively correlated with the survival and negatively correlated with the
classiﬁcation.
As mixture of the Cox and logistic regression, the Coxlogit model
produces risk scores that are interpretable both in terms of hazard
functions and risk group probabilities. The Coxlogit model can also
be viewed as a generalized linear model. It has a convex loss func-
tion which can be easily optimized, for example with an iteratively
reweighted least square. Similarly as for the Cox and logistic regression,
the Coxlogit model could even be kernelized to deal with non-linearity
in the data [57, 84].
We have shown in this work that combining generalized models is
a simple and powerful solution to exploit multiple surpervisions. Our
approach could be extend to regression, combining a continuous response
with the survival data. This continuous response can even be survival
times. A similar approach combining regression and ranking constraints
in a survival SVM was proposed by Van Belle et al. [138]. Their solution,
however, does not allow an interpretation of the predictions in terms of
hazards and is computationally heavy.
An other extension could be implemented using an ordered logistic
regression. This extension could be useful to deal with more than two
risk groups, for example a low, intermediate and high risk group.
The Coxlogit model can also easily be extend to data where each
patient may not have both supervisions. Such situation does not even
require any changes in the proposed methodolodgy (section 6.2). We
can simply assign patients without labels to a speciﬁc group with label
yi = 0 and replace missing survival data by negative censoring times,
(ti = −1, δi = 0). These replacement labels and survival data will
disappear in the computation of the gradient of the Coxlogit likelihood.
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We can push further this idea while using the Coxlogit model simul-
taneously on two datasets (with no common patients): one with survival
data and one with classiﬁcation data. The Coxlogit model could then
be used to ﬁnd signatures of genes that are jointly predictive of both the
survival and the class labels.
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Figure 6.11: Learning curves of the Cox, logistic and Coxlogit model on
breast cancer data. The feature set size is ﬁxed to 10.
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Figure 6.12: Learning curves of the Cox, logistic and Coxlogit model on
breast cancer data. The feature set size is ﬁxed to 2.
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Figure 6.13: Learning curves of the Cox, logistic and Coxlogit model on
breast cancer data. The feature set size is ﬁxed to 20.
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Figure 6.14: Learning curves of the Cox, logistic and Coxlogit model on
breast cancer data. The feature set size is ﬁxed to 50.

Chapter 7
Random Non-linear Projection
for Survival Analysis
7.1 Introduction
In section 2.4, we show how the Cox model can be used to model and
predict the survival of patients from their covariates, such as gene expres-
sion values. However, Cox models cannot handle as such non-linearities
in their covariates, what may restrict their usefulness in some settings.
This chapter aims to show that Cox models can easily handle non-
linear relationships if one uses random non-linear projections. Such
tools have been used in extreme learning [69] to obtain results which
are close to those of support vector machines, but at a much smaller
computational cost. Random projections are used here with Cox models
and a feasibility study is performed. Results are comparable to those of
standard Cox models, but the proposed method can be used to handle
data with non-linear relationships.
Section 7.2 explains what random non-linear projections are and how
to use them. Section 7.3 details the proposed methodology to extend
the Cox model, which is experimentally assessed in Section 7.4.
• Branders, S., Fre´nay, B., and Dupont, P. (2015b). Survival Anal-
ysis with Cox Regression and Random Non-linear Projections.
Proceedings of the 23th European Symposium on Artiﬁcial Neu-
ral Networks , pages 119–124
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7.2 Non-linear random projections
A potential limitation of the Cox model is that it cannot deal with non-
linear relationships. Hence, a natural extension consists in adding sup-
port for features which must be non-linearly transformed to compute the
hazard function. Many approaches exist in machine learning to obtain
non-linear models like kernels or neural networks. However, kernelized
Cox models [84] and survival-SVMs [138] come with the additional com-
plexity of deﬁning an appropriate non-linear kernel, whereas survival
neural networks [11] are slow to learn. The proposed method focuses on
a diﬀerent approach which allows one to keep the interpretability and
simplicity of Cox regression.
In extreme learning, it has been shown that random non-linear pro-
jections of the inputs [69] can be used to achieve state-of-the-art results
in both non-linear classiﬁcation and regression [68]. Those non-linear
projections are obtained independently from training data: only their
dimensionality p and the number of non-linear projections m must be
known. The l-th projection is deﬁned as:
zl(xi) = σ
 p�
j=1
wjlxij + bl
 (7.1)
where σ is a non-linear function, wjl is the weight between the j-th
input xij and the l-th projection and bl is the bias used for the l-th pro-
jection. Non-linear projections could be optimized but Huang et al. [69]
have shown that one can simply (i) draw the weights and biases in Equa-
tion (7.1) randomly (e.g. from a uniform or Gaussian distribution) and
(ii) keep them ﬁxed during learning.
The advantage of the above strategy is that state-of-the-art results
are obtained in non-linear classiﬁcation and regression [68] at the cost
of linear methods. Indeed, the matrix of inputs X is replaced by the
matrix Z of random non-linear projections, which is ﬁxed for a given
dataset and needs not be trained.
Z =
z1(x1) · · · zm(x1)... . . . ...
z1(xn) · · · zm(xn).
 (7.2)
Afterwards, fast, linear methods (linear regression, logistic model, etc)
can be used with Z instead of X. Using random non-linear projections
oﬀers a good compromise between computation needs and prediction
accuracy. This view has been popularized in [86, 93, 50] where it is
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shown that the number of random projections can be set to a large
number (e.g. m = 103) or even be inﬁnite [51] if regularization is used
to control the model complexity.
7.3 Proposed methodology
We propose to use random non-linear projections Z ∈ Rn×m as input to
a Cox model rather than the original covariates X ∈ Rn×p. The main
advantage is that non-linear relationships can now be modeled, while the
interpretability of the Cox model output is preserved in terms of hazard.
Also, contrarily to e.g. SVMs, we do not need to choose a kernel nor to
tune its parameters. Since works like [86, 93, 50, 51] show that regular-
ized linear methods work well with large numbers of random non-linear
projections, L2 regularization can be used to control the complexity of
the resulting non-linear Cox model. The algorithm 7.1 is used here to
generated the projections. Weights and biases are drawn from a uniform
distribution between -2 and 2, and the inputs are normalized before be-
ing non-linearly transformed with an hyperbolic-tangent. Section 7.4
assesses this methodology.
Algorithm 7.1: Random non-linear projections
Data: The normalized data matrix X ∈ Rn×p, the number of
random non-linear projections m.
Result: The matrix of random non-linear projections Z ∈ Rn×m.
Generate a matrix W ∈ Rp×m such that wi,j ∼ U([−2, 2]);
Generate a vector b ∈ R1×m such that bj ∼ U([−2, 2]);
Z = tanh
�
XW + 1n×1b
�
;
7.4 Experiments
This section validates the use of random non-linear projections with a
Cox model. Experiments are performed on synthetic and real datasets;
performances in survival regression are assessed according to the con-
cordance index (C-index) on the risk scores (see section 4.12). The L2
regularization constant λ of the Cox model is tuned with an internal
10-fold cross-validation on the training set.
A 10-fold cross-validation is used in all experiments with real datasets.
All results are reported in forest plots containing: the average test per-
formance in C-index for each model and the p-values of a paired t-test
against the standard Cox proportional hazards model. The black squares
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are centered on the average C-index. The horizontal grey lines corre-
spond to the 95% conﬁdence intervals.
7.4.1 Results on artiﬁcial non-linear datasets
Artiﬁcial data are considered ﬁrst to assess to which extent our approach
is able to deal with non-linear features. A data matrix X ∈ Rn×p is
drawn from a standard distribution N (0, 1). The survival data (ti, δi)
are generated from two Weibull distributions (for event and censoring
times, respectively) such that the hazard hi(t) depends on a combination
f(xi) of the features: hi(t) ∝ exp(f(xi)). The Weibull shape parameters
are set to 2.5 and 1 respectively for censoring and event times. The
scaling parameters are 2914 and 20000 exp(−1.5f(xi)/σ), where σ is the
standard deviation of f(xi) over all generated samples
1. Two non-linear
combinations and one linear combination of features are considered here:
f1(xi) =
d�
j=1
x2ij (7.3)
f2(xi) =
d�
j=1
exp(−x2ij) (7.4)
f3(xi) =
d�
j=1
ajxij . (7.5)
Results are averaged in Figure 7.1 over 10 independent runs with
n = 1000 instances (200 for training, 800 for validation) and p = 5
features. The Cox proportional hazard model is trained (i) on the 5
original features and (ii) using between 100 and 5000 random non-linear
transformations of those features.
As expected, a standard (linear) Cox model is not able to deal with
non-linear features (f1 and f2). The Cox model oﬀers signiﬁcantly better
results when the original features are ﬁrst transformed through non-
linear random projections. Such a strategy is even not detrimental in
the linear case (f3). If a suﬃciently large number (here 2000) of random
projections is considered, the results are not signiﬁcantly diﬀerent from
those of a standard Cox model. In general, the number of random
projections to consider needs not be carefully tuned provided it is chosen
large enough.
1Those values were chosen to produce events and censoring times similar to real
data.
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7.4.2 Results on real-world datasets
This section shows results for three real-world cancer datasets. The ﬁrst
real dataset is the ﬂchain2 dataset, which contains 8 features for 7874
patients. Multiple causes of death were recorded and the death due to a
circulatory system diseases is considered here. Others causes of death are
seen as censoring, which is one way to deal with competing risks [101].
The second dataset consists of ﬁve pooled breast cancer datasets from
the GEO database (accession numbers: GSE2034, GSE5327, GSE7390,
GSE2990, GSE11121 and GSE6532). 75% of the features with the low-
est variances are removed, which is a standard pre-ﬁltering of such high-
dimensional data. The ﬁnal dataset contains 1054 patients with 5571 fea-
tures. The third dataset consists of seven pooled colon cancer datasets
from the GEO database (accession numbers: GSE39582, GSE17536,
GSE17537, GSE14333, GSE29621, GSE29623 and GSE38832). After a
similar pre-ﬁltering, the ﬁnal dataset contains 1234 patients with 13669
features.
Figure 7.2 shows results obtained for the ﬂchain, breast and colon
datasets. The C-index reaches a plateau when the number of projections
increases. Globally these results do not exhibit statistically signiﬁcant
diﬀerences with those of a standard Cox model. They illustrate that the
proposed approach is eﬀective even though explicit non-linearities might
not be required for these datasets.
The sensitivity of results to the choice of the L2 regularization pa-
rameter λ is studied in Figure 7.3 using the ﬂchain dataset. The number
of random projections is ﬁxed to 200 and 500 and results are reported
with λ equal to {13 , 12 , 23 , 1, 10, 20} times the number of dimensions. Re-
sults are improving while increasing λ and reach a plateau, here when
λ is roughly equal to the number of projections. The choice of λ seems
robust and it does not seem diﬃcult to tune.
7.5 Conclusion
This chapter shows how random non-linear projections used in extreme
learning can also be used to extend Cox models. Using the proposed
methodology, survival analysis can be performed even with non-linear
relationships between covariates and the associated risk scores. The
computational cost is comparable to the cost of learning standard Cox
models. Since Cox models are essentially used to compute risk scores,
the results are still readily interpretable in terms of hazards. Such an
2available at http://cran.r-project.org/web/packages/survival/ in the survival R
package.
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approach avoids the additional complexity of deﬁning an appropriate
non-linear kernel or of training complex neural networks.
One of the drawback of this approach is the model interpretation.
The ﬁnal model is a multivariate combination of non-linear random pro-
jections which is diﬃcult to interpret. However, one can look at the
random projections that are important in the model, e.g. with a high
absolute weight in the model. The interesting features could be the fea-
tures with a high weight in those important random projections. Prelim-
inary results show that such an approach could be used as a non-linear
feature selection.
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Figure 7.1: Results in C-index on synthetic data sets with p = 5 features.
Top, center and bottom plots respectively for f1, f2 and f3. The results
are reported for a Cox model with either the original features (Cox)
or random non-linear projections (Cox-R). The number of projections
varies from 100 to 5000.
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Figure 7.2: Results in C-index with the ﬂchain, breast and colon
datasets, respectively at the top, center and bottom. These three
datasets have respectively 8, 5571 and 13669 original features. The re-
sults are reported for a Cox model with either the original features (Cox)
or random non-linear projections (Cox-R). The number of projections
varies from 100 to 15000.
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Figure 7.3: Results with the ﬂchain dataset changing the regularization
constant λ. Top and bottom plots respectively for 200 and 500 random
projections.

Chapter 8
Balanced Hazard Ratio
8.1 Introduction
In chapter 4, we present several metrics used to assess risk groups and in
particular how they ﬁt with the observed survival data. In this chapter,
we extend the discussion, started in section 4.2, on the limitations of
these metrics. Our ﬁrst contribution is to argue why the hazard ratio
and C-index, while being perfectly sound to assess risk scores, are much
less appropriate to evaluate risk groups.
Part of the issue comes from the choice of the threshold (or cut-oﬀ)
values on risk scores to obtain the risk groups. We show in particular
that the HR may be artiﬁcially increased by considering highly unbal-
anced groups: an extremely unbalanced choice would, for instance, con-
sider a single patient with the shortest survival time (or the highest risk
score) as the unique member of the high risk group, while putting all
other samples in a presumably low risk group. Such an extreme choice
is likely to lead to a very high HR but is unlikely to be valuable from
an accurate prognosis viewpoint. A perfect balance, say 50%/50% be-
tween high and low risk groups, needs not be relevant either. Unless
some prior information exists about the relative size of the risk groups,
which is rarely the case when assessing the prognostic values of new
candidate markers, the deﬁnition of risk groups looks ill-deﬁned when
assessed through the standard HR. We stress that this problem occurs
beyond extremely unbalanced cases as a consequence of the HR mea-
sure exhibiting potentially many local optima and being particularly
non-smooth. Therefore, very small modiﬁcations of the proportions be-
tween risk groups (through marginal cut-oﬀ modiﬁcations) can lead to
highly diﬀerent HR values. We also show that maximizing HR versus
96 Chapter 8. Balanced Hazard Ratio
minimizing its associated p-value could lead to drastically diﬀerent risk
groups.
Our second contribution is the deﬁnition of a new performance met-
ric, called the balanced hazard ratio (BHR) to ﬁx the issues raised above.
The BHR keeps an intuitive interpretation and is as simple to compute
as the original HR, meaning that it can be easily used by clinicians
accustomed to the hazard ratio. Yet, the BHR penalizes artiﬁcially un-
balanced risk groups and, more generally, oﬀers a smoother proﬁle with
a natural optimum. Interestingly, such optimum is data-dependent and
needs not correspond to a perfect balance between groups. Our third
contribution is to show that the BHR leads to a natural deﬁnition of
cut-oﬀ values on risk scores to deﬁne associated risk groups.
We illustrate the proposed methodology on breast cancer studies as-
sessing the quality of prognostic gene signatures. Section 8.2 brieﬂy
describes those studies, which are chosen here as running examples. Yet
we believe that our conclusions fully apply to the general evaluation of
risk groups from survival data. Section 8.3 illustrates, on some running
examples, the inﬂuence of cut-oﬀs on the deﬁnition and the performances
of risk groups. In particular, we discuss the inﬂuence of cut-oﬀs on the
original hazard ratio and why its use is problematic to assess risk groups.
This discussion is extend in section 8.4 to the other performance met-
rics presented in section 4.2. We compare them to the hazard ratio
and we discuss their relevance for evaluating risk groups. Section 8.5
presents the balanced hazard ratio. We argue why it is well designed
for evaluating risk groups, while keeping a natural interpretation along
the same lines as the original hazard ratio. Section 8.6 describes how
the balanced hazard ratio, originally deﬁned for two risk groups, can be
easily generalized to an arbitrary number of risk groups. Section 8.7
describes how the BHR can be used to choose natural cut-oﬀ values on
risk scores. Section 8.8 further illustrates the soundness of the proposed
methodology on controlled experiments for which an underlying thresh-
old between risk groups is ﬁxed by design. We conclude our work and
discuss additional perspectives in section 8.9.
• Branders, S. and Dupont, P. (2015). A balanced hazard ratio for
risk group evaluation from survival data. Statistics in Medicine,
34(17)
8.2 Illustrative clinical studies
Risk group prediction and evaluation are illustrated in here on known
clinical studies of breast cancer prognosis. These studies oﬀer a variety
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of data sets publicly available from the GEO database with existing
prognostic markers, often made of gene expression signatures. The high
prevalence of breast cancer and the availability of several prognostic
indexes for essentially the same task drove our choice on those examples
but our conclusions are aimed to be applicable to any evaluation of risk
groups from prognostic indexes and survival data. In particular, similar
results with additional prognosis models for breast cancer, and further
results on colon and ovarian cancers are presented in our paper [17].
The Gene76 prognostic model is built from 76 genes to identify pa-
tients who developed distant metastasis within 5 years. All patients
considered are node negative and untreated. The gene expression and
survival data for this study form the Veridex (VDX) data set [143]:
n = 344 samples, GEO accession numbers GSE2034 and GSE5327.
The Gene76 prognostic model has been further validated on an inde-
pendent study conducted by the TRANSBIG (TBG) consortium. The
TBG data set includes untreated patients with primary breast cancer
and a node negative status [35]: n = 198 samples, GEO accession num-
ber GSE7390.
The data set UNT comes from a study investigating the links be-
tween histopathological grades and gene expressions [124]. To focus on
comparable data sets, we consider only untreated patients from this
study with a node negative status after removing samples also present
in VDX or TBG: n = 84, GEO accession number GSE2990.
In all those studies, distant metastasis is used as end point and no
information is available about possible competing risks. Gene expression
data are measured on the Aﬀymetrix HGU133a microarray platform.
All data sets were summarized according to the MAS5.0 procedure and
represented in log2 scale. Practical experiments were conducted using
the R statistical language, including speciﬁc breast cancer prognostic
models implemented in the genefu R package [61] from Bioconductor.
8.3 Risk groups and hazard ratio
In chapter 3, we present several methods/models to compute and to
predict the risk scores and risk groups of patients. These models usually
deﬁne the continuous risk score of a patient i as a linear combination of
its covariates xi:
ri = β
�xi (8.1)
The risk groups are then deﬁned from a cut-oﬀ θ on these risk scores.
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gi = sign(β
�xi − θ) (8.2)
gi =
� −1 if ri < θ
1 if ri ≥ θ (8.3)
Without access to observed risk groups yi, the choice of θ can be
viewed as an unsupervised or partially supervised problem. The sur-
vival models presented in section 3.3 compute a risk score but do not
give any estimate of θ. The cut-oﬀ should be estimated in a second step
to predict risk groups from the Cox or survival SVM continuous risk
scores.
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Figure 8.1: Risk groups on the VDX dataset with the original Gene76
cut-oﬀ.
To illustrate the inﬂuence of the cut-oﬀ choice, we consider the
Gene76 prognostic index on the VDX dataset. This index ﬁrst parti-
tions the patients depending on their estrogen receptor status, being
either positive or negative. For each status, the risk score is deﬁned
through a speciﬁc combination of univariate Cox models. Figure 8.1
reports the Kaplan-Meier curves for the 2 risk groups as deﬁned by this
model and its original cut-oﬀ. The speciﬁc details on how this original
cut-oﬀ was chosen are further discussed in section 8.7. We focus here
on the impact of this choice versus possible alternatives. Kaplan-Meier
curves present the proportion of patients still at risk (i.e. without hav-
ing experienced the event) along the follow-up time (expressed here in
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years). Crosses on the curves represent censored data. There is one
curve for each risk group with the corresponding number of patients in
each group being reported below the x-axis. Informally speaking, the
more separated the 2 curves, the better the prognostic index and its un-
derlying predictors as prognostic markers. To evaluate such a diﬀerence,
the hazard ratio (HR) is commonly considered, together with its 95%
conﬁdence interval and a p-value of a statistical test assessing whether
HR signiﬁcantly diﬀers from 1.
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Figure 8.2: Risk groups on the VDX data set deﬁned by the Gene76
model with alternative cut-oﬀs.
In this regard, Gene76 looks to be a good prognostic index, as eval-
uated on the VDX dataset, since its HR is high (6.18), with a 95%
conﬁdence interval = [3.53, 10.80] and a very small p-value. Yet, this
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would need to be conﬁrmed on additional samples independently from
those used to estimate this model, as further discussed in section 8.7. In-
deed, the assessment of a cut-oﬀ on the same data used for its estimation
can be subject to a large bias [2].
We focus here on a diﬀerent issue. Alternative cut-oﬀ choices are
possible and could lead to strongly diﬀerent HR evaluation. The ﬁg-
ure 8.2 presents the survival curves of the high and low risk groups from
the same Gene76 model evaluated on the same dataset (VDX) but with
alternative cut-oﬀs.
Changing the cut-oﬀs logically aﬀects the number of patients in the
low versus high risk groups but it also largely modiﬁes the HR values.
In particular, a HR value larger than 9 is reported in ﬁgures 8.2(a) and
8.2(c), which is much higher than the original HR. In the ﬁrst case, the
number of patients in the low risk group has been decreased (from 133
to 82 at time 0). In the latter case, nearly all patients (341 out of 344
at time 0) now belong to the low risk group, which forms a particularly
imbalanced splitting between risk groups. Such observations tend to
show that an appropriate cut-oﬀ choice is critical. Before revisiting this
question, we argue why assessing risk group prediction through a group
hazard ratio is problematic. The results presented in ﬁgure 8.2 will be
used as running examples throughout this chapter.
As illustrated in ﬁgure 8.2, a speciﬁc cut-oﬀ choice on the risk scores
may largely inﬂuence the proportion of samples in each risk groups and
the resulting HR values. Figure 8.3 generalizes this analysis by reporting
the HR values (along the left y-axis) obtained for all possible cut-oﬀs
deﬁning a proportion of samples in the low risk group varying from 0%
to 100% (along the x-axis). Results presented in ﬁgure 8.2 correspond to
3 speciﬁc cut-oﬀs, hence 3 speciﬁc points on this HR curve, illustrated by
black, red and green dots respectively while the original Gene76 cut-oﬀ is
represented with a dashed line. The HR value can clearly be artiﬁcially
increased by considering extremely unbalanced risk groups, which would
nevertheless be uninformative from a prognostic point of view. The
problem is even more serious since this HR (plain) curve exhibits many
local optima and is far from being smooth. In other words, marginal
changes in the relative proportions between risk groups may drastically
aﬀect the observed hazard ratio while potentially modifying, positively
or negatively, the estimated quality of the predictors used as prognostic
markers. Finally, due to those ﬂuctuations, the evolution of the HR
values are inconsistent with the associated p-values (dashed orange line,
− log scale along the right y-axis). Hence risk groups maximizing the
HR value (e.g. the green dot) is largely diﬀerent from those minimizing
the associated p-values (e.g. the red dot).
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All the above results illustrate that using the hazard ratio to assess
the quality of prognostic markers to discriminate between risk groups is
highly questionable.
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Figure 8.3: Plain line: hazard ratio of the Gene76 model on the VDX
dataset while varying the proportions in each risk group through diﬀer-
ent cut-oﬀ choices (HR value on the left y-axis). The dashed vertical
line corresponds to the original cut-oﬀ. Dashed orange line: associated
p-values plotted in − log scale (right y-axis, the higher the better on
such a plot).
We stress that the issues raised here directly follow from the use of
a discrete indicator variable gi in the deﬁnition of the group hazards
(section 4.2.1). Another classical deﬁnition of HR considers a contin-
uous risk score ri instead of the discrete (and here binary) gi. In the
continuous case, let us assume for example HR = 2 while comparing the
risk scores ri > rj , associated to patients i and j still at risk. Such a HR
value would mean that the probability of experiencing the event is twice
as large for patient i. This is a perfectly sound use of the HR measure
to assess the relevance of risk scores. The problems raised above appear
whenever cut-oﬀs are chosen on those scores and discrete groups are de-
ﬁned accordingly. Such discretization needs however to be considered as
it is routinely used by clinicians to decide whether a speciﬁc treatment
should be given to a patient. Such decision is indeed often based on
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the assignment of the patient to a particular risk group. Royston et al.
[110] argue that this discretization should only be applied on risk scores
at the very end of the model-building process. The dichotomization of
the continuous predictor variables may indeed introduce problems such
as loss of information, reduction in power, uncertainty in deﬁning the
cutpoints.
We introduce in section 8.5 a novel performance metric, called the
balanced hazard ratio, which ﬁxes those issues while keeping an interpre-
tation similar to the original hazard ratio. In the meantime, we extend
the previous results to alternative performance metrics.
8.4 Alternative performance metrics
In section 4.2, we presented several performance metrics proposed in
the literature to evaluate risk group prediction models, including the
concordance index, the logrank test, the SEP and the pair sensitivity
and speciﬁcity.
We study here the relative behaviors of these various performance
metrics on our running example. Figure 8.4 further extends ﬁgure 8.3
by reporting the ﬁve metrics under study after rescaling all of them
between 0 and 1 to ease the comparison (BCR is reported at 5 years
after treatment, for all possible risk score cut-oﬀs).
We note that the C-index behaves very similarly to the hazard ratio:
one can trivially optimize them while considering artiﬁcially unbalanced
groups, they both exhibit many local optima and sharp ﬂuctuations for
marginally diﬀerent group proportions. In contrast, the logrank test, the
SEP and the BCR look more appropriate as they oﬀer quite smoother
curves with a similar global optimum observed for more balanced groups.
We note that this optimum is data dependent and needs not correspond
exactly to a 50%/50% balance between groups. Yet those measures are
not fully satisfactory either. The logrank statistics is a sum of hyperge-
ometric random variables which does not oﬀer an easy interpretation in
terms of survival times diﬀerences between risk groups, unlike the haz-
ard ratio and the C-index. Yet, actual survival times are key features
for the patients and for choosing appropriate treatments.
The SEP metric oﬀers a more direct interpretation than the logrank
and provides an estimate of the degree of separation of the diﬀerent risk
groups. SEP and logrank behave very similarly but also share a common
disadvantage: they are insensitive to the ordering of the risk groups. In
other words, those values are unchanged after inverting risk groups and
wrongly assigning the patients with a lower risk score to the higher risk
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group. This problem becomes even more serious with more than 2 risk
groups (see section 8.6).
As for the BCR, it is not a distance measure between survival curves
but rather a balanced measure of classiﬁcation rates in each group. It
also depends on a critical time value (here chosen at 5 years after treat-
ment) which is somewhat arbitrary and moreover largely dependent on
the pathology under study. Finally, speciﬁcity/sensitivity measures are
not perfectly suited to censored data because they simply ignore the pa-
tients who did not experience the event and have been censored before
the critical time considered.
Section 8.5 introduces a novel performance metric to address those
issues.
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Figure 8.4: The various performance metrics evolution while varying
the proportions in each risk group through adjusting the cut-oﬀ on risk
scores. The original Gene76 cut-oﬀ corresponds to the dashed line.
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8.5 Balanced Hazard Ratio
The balanced hazard ratio (BHR) computes the hazard ratio between
three curves: the survival curves of the high and low risk groups (as
for HR) and a third global survival curve over all patients (we present a
generalization to more than 2 risk groups in section 8.6). Each sample is
now considered as a member of 2 groups: its actual risk group (gi = −1,
for low risk, or gi = 1, for high risk) and the global risk group (gi = 0)
for all patients. Such a global risk group represents the hazard (or
survival time) over the whole population of patients and one measures
now how much each speciﬁc risk group departs from the global curve.
Figure 8.5 illustrates those survival curves on our running example with
the 3 diﬀerent proportions between risk groups considered so far.
The hazard function is now deﬁned over those 3 groups:
hi(t) = h0(t) exp (βgi),with gi = −1, 0, or 1 (8.4)
The quantity h0(t) represents here the hazard of the whole popula-
tion, h0(t)/ exp (β) the hazard of the low risk group and h0(t) exp (β)
the hazard of the high risk group. The balanced hazard ratio, BHR =
exp (β) is simply the multiplicative factor to get the hazard of the high
risk from the global hazard or from the low risk to the global one. We
also note that the square of this value, [exp (β)]2, has the same scaling
as the original hazard ratio and can be interpreted as the relative hazard
between the high and low risk groups. However, note that if BHR2 has
a similar interpretation, it is not equal to the HR. Indeed, the β value
is found by ﬁtting a partial likelihood according to the 3 curves (see
below).
According to the BHR formulation, whenever the vast majority of
patients are artiﬁcially considered in one group, the diﬀerence between
the global survival and the survival of this group will be small (see,
for example, Fig. 8.5(a) and Fig. 8.5(c)). As such, the BHR penalized
extremely unbalanced risk groups without forcing risk groups to be of
equal size. The consideration of the global survival curve also has a
smoothing eﬀect on the BHR because a change in survival times for one
speciﬁc group only aﬀects the hazard ratio between this group and the
global survival curve.
Figure 8.7 (a) further details our running example while reporting the
BCR, logrank, HR and BHR (we left out the C-index and SEP for clarity
as they behave like the HR and the logrank, respectively). The BHR
exhibits a behavior similar to the BCR and the logrank while oﬀering a
natural interpretation in terms of survival diﬀerences between groups as
8.5. Balanced Hazard Ratio 105
0
0.
2
0.
4
0.
6
0.
8
1
D
is
ta
nt
 m
et
as
ta
si
s−
fre
e 
su
rv
iva
l
0 1 2 3 4 5 6 7 8 9 10
Years
Nb at risk
82 82 80 80 80 75 68 60 42 29 15
262 242 212 187 172 156 139 124 94 60 38
Low Risk
Global
High Risk
(a)
0
0.
2
0.
4
0.
6
0.
8
1
D
is
ta
nt
 m
et
as
ta
si
s−
fre
e 
su
rv
iva
l
0 1 2 3 4 5 6 7 8 9 10
Years
Nb at risk
188 185 177 173 171 161 145 128 94 61 35
156 139 115 94 81 70 62 56 42 28 18
Low Risk
Global
High Risk
(b)
0
0.
2
0.
4
0.
6
0.
8
1
D
is
ta
nt
 m
et
as
ta
si
s−
fre
e 
su
rv
iva
l
0 1 2 3 4 5 6 7 8 9 10
Years
Nb at risk
341 321 292 267 252 231 207 184 136 89 53
3 3 0 0 0 0 0 0 0 0 0
Low Risk
Global
High Risk
(c)
Figure 8.5: Risk groups with 3 diﬀerent cutoﬀs and the global survival
curve (in green) for the Gene76 model on the VDX dataset.
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the original HR. In particular, BHR is much smoother than HR, exhibits
a data-dependent global optimum and penalizes artiﬁcially unbalanced
groups. Those results are extend in appendix C while comparing the
hazard ratio, SEP and D-index to the balanced hazard ratio.
The smoother proﬁle of the BHR compared to the HR can be explain
by the diﬀerences in the size of their conﬁdence intervals. Figure 8.6
presents the BHR and the HR with their 95% conﬁdence intervals. Here,
the balanced hazard ratio is squared to be on the same scale as the haz-
ard ratio and to ease comparison. The conﬁdence interval is much bigger
for the hazard ratio than the BHR2. Those problems of variability and
extreme values of the hazard ratio occurs beyond extremely unbalanced
cases, e.g. the HR conﬁdence interval is already twice as big as the
BHR2 conﬁdence interval with a low risk group proportion of 0.4.
Unlike the logrank and the SEP, the BHR is sensitive to the risk
group ordering: inverting the risk groups would lead to a BHR value
below 1 while BHR tends to 1 when the survival diﬀerences between the
risk groups tend to vanish.
The estimation βˆ of the β value from the balanced hazard ratio
(see equation (8.4)) is computed through the maximization of a partial
likelihood, similarly to the original HR [32]. For the BHR, the partial
likelihood is slightly modiﬁed to include the global survival without du-
plicating the patients. The partial likelihood for the balanced hazard
ratio (with the standard Breslow approximation for ties [28]) is:
L =
n�
i=1
 exp (βgi)��
k∈R(ti) exp (βgk) + 1
�2

δi
,with gi = −1 or 1 (8.5)
The βˆ value has most good properties of a maximum likelihood es-
timate and has an asymptomatically normal distribution. The variance
of βˆ can be estimated with the inverse of the Fisher information [32]
and can be estimated through the second derivative of the log-likelihood
with respect to β:
var(βˆ) ≈ −
�
d2logL(βˆ)
dβ2
�−1
(8.6)
One can thus easily compute conﬁdence intervals and use standard
statistical tests (Wald, likelihood ratio, score test [28]) to assess to which
extent the BHR signiﬁcantly departs from 1.
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Figure 8.6: Hazard ratio, squared balanced hazard ratio and their con-
ﬁdence intervals on the VDX dataset while varying the proportions in
each risk group. The balanced hazard ratio is squared to be on the same
scale as the hazard ratio.
108 Chapter 8. Balanced Hazard Ratio
Figure 8.7 (b) illustrates that the associated p-values are fully con-
cordant with the BHR values: an increase of BHR goes along a decrease
of the associated p-value (here plotted in − log scale). Those results
drastically contrasts with those obtained for the original HR (see ﬁg-
ure 8.3).
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Figure 8.7: (a) Performance metrics on the VDX dataset while varying
the proportions in each risk group. The original Gene76 cut-oﬀ corre-
sponds to the dashed line. (b) Dashed orange line: p-values associated
to BHR plotted in − log scale (right y-axis, the higher the better on such
a plot)
To compare two prognostic models on the same data, we compare
their BHRs with a t-test for dependant samples, similarly as in [60].
t =
βˆ1 − βˆ2�
sˆ21 + sˆ
2
2 − 2rsˆ1sˆ2
(8.7)
where βˆ1 and βˆ2 are the two estimated log balanced hazard ratios, sˆ
2
1 and
sˆ22 are their estimated variances. r is the Spearman’s rank correlation
coeﬃcient between the predicted risk groups (i.e. without the global
risk group) of the two prognostic models. Under the null hypothesis
that the estimated BHRs are equal, the statistic (8.7) follows a student
distribution of n− 1 degrees of freedom, where n is the original number
of patients.
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8.6 BHR generalized to more than two risk groups
The original balanced hazard ratio (see equation (8.4)) is formulated
with 2 risk groups and an additional global group representing all pa-
tients. The BHR can be easily generalized to an arbitrary number of
original risk groups. The k original risk groups are assumed to be or-
dered from lower to higher risk and arbitrarily numbered 1, 3, . . . 2k− 1.
For each pair (i, i + 2) of consecutive risk groups following this order,
one additional risk group numbered i+1 is considered gathering the pa-
tients of this pair of groups. In total, one considers 2k− 1 (original and
additional) risk groups. The hazard function is now deﬁned as follows:
hi(t) = h0(t) exp (βgi),with gi ∈ [1 : 2k − 1] (8.8)
The balanced hazard ratio, BHR = exp (β) is the multiplicative factor
between the hazards of two consecutive groups i and i+1. This formula
is equivalent1 to the original BHR deﬁnition whenever k = 2.
The SEP and BHR metrics are similar when restricted to 2 groups as
they both compare the survival of each risk group to the global survival
(yet only BHR is sensitive to the group ordering). When considering
a larger and arbitrary number k of groups, those metrics diﬀer more
strongly since the BHR introduces multiple new groups while SEP only
compares the survival in each (arbitrarily ordered) risk group to the
global survival.
The BHR can also be extended to continuous risk scores. Indeed,
the limit case consists in assigning one single patient to each risk group.
Each risk group would then be representative of a speciﬁc risk score and
those groups can be sorted accordingly. While this is a natural limit case,
it does not oﬀer speciﬁc advantages over the HR computed on those risk
scores. The purpose of introducing the BHR is to address the problems
of the original HR whenever continuous risk scores are discretized into
risk groups, as discussed in section 8.3.
8.7 Cut-oﬀ choice and risk group prediction
A relevant cut-oﬀ value is necessary to deﬁne risk groups from continuous
risk scores, as formalized in equation (8.3). The choice of a speciﬁc cut-
oﬀ is not always clearly motivated in the literature and sometimes not
even explicitly described. However, given its potentially critical eﬀect
1up to an arbitrary shift in group numbering.
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on the estimated quality of a prognostic model and its associated prog-
nostic markers, it looks important to use an appropriate methodology to
ﬁx cut-oﬀs. For instance, the original cut-oﬀ associated to the Gene76
prognostic index [143] has been chosen to achieve 100% of sensitivity
and the highest speciﬁcity on the training set (an undisclosed fraction of
the VDX dataset). Whether such choice is really optimal for the accu-
rate prognosis on independent samples requires an additional validation
as detailed below. In any case, even on the VDX dataset from which
the Gene76 model has been estimated, the dashed line on ﬁgure 8.7
illustrate that such cut-oﬀ is arguably sub-optimal. Besides, choosing
among all possible cut-oﬀs the one minimizing the associated p-value
underestimates such p-value due to the multiplicity of the test [2].
The BHR measure oﬀers a natural way to choose a relevant cut-oﬀ
and the associated risk groups. One typically considers a training and a
validation set. Such validation set can be made of independent samples
from the same study or, preferably, from an independent study on the
same medical question. Such a scheme can even be generalized to a cross-
validation protocol or while using several independent resamplings from
various related clinical studies. In any case, the training data should
typically be used to estimate the parameters of a prognostic model (i.e.
the identity of the prognostic markers and the way to combine their
values in a single risk score) as well as the cut-oﬀ on the risk scores.
In particular, unless there is some prior knowledge on the relative size
of each risk group, we recommend to choose the cut-oﬀ maximizing the
BHR on the training set.
We illustrate the proposed methodology with the Gene76 model
while changing its cut-oﬀ to maximize BHR on the VDX data from which
it was originally estimated. We compare the predictive performances ob-
tained on independent samples for various cut-oﬀ choices made on the
training data. The BHR cut-oﬀ precisely corresponds on the training
set (here the VDX data) to the risk group proportion deﬁned by the
red dot on ﬁgure 8.7. The original Gene76 cut-oﬀ is represented by the
dashed line while the cut-oﬀ optimizing HR is represented by a green
dot.
Figure 8.8 illustrates the impact of those 3 cut-oﬀ choices on indepen-
dent samples for breast cancer prognosis. Their predictive performances
were assessed in terms of BCR, hazard ratio, balanced hazard ratio, C-
index and logrank. We consider in particular the TBG [35] and UNT
[124] clinical studies as an independent validation set.
Figure 8.8(a) reports the survival curves of the risk groups resulting
from Gene76 with the cut-oﬀ optimizing BHR on the training. Such
choice leads to the best validation results. In contrast, choosing the cut-
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Figure 8.8: Prognostic performances on an independent validation set
(TBG and UNT datasets) according to various cut-oﬀ choices on the
training (VDX): largest BHR (a), largest HR (b), and the original
Gene76 cut-oﬀ (c).
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oﬀ to optimize the HR on the training leads to artiﬁcially unbalanced
groups both on the training and on the validation set (Figure 8.8(b))
and much degraded validation performances. Figure 8.8(c) reports the
validation results of the Gene76 model using its original cut-oﬀ. Those
results are sub-optimal as well and illustrate that the Gene76 model
could be made more eﬀective by our proposed methodology to deﬁne
risk groups. In particular the original cut-oﬀ leads to lower BHR, BCR,
SEP and logrank values, which are the 4 metrics not favoring artiﬁcially
unbalanced risk groups.
Figures 8.9 and 8.10 conﬁrm these results on the same breast can-
cer data with two other prognostic models, respectively Gene70 and
CoxTtest. Gene70 speciﬁcally refers to the model described in van ’t
Veer et al. [141]. CoxTtest is a multivariate Cox model built on the 100
most diﬀerentially expressed genes in the VDX dataset. For the estima-
tion of this gene signature, two conditions are deﬁned (event observed or
not before the critical time point). We chose here 5 years after treatment
as commonly accepted for breast cancer studies.
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Figure 8.9: Prognostic performances on an independent validation set
(TBG and UNT datasets) according to two cut-oﬀ choices on the train-
ing (VDX): largest BHR (a) and largest HR (b). Prognostic model:
Gene70.
The proposed methodology to ﬁx a cut-oﬀ maximizing BHR on the
training set is further validated with other prognosis models and other
cancer studies (on the supplementary materials of our paper [17]). In
all cases, those results illustrate the beneﬁts on independent validation
samples of considering BHR instead of HR for ﬁxing those cut-oﬀ values.
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Figure 8.10: Prognostic performances on an independent validation set
(TBG and UNT datasets) according to two cut-oﬀ choices on the train-
ing (VDX): largest BHR (a) and largest HR (b). Prognostic model:
CoxTtest.
This methodology is also assessed on controlled experiments described
in the next section.
8.8 Controlled experiments
The results presented in section 8.7 show that maximizing the BHR to
choose a cut-oﬀ on risk scores is a good approach to optimize prognosis
performances on new and independent samples. We further motivate
this approach in controlled experiments for which an underlying thresh-
old between risk groups is a priori ﬁxed according to a prescribed pro-
portion between a high or low risk proﬁle. We assess in particular to
which extent the proposed methodology is able to recover the appropri-
ate proportions between risk groups and hence the underlying cut-oﬀ to
be set on risk scores.
Synthetic data are generated for n patients separated into a low (gi =
−1) or high (gi = 1) risk group according to prescribed proportions,
ρ and 1 − ρ respectively. Survival data and risk scores (ti, δi, ri) are
randomly generated for each sample i ∈ [1, n]. The time to event tei of
patient i is drawn from a Weibull distribution and the censoring time
tci is drawn from an exponential distribution:
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tei ∼Weibull(λ1 exp(−
µgi
2k
), k) (8.9)
tci ∼ Exp(λ2) (8.10)
The scaling parameters λ1 = 0.002 and λ2 = 0.01 are ﬁxed according
to [108] from which these experiments are inspired. The shape parameter
k varies in [0.5, 1.5] in our experiments. Patient i is censored (δi = 0) if
his censoring time tci occurs before the time to event tei and the time ti
is simply deﬁned as the minimum between both times: ti = min (tei , tci).
The true hazard ratio between groups can be directly controlled using
this protocol since it is given by HR = exp(µ).
The risk score of a patient i is drawn from a Normal distribution
centered on gi, -1 or 1, respectively for low or high risk group. The
risk scores are then distributed according to a mixture of the two Nor-
mal distributions, according to the prescribed proportion ρ between risk
groups: ri ∼ ρN (−1, 0.5) + (1− ρ)N (1, 0.5). The underlying threshold
to be discovered is deﬁned as the ρ-percentile of this distribution. We
note that a perfect discrimination between risk groups could hardly be
obtained since risk scores overlap across risk groups, as expected in a
real scenario. Results are reported below over 500 independent runs of
such controlled experiments.
Figure 8.11 reports the hazard ratio (HR) and balanced hazard ratio
(BHR) computed while varying the cut-oﬀ used to deﬁne the risk groups.
Results are reported here for two prescribed proportions ρ = 50% or
ρ = 80% of the low risk proﬁle but the same conclusions can be drawn
from other ρ values. In particular, maximizing BHR leads to chose a
cut-oﬀ on risk scores which, when averaged over 500 runs, corresponds
to the correct underlying proportion between risk groups. In contrast,
maximizing HR may lead to an inappropriate cut-oﬀ choice favoring
strongly unbalanced groups.
Figure 8.12 oﬀers a closer look at the distribution over these 500 runs
of the proportions between risk groups for which BHR, respectively HR,
is maximum. The true proportion ρ in the low risk group was here ﬁxed
to 80%. The maximal BHR is clearly more concentrated around the
true underlying proportion while the maximum HR distribution is much
more dispersed and skewed towards an excessively large value. Similar
results are presented using the D-index and SEP metrics in appendix C.
Figure 8.13 generalizes the above analysis while changing the shape
parameter k of the Weibull distribution used to generate the survival
data. It illustrates that selecting a cut-oﬀ value while maximizing HR
would be even more inappropriate as k is increased to 1.5 (see, in par-
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Figure 8.11: Evolution of HR and BHR, averaged over 500 runs, while
varying the proportions in each risk group through adjusting the cut-oﬀ
on risk scores. The experiments are conducted with n = 200 patients,
the shape parameter k = 1 and the true group hazard ratio exp(µ) = 3.
The true proportion ρ of patients in the low risk group was set to 50%
(Figure 8.11 (a)) or 80% (Figure 8.11 (b)).
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Figure 8.12: Distribution over 500 runs of the low risk group proportion
for which BHR (a) respectively HR (b), is maximum. The experiments
are conducted with n = 200 patients, the shape parameter k = 1 and
the true group hazard ratio exp(µ) = 3. The true underlying proportion
of patients in the low risk group was set to 80%.
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ticular, Figure 8.13 (b)). In contrast, maximizing BHR remains an ap-
propriate methodology across various shape values.
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Figure 8.13: Evolution of HR and BHR, averaged over 500 runs, while
varying the proportions in each risk group through adjusting the cut-oﬀ
on risk scores. The experiments are conducted with n = 200 patients,
the true proportion ρ = 0.8 in the low risk group and the true group haz-
ard ratio exp(µ) = 3. The shape parameter k of the Weibull distribution
was set to 0.5 (a) or 1.5 (b).
Our ﬁnal experiments is considering a true group hazard ratio exp(µ)
equal to 1. In other words, the data is generated such that there is actu-
ally no survival diﬀerences between both groups. Figure 8.14 reports the
averaged BHR and HR values over 500 runs while changing the cut-oﬀ on
risk scores. The ﬂat BHR curve illustrates that no speciﬁc cut-oﬀ should
be chosen here and hence all patients should be assigned to a common
risk group. In contrast, when maximizing HR, a dichotomization into
highly unbalanced groups is again promoted.
8.9 Conclusion and perspectives
Properly assessing risk group prediction from survival data is essential
to analyze the relevance of candidate prognosis markers. We show here
that the group hazard ratio (HR) and the concordance index, often used
in such a context, can be inappropriately optimized by considering ar-
tiﬁcially unbalanced risk groups. They also exhibit many local optima
and non smooth behaviors which make their evaluation highly sensitive
to small ﬂuctuations. Alternative existing metrics include the logrank
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Figure 8.14: Evolution of HR and BHR, averaged over 500 runs, while
varying the proportions in each risk group through adjusting the cut-oﬀ
on risk scores. The experiments are conducted with n = 200 patients,
ρ = 0.5 and a true group hazard ratio exp(µ) equal to 1 (no survival
diﬀerence between groups). The shape parameter k of the Weibull dis-
tribution was set to 1 (a) or 1.5 (b).
statistics, the SEP metric and the average between sensitivity and speci-
ﬁcity, also called BCR. While the logrank is harder to interpret in terms
of survival diﬀerences between risk groups, the BCR is not fully adequate
to censored data and relies on an additional critical timepoint that is
highly dependent on the pathology. Moreover, the logrank and the SEP
are insensitive to a speciﬁc ordering of the risk groups. They measure
survival diﬀerences between risk groups but not the orientation of those
diﬀerences.
We present here the balanced hazard ratio (BHR) which has a simi-
lar interpretation as the original HR, arguably the most common metric
used by clinicians and bio-statisticians to assess risk groups. The BHR
penalizes extremely unbalanced risk groups and, more generally, oﬀers
a smoother proﬁle with a natural optimum. Its value is much less inﬂu-
enced by marginal changes in the proportions between risk groups and
its behaves consistently with its associated p-value.
We further show how the BHR may be generalized to an arbitrary
number of risk groups and how it can be used to choose an appropri-
ate cut-oﬀ on risk scores to deﬁne risk groups. Such a methodology
is both simple computationally and is shown to be sound in controlled
experiments as well as real clinical studies.
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Our future work includes the design of estimation algorithms for
prognosis models optimizing BHR directly. Currently, Cox hazards mod-
els are typically estimated to optimize the partial likelihood on the train-
ing data. It looks preferable to ﬁt parameters optimizing directly the
ﬁnal performance metric of the prognostic model. We have shown here
that optimizing the group hazard ratio would be largely inappropriate.
Fitting a model to optimize the BHR instead looks to be a promising
alternative.
The balanced hazard ratio could also be extended to competing risks.
Competing risks are modeled either through cause-speciﬁc hazards [101]
or cumulative incidence functions [49]. The other causes of events are
dealt with in such models either through censoring or as events occurring
at an inﬁnite time. Similarly to our proposal, a third global risk group
could be introduced in these models to penalize extremely unbalanced
risk groups.
An online tool and a R package are in development to make the
balanced hazard ratio available to any clinician or bio-statistician.
Chapter 9
Balanced Hazard Ratio p-value
9.1 Introduction
In this chapter, we detail how p-values can be computed respectively for
the hazard ratio (HR) and the balanced hazard ratio (BHR) [17] using
a score test statistic. Both HR and BHR are computed here accord-
ing to two risk groups deﬁned as gi = {−1, 1}. This deﬁnition of the
risk groups gives a consistent scaling between both measures with no
loss of generality. In such a setting we show that the BHR p-value is
conservative with respect to the HR p-value.
9.2 Hazard ratio
The group hazard ratio (HR) evaluates the diﬀerence between survival
curves computed by a Cox proportional hazards model. It represents the
increase in the risk of event between the low and high risk groups. When
used to evaluate risk groups, the hazard ratio is computed with a Cox
model using the binary group variable gi ∈ {−1, 1} as single covariate.
The hazard function hi(t) for a patient i is then written as:
hi(t) = h0(t) exp (βgi) (9.1)
Since gi equals −1 or 1 for the patients in respectively the low risk
or high risk group, the hazard of each risk group is given by:
hHigh(t) = h0(t) exp (β) (9.2)
hLow(t) = h0(t) exp (−β) (9.3)
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The hazard ratio HR is the ratio between the hazard of the two risk
groups.
HR =
hHigh(t)
hLow(t)
(9.4)
=
h0(t) exp (β)
h0(t) exp (−β) = exp (β)
2 (9.5)
With the proportional hazard assumptions [30], the baseline hazard
h0(t) vanishes in the estimation of the hazard ratio. The hazard ratio is
computed as the solution of ﬁtting a Cox model with only one covari-
ate gi and one parameter β. This parameter β maximizes the partial
likelihood of the Cox model:
L(β) =
�
i|δi=1
exp(βgi)�
k∈R(ti) exp(βgk)
(9.6)
L(β) =
n�
i=1
�
exp(βgi)�
k∈R(ti) exp(βgk)
�δi
(9.7)
where δi = 1 if patient i experienced the event (δi = 0, otherwise) and
R(ti) denotes the set of patients still at risk at time ti.
It is worth noting that this likelihood is only exact when there are no
ties in the event times. This simpliﬁcation, commonly used in survival
softwares, is a good approximationn when there are not too many tied
events, and is known as the Breslow approximation [21].
This likelihood (9.7) is known as the partial likelihood (partial in con-
strast to a full likelihood which takes into account the baseline hazard
function not considered here). The maximization of this partial like-
lihood gives an estimate βˆ of the Cox model parameter β. Cox shows
that maximum partial likelihood estimates are consistent and asymptot-
ically normal [31]. With an increasing number of patients, the estimates
converge and are asymptotically unbiased. In many realistic situations,
these estimators are also asymptotically fully eﬃcient [40]. This means
that with a suﬃcient number of patients, the variances of the estimates
will not be much larger than if we were using the full likelihood. The
estimate βˆ has most of the good properties of a maximum likelihood
estimator. Standard MLE inference methods can thus be used on the
maximum partial likelihood estimators of the Cox model [31].
In particular, the variance of βˆ is the inverse of the Fisher infor-
mation [32] and can be estimated through the second derivative of the
log-likelihood with respect to β estimated in βˆ:
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var(βˆ) ≈ −
�
d2logL(β)
dβ2
�−1�����
β=βˆ
(9.8)
9.2.1 Derivatives of the Cox partial log-likelihood
The likelihood of the Cox model is given by
L(β) =
n�
i=1
�
exp(βgi)�
k∈R(ti) exp(βgk)
�δi
(9.9)
The log-likelihood, its ﬁrst and second derivatives are given by
l(β) =
n�
i=1
δiβgi −
n�
i=1
δi log
 �
k∈R(ti)
exp(βgk)
 (9.10)
dl(β)
dβ
=
n�
i=1
δigi −
n�
i=1
δi
��
k∈R(ti) gk exp(βgk)
�
��
k∈R(ti) exp(βgk)
� (9.11)
d2l(β)
dβ2
= −
n�
i=1
δi

��
k∈R(ti) g
2
k exp(βgk)
���
k∈R(ti) exp(βgk)
�
−
��
k∈R(ti) gk exp(βgk)
�2
��
k∈R(ti) exp(βgk)
�2

(9.12)
The ﬁrst derivative is known as the eﬃcient score of β and is denoted
u(β) [28]. The negative of the second derivative of the log-likelihood
function is called the observed information function and is denoted i(β).
9.2.2 P-value of the hazard ratio
To compute the p-value of the hazard ratio, we can compute the score
test statistic:
{u(0)}2
i(0)
(9.13)
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This statistic has an asymptotic chi-squared distribution with 1 d.f.
under the null hypothesis that β = 0. The values u(0) and i(0) can be
computed from equations (9.11) and (9.12).
u(β) =
n�
i=1
δigi −
n�
i=1
δi
��
k∈R(ti) gk exp(βgk)
�
��
k∈R(ti) exp(βgk)
� (9.14)
u(0) =
n�
i=1
δigi −
n�
i=1
δi
��
k∈R(ti) gk
�
��
k∈R(ti) 1
� (9.15)
=
n�
i=1
δigi −
n�
i=1
δi
��
k∈R(ti) gk
�
|R(ti)| (9.16)
i(β) =
n�
i=1
δi

��
k∈R(ti) g
2
k exp(βgk)
���
k∈R(ti) exp(βgk)
�
−
��
k∈R(ti) gk exp(βgk)
�2
��
k∈R(ti) exp(βgk)
�2

(9.17)
i(0) =
n�
i=1
δi
��
k∈R(ti) g
2
k
���
k∈R(ti) 1
�
−
��
k∈R(ti) gk
�2
��
k∈R(ti) 1
�2 (9.18)
=
n�
i=1
δi
��
k∈R(ti) g
2
k
�
(|R(ti)|)−
��
k∈R(ti) gk
�2
|R(ti)|2 (9.19)
The score test statistic {u(0)}
2
i(0) is the logrank statistic when there is
no tied event and when two risk groups are deﬁned with gi ∈ {0, 1} [28].
9.3 Balanced hazard ratio
The balanced hazard ratio (BHR) computes the hazard ratio between
three curves: the survival curves of the high and low risk groups (as for
HR) and a third global survival curve over all patients. Each sample is
now considered as a member of 2 groups: its actual risk group (gi = −1,
for low risk, or gi = 1, for high risk) and the global risk group (gi = 0) for
all patients. Such a global risk group represents the hazard (or survival
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time) over the whole population of patients and one measures now how
much each speciﬁc risk group departs from the global curve. The hazard
function is now deﬁned over those 3 groups:
hi(t) = h0(t) exp (βgi),with gi = −1, 0, or 1 (9.20)
The quantity h0(t) represents here the hazard of the whole popula-
tion, h0(t)/ exp (β) the hazard of the low risk group and h0(t) exp (β)
the hazard of the high risk group. The balanced hazard ratio, BHR =
exp (β) is simply the multiplicative factor to get the hazard of the high
risk from the global hazard or from the low risk to the global one. The
hazard ratio between the hazard of the two risk groups (computed with
the balanced hazard ratio) is here:
hHigh(t)
hLow(t)
=
h0(t) exp (β)
h0(t) exp (−β) = exp (β)
2 = BHR2 (9.21)
However, note that if BHR2 has a similar interpretation, it is not
equal to the HR (as computed in section 9.2). Indeed, the β value is
found by ﬁtting a partial likelihood according to the 3 curves (see below).
The estimation βˆ of the β value from the balanced hazard ratio (see
equation (9.20)) is computed through the maximization of a partial like-
lihood, similarly to the original HR. For the BHR, the partial likelihood
is slightly modiﬁed to include the global survival without actually dupli-
cating the patients. The partial likelihood for the balanced hazard ratio
(with the standard Breslow approximation for ties [28]) is:
LBHR(β) =
n�
i=1
 exp(βgi)��
k∈R(ti) exp(βgk) + 1
�2

δi
(9.22)
We can compute the BHR log-likelihood and its derivatives similarly
to the HR log-likelihood.
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l(β) =
n�
i=1
δiβgi − 2
n�
i=1
δi log
 �
k∈R(ti)
exp(βgk) + 1
 (9.23)
dl(β)
dβ
=
n�
i=1
δigi − 2
n�
i=1
δi
��
k∈R(ti) gk exp(βgk)
�
��
k∈R(ti) exp(βgk) + 1
� (9.24)
d2l(β)
dβ2
= −2
n�
i=1
δi

��
k∈R(ti) g
2
k exp(βgk)
���
k∈R(ti) exp(βgk) + 1
�
−
��
k∈R(ti) gk exp(βgk)
�2
��
k∈R(ti) exp(βgk) + 1
�2

(9.25)
Using the same results as for the hazard ratio, the BHR estimate βˆ
has most of the good properties of a maximum likelihood estimator [31].
9.3.1 P-value of the balanced hazard ratio
Usually duplicating patients in a statistical test will decrease the p-value
of this test. In the BHR however, the whole set of patients is not truly
duplicated but is rather used as a form of normalization. To observe the
eﬀect of this normalization, we compute the score test statistic which
is used to compute the BHR p-value:
{u(0)}2
i(0)
(9.26)
This statistic has an asymptotic chi-squared distribution with 1 d.f.
under the null hypothesis that β = 0. The values u(0) and i(0) can be
computed from equations (9.24) and (9.25).
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u(β) =
n�
i=1
δigi − 2
n�
i=1
δi
��
k∈R(ti) gk exp(βgk)
�
��
k∈R(ti) exp(βgk) + 1
� (9.27)
u(0) =
n�
i=1
δigi − 2
n�
i=1
δi
��
k∈R(ti) gk
�
��
k∈R(ti) 2
� (9.28)
=
n�
i=1
δigi − 2
n�
i=1
δi
��
k∈R(ti) gk
�
2|R(ti)| (9.29)
=
n�
i=1
δigi −
n�
i=1
δi
��
k∈R(ti) gk
�
|R(ti)| (9.30)
We observe that u(0) computed with the BHR is equivalent to u(0)
computed with the hazard ratio (see section 9.2.2).
i(β) = 2
n�
i=1
δi

��
k∈R(ti) g
2
k exp(βgk)
���
k∈R(ti) exp(βgk) + 1
�
−
��
k∈R(ti) gk exp(βgk)
�2
��
k∈R(ti) exp(βgk) + 1
�2

(9.31)
i(0) = 2
n�
i=1
δi
��
k∈R(ti) g
2
k
���
k∈R(ti) 2
�
−
��
k∈R(ti) gk
�2
��
k∈R(ti) 2
�2 (9.32)
= 2
n�
i=1
δi
��
k∈R(ti) g
2
k
�
(2|R(ti)|)−
��
k∈R(ti) gk
�2
4|R(ti)|2 (9.33)
=
n�
i=1
δi
��
k∈R(ti) g
2
k
�
(|R(ti)|)− 12
��
k∈R(ti) gk
�2
|R(ti)|2 (9.34)
The value i(0) computed with the balanced hazard ratio is very sim-
ilar to the one computed with the hazard ratio (see section 9.2.2). The
only diﬀerence is the 12 factor which is present here. Since the value��
k∈R(ti) gk
�2
is positive, the ﬁsher (observed) information function
i(0) should be greater for the balanced hazard ratio. The BHR score
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test statistic {u(0)}
2
i(0) is thus smaller while having the same asymptotic
chi-squared distribution with 1 d.f., under the null hypothesis that β = 0.
The p-value computed with a balanced hazard ratio is thus conservative
with respect to a hazard ratio.
As the groups are deﬁned with gi ∈ {−1, 1}, we can further simplify
equation (9.34).
i(β) =
n�
i=1
δi
��
k∈R(ti) g
2
k
�
(|R(ti)|)− 12
��
k∈R(ti) gk
�2
|R(ti)|2 (9.35)
=
n�
i=1
δi
��
k∈R(ti) 1
�
(|R(ti)|)− 12
��
k∈R(ti) gk
�2
|R(ti)|2 (9.36)
=
n�
i=1
δi
|R(ti)|2 − 12
��
k∈R(ti) gk
�2
|R(ti)|2 (9.37)
We can observed that this additional factor (12) will have no impact
when the
�
k∈R(ti) gk are close to zero. Those values are close to zero
when the class are well balanced. This is consistent with the empirical
observation that HR and BHR tend to the same values in this special
case.
9.4 Conclusion
In chapter 8, we presented the balanced hazard ratio for risk groups
evaluation from survival data. This chapter shows that in the two risk
groups setting the BHR p-value is conservative with respect to the HR
p-value. Similarly as what was observed with the BHR and HR metrics,
their p-values are closer when the risk groups are well balanced. Our
futur works include extensions of these results to a number of risk groups
larger than 2.
Part III
Hypoxia Signatures for
Cancer Prognosis

Chapter 10
Hypoxia Signatures for Cancer
Prognosis
In this chapter, we investigated the use of hypoxia-related gene signa-
tures as prognostic biomarkers of cancer progression. In particular, we
developed two signatures from the transcriptomic analysis of tumor cell
lines exposed to cycling and continuous hypoxia, the CycHyp and Con-
tHyp signatures, respectively. Clinical data sets were then used to assess
their prognostic performance.
Unlike the rest of this machine learning thesis, this chapter is more
focused on biomedical ﬁndings than on methodological issues. This work
resulted from a collaboration between the teams of Olivier Feron and
Pierre Dupont, my two thesis supervisors.
This work was however the trigger for most methodological contri-
butions developed afterwards, such as the Coxlogit model and Balanced
hazard ratio. For the thesis, we actually re-analysed the results pre-
sented in our paper [15] in the light of the balanced hazard ratio (chap-
ter 8). Results previously reported in terms of hazard ratio, C-index and
BCR remained fully concordant with those obtained using the balanced
hazard ratio.
• Boidot, R., Branders, S., Helleputte, T., Rubio, L. I., Dupont, P.,
and Feron, O. (2014). A generic cycling hypoxia-derived prog-
nostic gene signature: application to breast cancer proﬁling. On-
cotarget , 5(16)
• Feron, O., Boidot, R., Branders, S., Dupont, P., and Helleputte,
T. (2015). Signature of cycling hypoxia and use thereof for the
prognosis of cancer. WO Patent App. PCT/EP2014/066,643
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10.1 Motivations
Hypoxia is nowadays described as a hallmark of tumors [115, 10]. Tu-
mor angiogenesis and glycolytic metabolism are two extensively studied
responses of cancer cells to a deﬁcit in oxygen [115]. The building of new
blood vessels to bring O2 and the respiration-independent metabolism
to survive under low O2 are actually complementary responses of tumors
to hypoxia [115, 10]. These somehow opposite modes of adaptation ac-
count for local and temporal heterogeneities in tumor O2 distribution.
The terms “intermittent hypoxia” or “cycling hypoxia” were settled to
describe this phenomenon of ﬂuctuating hypoxia in tumors [22, 39]. As
a corollary, the extent of cycling hypoxia reﬂects tumor plasticity and
thus measures the capacity of tumor cells to survive and proliferate in a
hostile environment [22].
Although the existence of cycles of hypoxia and/or ischemia was
demonstrated in mouse, canine and human tumors [38, 146], technolo-
gies aiming to routinely measure tumor O2 ﬂuctuations in the clinics are
not (yet) available despite important progresses in the in vivo imaging
of hypoxia [6, 5, 91, 26, 80]. In the absence of readily accessible moni-
toring strategies, the analysis of the transcriptome associated with this
phenomenon could represent a prognostic biomarker of cancer progres-
sion. Indeed, although mutations and defects in tumor suppressor genes
directly inﬂuence the whole genetic proﬁle of a given tumor cell clone,
cycling hypoxia could be envisioned as a supra-oncogenic phenomenon
inﬂuencing gene expression [22]. In other words, independently of the
genetic background of tumor cells, cycling hypoxia has the potential to
lead to common alterations in the expression of some transcripts, and
thus to a possible clinically exploitable signature.
Clinical data sets derived from breast cancer patients could be used
to evaluate the performance of such cycling hypoxia-related gene signa-
ture. The clinical and genetic heterogeneities of this disease and the very
large panel of data sets available represent indeed good opportunities to
evaluate new prognostic gene expression signatures [105]. Whole genome
analysis already provided several molecular classiﬁcations for breast can-
cer beyond standard clinicopathologic variables [105, 100, 141, 98, 123,
143, 125, 122, 85, 119]. The latter include tumor size, presence of lymph
node metastasis and histological grades [102] but also encompass three
predictive markers of response, namely expression of oestrogen (ER),
progesterone (PR) and HER2 receptors [105]. Treatment guidelines
are nowadays still largely based on algorithms integrating these infor-
mations such as the Notthingham Prognostic Index [102, 54] or Adju-
vant! Online [103]. Accordingly, for early-stage breast cancer, adjuvant
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chemotherapy is recommended for most patients with ER-negative or
HER2-positive tumors [100, 42, 41, 70]. The challenge actually resides
in selecting patients with ER-positive HER2-negative disease who could
beneﬁt from chemotherapy.
The aim of this study was:
• To extract a gene signature of cycling hypoxia, the CycHyp signa-
ture.
• To better understand the diﬀerences between cycling and contin-
uous hypoxia.
• To build a prognostic model with CycHyp in order to yield better
breast cancer prognostication, in particular for ER-positive HER2-
negative patients.
• To conﬁrm the link between hypoxia and cancer prognosis.
10.2 Materials and methods
The general protocol of this study, summarized in ﬁgure 10.1, can be
decomposed in three main parts.
First, twenty cell lines derived from various human tumors were ex-
posed to three controlled hypoxia conditions: normoxia, continuous hy-
poxia and cycling hypoxia. Section 10.2.1 presents the diﬀerent cell lines
used and how the three conditions where reproduced.
The transcriptome associated with these conditions was then anal-
ysed to identify two hypoxia-related gene signatures (section 10.2.2).
The CycHyp signature (resp. ContHyp) is formed with the most diﬀer-
entiated probesets (genes) between normoxia and cycling (resp. contin-
uous) hypoxia.
The sections 10.2.4 and 10.2.5 present respectively the data sets and
the construction of the models used to validated the signatures on public
breast cancer data sets.
10.2.1 Cell lines data
Twenty cell lines derived from various human tumors and character-
ized by a large variety of distinct genetic anomalies (see table A.1 in
appendix) were submitted to cycling hypoxia (CycHyp), i.e. 24 cycles
of 30 min incubation under normoxia and 30 min incubation under hy-
poxic (1% O2) conditions to reproduce tumor hypoxic ﬂuctuations, as
previously reported [38, 37]. At the end of some hypoxic periods (after
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Figure 10.1: General scheme of the study: from cell lines to signature
validation.
1, 2, 3 and 24 cycles), the induction of the transcription factor HIF-1α
was conﬁrmed by immunoblotting. Also, we veriﬁed that the HIF-1α
immunoblot signal was absent after 30 min incubation under normoxia
(post-hypoxia). These results validated that the imposed changes in
the atmospheric pO2 were sensed by the cells bathing in their culture
medium. We also considered control conditions of 24 h continuous expo-
sure of tumor cells to either 21% O2 (Normoxia) or 1% O2 (ContHyp).
For each culture condition, cells were immediately snap-frozen at the end
of the last incubation period. mRNA extracts from each tumor cell cul-
tured under the three above conditions (normoxia, cycling hypoxia and
continuous hypoxia) were analysed by hybridization on Human Gene 1.0
ST Aﬀymetrix microarrays (GEO access number: GSE42416).
10.2.2 Identiﬁcation of the CycHyp signature
Gene expression proﬁles of each cell type under normoxia, continuous hy-
poxia and cycling hypoxia were produced to identify two gene signatures:
CycHyp and ConHyp. The CycHyp signature is made of diﬀerentially
expressed genes between cycling hypoxia and normoxia. The ContHyp
10.2. Materials and methods 133
signature is made of diﬀerentially expressed genes between continuous
hypoxia and normoxia.
A preﬁltering is performed ﬁrst to remove non-annotated and control
probesets. This preprocessing step simpliﬁes the signature interpretation
and the signature transfer to other aﬀymetrix microarray platforms.
The methodology used to identify the signatures is an ensemble fea-
ture selection similar to [1]. It relies on a resampling mechanism to
repetitively look at the data from complementary viewpoints and to
build a signature robust to small data perturbations. For every resam-
pling experiment, a subset of 90% of the samples is chosen uniformly
at random without replacement and forms a training set. Diﬀerentially
expressed probesets are assessed on each subset according to a paired
t-test to discriminate between both conditions. FDR corrected p-values
are reported. The top 100 probesets with the smallest corrected p-values
averaged over 200 resamplings form the ﬁnal signature.
The t-test was chosen as it is both simple and computationally eﬃ-
cient. More complex alternatives exist such as SAM [135] and limma [118].
They are both moderated t-statistics similar to the t-test except that the
variance is moderated across genes. However, the three methods have
very similar results in terms of gene lists produced [74, 73]. Moreover,
we use the methodology proposed by Boulesteix et al. [16] to conﬁrm
that the t-test rankings are not aﬀected by outliers or extreme values
(see appendix A.2).
For each resampling experiment, the 10 % remaining data form a
small independent test set used to estimate the discrimination capability
between both conditions. More speciﬁcally, a linear SVM (presented
in section 3.2.2) is estimated using the 100 probesets with the lowest
p-values on the 90 % training and its classiﬁcation accuracy between
normoxia and cycling (resp. continuous) hypoxia is evaluated on the
validation set. The average accuracy is reported over 200 resamplings.
This evaluation protocol is summarized hereafter.
1. Remove non-annotated and control probesets
2. Repeat 200 times :
(a) Random sampling of the data (20 samples in each condition):
90% train, 10% test
(b) For each probeset, compute an FDR corrected p-value from
a paired t-test (on train)
(c) Estimate on train a linear SVM using the 100 probesets with
lowest p-values
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(d) Compute the SVM classiﬁcation accuracy on the test
3. Average the FDR corrected p-values and accuracy over the 200
resamplings
The 100 probesets with the lowest p-values, averaged over 200 resam-
plings, formed the ﬁnal CycHyp (resp. ContHyp) signature discriminat-
ing between normoxia and cycling (resp. continuous) hypoxia. These
two signatures are reported in table A.2 and table A.4.
We use this resampling mechanism to produced robust gene signa-
tures and to have estimates of their predictive power. Doing so, we avoid
an optimistic selection bias that would result from considering the same
data to identify signatures and to estimate their predictive power. Yet,
those results do not represent the predictive power of the CycHyp and
ContHyp signatures themselves. Indeed, those signatures are eventually
estimated by averaging results over all resamplings, leaving no indepen-
dent cell lines data to assess their predictive performances. We do not
consider this to be problematic since the predictive power of those signa-
tures is evaluated anyway on a much harder task and independent data:
a risk group prognosis from human breast cancer samples.
10.2.3 Transfer of the signatures across microarray tech-
nologies
The CycHyp and ContHyp signatures were identiﬁed on cell lines using
the Aﬀymetrix HGU1.0ST microarray technology (see sections 10.2.1
and 10.2.2). Assessing the prognostic value of those signatures on pub-
licly available breast cancer data requires to transfer those signatures to
a former generation of Aﬀymetrix chips.
The CycHyp and ContHyp signatures were transferred from the
Aﬀymetrix HGU1.0ST to HGU133a using the ENTREZ gene id. The
CycHyp (and ContHyp) HGU133a signature is deﬁned as all HGU133a
probesets with an ENTREZ gene id present in the original HGU1.0ST
signature of 100 probesets. The HGU133a CyHyp signature contains
87 probesets (123 for ContHyp). These two signatures are presented in
tables A.3 and A.5.
10.2.4 Breast data sets
Table 10.1 presents the 9 data sets of primary breast cancer used to
estimate the prognostic potential of the CycHyp and the ContHyp sig-
natures.
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Data set Technology Nb patients source GEO
1 VDX [143, 95] HGU133a 344 GSE2034 GSE5327
2 TBG [35] HGU133a 198 GSE7390
3 UNT [124] HGU133a 189 GSE2990
4 MAINZ [113] HGU133a 200 GSE11121
5 UPP [94] HGU133a 251 GSE3494
6 LUM [87] HGU133plus2 414 GSE6532
7 BRC [76] HGU133plus2 327 GSE20685
8 IPC [111] HGU133plus2 266 GSE21653
9 MDA5 [130] HGU133plus2 298 GSE17705
Table 10.1: Primary breast cancer data sets used here.
All breast cancer expression data were summarized with MAS5 and
represented in log2 scale (except for GSE6532 already summarized with
RMA). The HGU133plus2 data sets were reduced to their HGU133a
probesets. Three breast cancer subtypes (ER+/HER2-, ER-/HER2-
and HER2+) were identiﬁed with the genefu R package [61]. Disease-free
survival was used as the survival endpoint. The data from all patients
were censored at 10 years to have comparable follow-up times across
clinical studies [60].
10.2.5 Prognostic model construction
The CycHyp model was estimated on the VDX data set (on the ER+/-
HER2-, node-negative and untreated population) and assessed on the 8
remaining datasets listed in the table 10.1. We used the VDX dataset
as training because of its large number of node negative untreated pa-
tients. Each data set is reduced to the population of interest and then
normalized (scaled and centered) separately (z score). A risk score for
each patient was computed from a penalized Cox proportional hazards
model (see section 3.3.1) implemented in the Penalized R package [55].
The parameters of the elastic net penalty were learned on the training
set by cross-validation. The ﬁnal L1 and L2 penalties are ﬁxed to 10
and 16, respectively.
To have comparable risk scores accross the data sets, the CycHyp
score was scaled per data set such that the 2.5% and 97.5% percentiles
are set to -1 and 1 respectively. This scaling, used in [61], is robust to
outliers.
A threshold on the risk scores is used to classify patients between
high and low risk groups. This threshold is computed from the ROC
curves (time dependent ROC curves at 5 years) to maximize the average
between sensitivity and speciﬁcity. This average is also named balanced
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classiﬁcation rate (BCR) (see section 4.2.5).
The very same CycHyp model was used to predict the clinical out-
come on the validation sets (8 datasets) while considering various sub-
populations of interest (all patients or the ER+/HER-, node- and ER+/-
HER- population). This procedure has the beneﬁt to compare the pre-
diction capabilities of always the same model for various populations
of patients. Additional experiments (not detailed) showed that results
are essentially unchanged if one estimates on VDX a diﬀerent model for
each population of interest.
10.3 Results
10.3.1 The CycHyp signature
The CycHyp and ContHyp signatures were identiﬁed using a resampling
protocol described in section 10.2.2. The 100 probesets with the lowest
p-values, averaged over 200 resamplings, formed the ﬁnal CycHyp (resp.
ContHyp) signature discriminating between normoxia and cycling (resp.
continuous) hypoxia. These two signatures are reported in table A.2 and
table A.4.
The resampling protocol used in the feature selection allows us to
compute an estimate of the predictive performance of the CycHyp sig-
nature. The accuracy to classify independent samples is on average
97.46% for cycling hypoxia versus Normoxia and 94.33% for continuous
hypoxia versus normoxia. The heatmaps made with the 100 probe sets of
the CycHyp signature conﬁrmed its excellent potential of discrimination
between cycling hypoxia and either normoxia (ﬁgure 10.2) or continu-
ous hypoxia (ﬁgure 10.3). Each row in the heatmaps corresponds to
a particular cell line in either normoxia, cycling hypoxia or continuous
hypoxia. These cell lines are identiﬁed by a number from 1 to 20. The
numbers can be used to access more information about each cell lines in
table A.1 in appendix. Similar results are obtained with the ContHyp
signature (heatmaps A.4 and A.5 in appendix).
Moreover, Gene Set Enrichment Analysis (GSEA) [129] indicated
that when considering diﬀerentially expressed probesets (after FDR cor-
rection), only 2 gene sets were signiﬁcantly enriched in the CycHyp sig-
nature (table A.6) whereas we identiﬁed 52 gene sets enriched in the
ContHyp signature, including 17 directly related to hypoxia (table A.7).
Also, when using the MSigDB molecular signature database refer-
ring to hypoxia or HIF (www.broadinstitute.org), we found 13 hypoxia
gene sets sharing, on average, only 1.4 gene with CycHyp (table A.8 in
appendix) whereas 44 hypoxia gene sets showed overlap with ContHyp
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Figure 10.2: Heatmap depicting the transcripts from the CycHyp sig-
nature either underexpressed (light blue) or overexpressed (dark blue)
(centered to median values). Each column corresponds to a speciﬁc hu-
man Gene 1.0 ST probeset ; each line represents a speciﬁc cell line either
maintained under normoxia (green) or exposed to cycling hypoxia (pur-
ple). The numbers (from 1 to 20) can be used to access information
about speciﬁc cell lines in table A.1 in appendix.
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Figure 10.3: Heatmap depicting the transcripts from the CycHyp sig-
nature either underexpressed (light blue) or overexpressed (dark blue)
(centered to median values). Each column corresponds to a speciﬁc
human Gene 1.0 ST probeset ; each line represents a speciﬁc cell line ei-
ther maintained under normoxia (green), exposed to continuous hypoxia
(blue) or exposed to cycling hypoxia (purple). The numbers (from 1 to
20) can be used to access information about speciﬁc cell lines in table A.1
in appendix.
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with an average of 6.6 (1-27) common genes (table A.9 in appendix).
We also compared the CycHyp signature to 13 other hypoxia-derived
signatures described by Seigneuric et al. [114] and Starmans et al. [126].
The CycHyp signature was again far from those signatures with an aver-
age of only 1 gene in common. The overlap was larger between ContHyp
and those signatures with an average of 6 genes in common (table A.10
in appendix).
Finally, using TFactS [43] to analyse transcription factors regulating
expression of genes associated to either signature, HIF-1α was only found
as positively associated with the ContHyp signature.
10.3.2 Validation on breast cancer data
To evaluate the prognostic value of the CycHyp signature, we focused
on breast cancer because of the very large amounts of well-annotated
clinical data sets available and a clearly identiﬁed need to discriminate
between patients at low and high risks among subgroups determined
on the basis of clinicopathologic criteria [105, 100]. Publicly available
GEO data sets allowed us to collect information on the survival of 2,150
patients with primary breast cancer (see section 10.2.4).
In order to exploit these data sets, we ﬁrst transferred the Gene
1.0ST datasets in the HU133 platform (see section 10.2.3). We then used
the VDX dataset (GSE2034 and GSE5327) as a reference because of its
large number of node negative untreated patients [143]. This training
dataset was used to estimate a prognostic multivariate Cox proportional
hazard model built on the CycHyp signature (see section 10.2.5 for de-
tails). The other eight datasets (table 10.1) were used according to the
methodology described by Haibe-Kains and colleagues [60], to assess the
prognostic performance of the CycHyp signature on independent sam-
ples.
The prognostic performance are reported here in balanced hazard
ratio (see chapter 8). The balanced hazard ratio (BHR) is very similar
to the hazard ratio but with better properties. With two risk groups,
the BHR compare the hazard of the global population of patients with
the hazard of each risk groups. It computes the multiplicative increase
(resp. decrease) of hazard for the patients at high risk (resp. low risk)
with respect to the average hazard of the patients. For the readers
unfamiliar with this metric, the squared balanced hazard ratio (BHR2)
has the same scale and can be compared to a standard hazard ratio.
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The CycHyp signature predicts clinical outcome in breast can-
cer patients
The prognostic potential of the CycHyp signature to discriminate be-
tween patients at low or high risk was conﬁrmed with a balanced hazard
ratio of 1.53 and a p-value=1.26e-18 whathever the treatment and the
tumor histology (ﬁgure 10.4(a)). We then focused on the ER+/HER2-
population which is known to be heterogeneous and thus diﬃcult to
treat [105, 100]. The discriminating capacity of the CycHyp signa-
ture remained strikingly high in the ER+/HER2- patient populations
(BHR=1.56, p-value=4.84e-13, ﬁgure 10.4(b)). Finally, among this sub-
population of patients, we considered those with a node negative status
(ﬁgure 10.4(c)) and among the latter, those who did not receive any
treatment (ﬁgure 10.4(d)). Balanced hazard ratios rose to 1.76 and 2.22
in these conditions (p-values=3.88e-9 and 9.01e-10, respectively), fur-
ther supporting the discriminating potential of the CycHyp signature.
In particular, the data presented in ﬁgure 10.4(d) allowed to exclude any
confounding inﬂuence of the potential beneﬁt arising from the treatment
administered to these patients and thus clearly identiﬁed a population of
patients who remained inadequately untreated. Other subpopulations
of patients were considered in appendix A.8.
Using the same methodology, we examined the prognostic capac-
ity of the ContHyp signature (discriminating between normoxia and
continuous hypoxia). The performance of the ContHyp signature was
satisfactory on the ER+/HER2- untreated population (BHR=1.61, p-
value=1.93e-4, see ﬁgure 10.5(a)) but was signiﬁcantly lower (p-value=
0.012, see ﬁgure 10.6) than the CycHyp signature.
The CycHyp signature provides signiﬁcant additional prognos-
tic information to available multigene assays
To evaluate the performance of the CycHyp signature, we compared it
with other well-established prognostic multigene assays for breast can-
cer, namely Gene70 or Mammaprint [141], Gene76 [143] and Oncotype
Dx [98]. Using the same set of ER+ HER2- node-negative untreated
patients as used in ﬁgure 10.4(d), we could determine the low vs. high
risk patient stratiﬁcation according to these signatures (prognostic mod-
els). The superior prognostic potential of the CycHyp signature could
be captured from the Kaplan Meier curves obtained with the Gene 70,
Gene76 and Oncotype DX signatures (compare ﬁgure 10.5 with ﬁg-
ure 10.4(d)). Balanced hazard ratios conﬁrmed the net advantage of
the CycHyp signature with a signiﬁcantly higher value than the three
other metagenes (ﬁgure 10.6). Similar results are reported in terms of
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Figure 10.4: Kaplan-Meier survival curves of patients with primary
breast cancer, as determined by using the CycHyp signature.
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hazard ratio, concordance index and BCR in our paper [15]. The sensi-
tivity and speciﬁcity to discriminate between patients with progressing
disease vs. disease-free at 5 years are reported in ﬁgure 10.6. The sen-
sitivity of the CycHyp signature was above 80% and the speciﬁcity was
well above the level of the three multigene assays.
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Figure 10.5: Kaplan-Meier survival curves of node-negative, untreated
ER+/HER2- patients, as determined by using the ContHyp signature,
Gene 70 (Mammaprint), Gene 76 and Oncotype Dx models.
Importantly, to further validate the prognostic signiﬁcance of the
CycHyp signature, a comparison with random gene signatures was per-
formed according to the methodology described by Venet et al. [142]
and Beck et al. [7]. For a fare comparison, the random signature had
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Figure 10.6: Comparison of the prognostic potential of the CycHyp
signature vs. ContHyp signature, Gene 70 (Mammaprint), Gene 76 and
Oncotype Dx models.
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the same size as the CycHyp and ContHyp signatures (resp. 87 and 123
probe sets). The data sets and the methodology were also the same as
presented in section 10.2.5. Figure 10.7 shows the distribution of the
p-values (logrank test in log 10) for 1000 randomly generated signatures
together with the p-values of the CycHyp and ContHyp signatures rep-
resented with the two red dots. The discrimination between risk groups
was signiﬁcantly higher (p-value < 0.001) with the CycHyp signature
as compared to each of the random signatures whereas the ContHyp
signature was not signiﬁcantly better (vs. random ones; P=0.141).
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Figure 10.7: Graph represents the power of discrimination in high vs.
low risk groups (expressed as the logarithm of the p-values of the lo-
grank) of the ContHyp and CycHyp signatures (see red dots) versus
1,000 randomly generated signatures (yellow shapes depicting their dis-
tribution).
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The CycHyp signature in association with NPI oﬀers a power-
ful prognostic tool
We then aimed to determine whether the CycHyp signature could im-
prove the Nottingham Prognostic Index (NPI) for better predicting
the survival of operable breast cancers. The NPI algorithm combines
nodal status, tumour size and histological grade and allows to model
a continuum of clinical aggressiveness with 3 subsets of patients di-
vided into good, moderate, and poor prognostic groups with 15-year
survival [102, 54, 41]. Since very few patients were assigned a poor
index, we merged here the moderate and poor indices into a high risk
group to facilitate the comparison with the CycHyp signature. We found
that by integrating the CycHyp signature, an important proportion of
patients could be reclassiﬁed to another risk group (ﬁgure 10.8). 44.1%
of patients classiﬁed at high risk using the NPI algorithm were identiﬁed
at low risk when using the CycHyp signature and were conﬁrmed to be
“false positive” since they actually exhibited a proﬁle of survival closer
to the low risk NPI patient (ﬁgure 10.8(a), BHR=1.3, p-value=0.20).
Inversely, using the CycHyp signature, we also identiﬁed in the patients
at low risk based on the NPI criteria, 33.1% of patients with a risk proﬁle
closer to the patients with a negative outcome (ﬁgure 10.8(b), BHR=1.1,
p-value=0.51). This increased discriminating potential remained highly
relevant when considering all patients or patients with a ER+ HER2-
status (and among the latter, those with a node negative status or the
untreated ones) (see section A.9 in appendix). In appendix A.10, we
also assess the performances of the CycHyp signature in each of the six
NPI subgroups deﬁned by Blamey et al. [13].
10.4 Conclusion and perspectives
This study demonstrates that a gene signature derived from the tran-
scriptomic adaptation of tumor cells to cycling hypoxia is prognostic
of breast cancer. The CycHyp signature that we have identiﬁed and
validated in this study has not only prognostic value independently of
molecular risk factors but also provides signiﬁcant additional prognos-
tic information to clinicopathologic criteria. Clinical outcome of breast
cancer patients is nowadays largely based on histological grade and the
status of ER, PR, and HER2 receptors [105, 100, 102]. In early breast
cancer, a lack of expression of ER (and PR) will almost systematically
lead to the administration of adjuvant chemotherapy in addition to lo-
coregional treatment [105, 42, 41]. Also, for patients with a tumor ex-
pressing HER2, chemotherapy and/or trastuzumab represents the option
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Figure 10.8: Kaplan-Meier survival curves of node-negative, untreated
ER+/HER2- patients stratiﬁed by using the CycHyp signature to detect:
(a.) false positive patients among those identiﬁed at high risk based on
the NPI nomenclature and (b.) false negative patients among those
identiﬁed at low risk based on the NPI nomenclature.
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the most likely to be beneﬁcial based on current clinical knowledge [105].
The impact of chemotherapy is actually more diﬃcult to anticipate for
the rest of early-stage breast cancer patients, i.e. those diagnosed with
a ER-positive and HER2-negative disease. These patients represent in-
deed a wide spectrum of diﬀerent risk proﬁles: for women with high-risk
disease, if chemotherapy is appropriate, others will derive little beneﬁt
from it. Our study therefore represents a signiﬁcant advance for this
population of patients, which consists of two third of all breast cancers.
We have indeed demonstrated that the CycHyp signature outperforms
the existing major prognostic gene expression signatures and oﬀers a
unique decision making tool to complement the discrimination of breast
cancer patients based on anatomopathologic evaluation.
More generally, the excellent prognostic value of CycHyp conﬁrms
the link between cycling hypoxia and cancer aggressiveness [39, 38]. This
gives credentials to the phenotypic adaptation of tumors resulting from
heterogeneities in blood ﬂow distribution as a trigger of cancer progres-
sion [22, 39]. Also, with the recent impetus in the understanding of
tumor metabolism [79, 47], it has become obvious that the capacity of
a given tumor cell to survive in both aerobic and anaerobic environ-
ments represents a critical advantage [145, 121, 14]. Interestingly, our
study also documents the higher prognostic value of a transcriptomic
signature derived from cycling hypoxia vs. continuous hypoxia. This
conﬁrms that although hypoxia is a frequent feature of poor-prognosis
tumors and was reported to drive gene signature associated with negative
outcome [25, 144, 23, 45], prognostic markers integrating ﬂuctuations in
the hypoxic status of tumors (this study) introduce an additional layer
of complexity that better ﬁts the in vivo situation.
Whether the CycHyp signature encompasses genes that actively drive
cancer progression or reﬂects a context of metabolic and hypoxic stress
favorable to increased mutagenesis and genetic instability [22], warrants
further studies. A few hints can however be gleaned from the comparison
of the diﬀerent signatures.
First, the comparison of the CycHyp and ContHyp signatures indi-
cates that the cycling nature of hypoxia leads to speciﬁc alterations in
mRNA expression since only 11 common transcripts were found in the
two gene lists (see symbols � in table A.2). Furthermore, among these 11
genes, most encode for proteins involved in housekeeping functions such
as chromatin packaging (HIST1H 1C, 2AC, 4A and 4C) and RNA pro-
cessing (RPS13 and 28). The only gene common to the two signatures
with a known function related to hypoxia is RBX1 or E3 ubiquitin ligase
which mediates the ubiquitination and subsequent proteasomal degra-
dation of target proteins [92], including the misfolded proteins known to
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accumulate under low pO2. Besides the RBX1 gene, the CycHyp signa-
ture does not actually contain genes known to be consistently regulated
in response to chronic hypoxia. By contrast, the ContHyp signature
contains 14 genes already reported to be overexpressed under low pO2
and even directly under the control of the transcription factor HIF-
1α, including those coding for glucose metabolism enzymes (ALDOA,
PFKB3, PFKB4, PGK1, PGAM1, GPI) and the angiogenic growth fac-
tor VEGFA. This HIF-dependent gene expression program of the Cont-
Hyp signature was actually conﬁrmed in the GSEA and MSigBD analy-
ses and was consistent with previously reported hypoxia-driven gene sig-
natures [25, 23, 45]. More generally, these ﬁndings position the CycHyp
signature far from the conventional hypoxia-derived signatures [114, 126]
but instead as a biomarker of a distinct tumor biology process involving
adaptation to ﬂuctuations in the tumor microenvironment.
Second, a large amount of transcripts of the CycHyp signature en-
code for proteins themselves involved in the regulation of transcription.
Data mining revealed that more than 18 transcripts of the CycHyp sig-
nature are transcription factors/regulators and 13 others are directly
involved in RNA processing (see symbols ∗ and § in table A.2 respec-
tively). This represents one third of the genes comprising the CycHyp
signature and reﬂects a major diﬀerence with the ContHyp signature.
While hypoxia is usually associated with cell cycle arrest and mTOR
inhibition, cycling hypoxia may be compatible with a maintained pro-
liferation potential. This is further supported by the suppression of
geroconversion (ie, the process leading from proliferative arrest to irre-
versible senescence) observed in response to hypoxia [81, 82] that oﬀers
tumor cells the opportunity to re-enter cell cycle when O2 is again avail-
able. Further studies are needed to compare the evolution of mTOR
activity and mTOR-dependent genes (including those encoding for ri-
bosomal proteins) during cycling and continuous hypoxia.
Finally, the in vitro conditions at the origin of the establishment of
the CycHyp signature may actually have speciﬁc bearing on its robust-
ness and applicability. Indeed, we previously documented that ﬂuctu-
ating oxygen levels could also directly impact endothelial cells within a
tumor [90, 33] indicating that non-tumor cells may also contribute to
the same transcriptomic adaptation as tumor cells, thereby reinforcing
the relevance of the CycHyp signature. Also, although we have used the
CycHyp signature as a prognostic biomarker for early-stage breast can-
cer, this signature was identiﬁed by integrating the information arising
from tumor cells of various origins and characterized by various onco-
genic alterations; the prognostic value of the CycHyp signature in other
cancers is currently under investigation in our laboratory.
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Altogether, the above ﬁndings indicate that the CycHyp signature
represents a new generation of prognostic biomarker reﬂecting a generic
environmental condition in tumors that diﬀers from the conventional
view of a static, continuous hypoxia occurring in tumors. When applied
to breast cancer, the CycHyp signature has a powerful prognostic value
independently of molecular risk factors but also oﬀers a unique deci-
sion making tool to complement the discrimination of patients based
on anatomopathologic evaluation. The CycHyp signature is distinct
from conventional hypoxia-related gene signature but also from existing
prognostic metagenes, and the rationale behind its discovery supports a
potential broad applicability to evaluate cancer patient outcomes.

Part IV
Conclusions and
Perspectives

Chapter 11
Conclusion
In this thesis, we focus on prognostic models of cancer progression. We
investigate most steps in the creation of new models from the feature
selection and the construction of models to the validation of their prog-
nostic potential.
A particular attention was given to the prediction of risk groups
through the development of the Coxlogit model and the balanced haz-
ard ratio, respectively presented in chapters 6 and 8. We focus on this
aspect of the survival analysis as it is too often overlooked. If the survival
analysis is usually viewed as a regression problem (e.g. the prediction of
a continuous risk score) and can be eﬃciently tackled as such, the true
ﬁnality of the survival prediction and prognostic models is to make de-
cisions. For example, clinicians are routinely required to decide whether
a speciﬁc treatment should be considered for a given patient. Such deci-
sion is precisely based on the assignment of this patient to a particular
risk group, which is a classiﬁcation task. Moreover, the challenges of risk
group prediction should be tackled as most survival results are reported
as such in the medical literature.
11.1 Future works and perspectives
This section presents some perspective and future works that could be
done to further improve prognostic models and their validation. Firstly,
we list some direct extensions to the models and methods presented in
this thesis. We then discuss two important aspects in the estimation
of prognostic models: the choice of hyper-parameters and the hetero-
geneity of cancer. These two points are a personal thought on some
methodological problems that still need to be addressed. Why they are
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problematic and how addressing them could improve prognostic models
in cancer research.
• In this thesis, we proposed the balanced hazard ratio to evaluate
survival risk groups. While having a similar interpretation as the
original hazard ratio, the BHR penalizes extremely unbalanced
risk groups and is much more appropriate to compare predicted
risk groups. An online tool and a R package are in development
to make the balanced hazard ratio available to any clinician or
bio-statistician.
• A Cox model in combination with random non-linear projections
can be used to predict the survival of patients from non-linear
data. This approach, which is both simple and computationally
eﬃcient, could be extended to perform feature selection. Such a
non-linear feature selection could be performed while comparing
the model parameters and random projections, selecting features
with high weight in important projections.
• We have shown the interest of combining two supervisions (risk
group labels and survival times) in the Coxlogit model to improve
the feature selection and the predictive performances. However,
the Coxlogit model is limited to binary risk groups predictions. In
many situations, three or more ordered risk groups are available
for example the TNM stages that are available in many cancers.
To deal with a number of groups larger than 2, we could replace
the logistic part of the model by an ordered logistic model.
• If the Coxlogit model could easily be extended to other combina-
tions of generalized linear models, the most promising perspective
is its use in transfer learning. One Coxlogit model could indeed
be use to link two datasets (or more) without a full or even a par-
tial overlap, e.g. one dataset with the survival of some patients
and an other with the class labels of other patients. Having a
unique model will enforce a consistency between the two tasks in
the selection of jointly predictive genes.
• In chapter 8, we discuss the use of the balanced hazard ratio to
select a cutoﬀ on risk scores. This cutoﬀ is then used to predict
the risk groups. In chapter 6, we used external labels (such as the
tumor grade, etc) to improve the risk group prediction. Within the
Coxlogit model, an implicit cutoﬀ is selected and could be compare
to the one selected be the BHR.
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11.1.1 Hyper-parameter and cross-validation
Through this thesis, I observed the diﬃculties of tuning hyper-parameters
through internal cross-validations. Examples of hyper-parameters are
the L1 and L2 regularization parameters (see section 3.1.1) but could
also be the size of the gene signature, etc. We perform internal cross-
validations (cross validations inside the training set) to estimate the
eﬀects of each hyper-parameter. This procedure allows us to select a set
of hyper-parameters that will be used to train the model on the whole
training set. We rely on cross-validation to avoid any optimistic bias on
the ﬁnal performance estimated on the validation set (or on the external
cross-validation). Indeed, tuning the parameters to maximize directly
the performance on the validation set will overestimate the performances
of the model [4].
However, if this cross-validation is needed and important, I observed
that it is not a very eﬀective way to tune hyper-parameters. The distri-
bution of the selected parameters is often not far from a uniform random
distribution. This variability in the hyper-parameters tend to increase
the variance of the ﬁnal reported performances. It could also lead to the
selection of hyper-parameters that are outside the acceptable range, e.g.
a too strong L1 regularization which gives a null model.
This observation is particularly true in our domain where the number
of samples is very low. This small number of samples is even more re-
duced while tuning the hyper-parameters in an internal cross-validation.
The amount of available samples can be problematic to build a model
but also to estimate its performance: How can we reliably estimate a
hazard ratio (or a balanced hazard ratio) on 10 samples? We can even
show that the balanced classiﬁcation rate (section 4.1.3) converge to the
accuracy (section 4.1.1) when estimated in cross-validation with a small
number of samples.
Even if we could have done a proper assessment of the performances
of each parameter, we are often at the beginning of the learning curve
where a prognostic model changes the most with the number of samples.
The optimal set of parameters on 90% of the training data may not be
the right one on the full training set. Examples of learning curves are
presented in section 6.3.3 on breast cancer data. In these examples, the
learning curves are particularly steep with less than 200 samples and still
growing with more than 400 samples. In practice, a dataset including
200 samples is often much more than what is actually available.
The diﬃculties in tuning the hyper-parameters are problematic for
the robustness of the prognostics model and the stability of the reported
results. They can also have an impact on the stability of the feature
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selection when sparse models are used. Avoiding these instabilities is
particularly important in the context of cancer research where it could
reduce the conﬁdence of clinicians in the proposed prognostic models
and the selected features.
Instabilities in prognostic models and their associated results are also
problematic when we want to compare diﬀerent prognostic models. The
negative bias and the increased variance may not give a correct idea of
the true performance of a each model. We could totally argue that the
diﬃculties of ﬁnding the best hyper-parameters are part of the model
performances. A model with very complex hyper-parameters to tune is
not a good model. Models simpler to tune or with less hyper-parameters
are thus better. We used this argument in chapter 7 in favor of random
non-linear projections for survival analysis.
However, this argument does not hold when the performance of a
prognostic model is used to assess the prognostic potential of a gene
signature (see section 5.3). In such cases, we are not interested by the
general performances of a model or its diﬃculties to be tuned. To be
extreme, we just want a good black box to test the links between a
signature and survival predictions. A black box that should also have
stable results to produce fair comparisons between signatures.
I think that assessing the quality of the hyper-parameters selection
and improving it could improve the robustness of models and the sta-
bility of their results. It can also simplify their comparison and improve
the validation of gene signatures.
Some works have already been done in automatic tuning of hyper-
parameters using random search [9] or Bayesian optimization [120, 131].
These methods are assessed in terms of predictive performances, but
nothing as already been done to analyse the stability of the resulting
models. Moreover, those results are reported on large datasets and may
not apply to very small ones. In particular, I think that we should
investigate the impact of using heuristics or no tuning.
11.1.2 Heterogeneity of cancer
Cancer is an heterogeneous disease with many subtypes and many fac-
tors explaining the survival of patients. For example, breast cancer
is often described with three subtypes: ER+/HER2-, ER-/HER2- and
HER2+. Results showed that the biological processes associated with
clinical outcome depend on these subtypes [36]. Some prognostic mod-
els already take into account those subtypes adapting the prognosis for
each [143, 61]. The prognosis or the responses to chemotherapy could
also change with mutations such as the P53 gene mutation [83, 134].
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Similar molecular subtypes classiﬁcation are deﬁned for many cancers
(e.g., colon cancer [89]).
Other factors could also have an impact on the survival such as the
nodal status, the age, the treatment, the size of the tumor, the grade,
etc. If these informations should be used when predicting the outcome,
it can also be viewed as confounding factors problematic when assessing
the performances of new prognostic models. For example in chapter 10,
we decided to report results while removing the node positive and treated
patients to have a more homogeneous population.
However, the best strategy to assess new prognostic models in the
presence of so many potential confounding factors is unclear. Removing
them to have a more homogeneous population can give better and clearer
results. But, the more patients we have, the better is the assessment.
Something in between could be done with a stratiﬁcation of the patients:
having a unique hazard ratio but with diﬀerent baseline hazards depend-
ing on these factors. We choose to treat them as confounding factors
in chapter 10, but we could introduce them in the models as features.
We could even introduce them as an additional supervision similarly as
what we have proposed in the Coxlogit model (see chapter 6).
I think that an assessment of these diﬀerent strategies should be
performed to know:
• what are the advantages and risks
• what is the best strategy depending on the objectives of the study
• what are the risks of overﬁtting while choosing the best populations
• how to take into account the fact that these factors are often a
discretization of continuous factors with no clear cuts
I also think that we are too often focus on trying to prove that a new
gene signature or a new model is better than others. The multiplications
of these prognostic models and subtype classiﬁcations tends diminish
their overall importance and the interest of these gene signatures in
the domain. However, I think that these models are important with the
insights they give on the tumor biology and its heterogeneity. We should
focus more on the biological interpretation of the results and less on the
hazard ratio of new models (especially since we developed the balanced
hazard ratio). This is particularly true since none of these models will
be used alone in a clinical settings.
I think that improving the medical guidelines is another task that
should be tackled independently of the validation of new gene signatures.
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Haibe-Kains et al. [61] proposed a meta model using a fuzzy classiﬁca-
tion of patients in subtypes combined with independent models for each.
A perspective of a real improvement of the survival prediction could be
to generalize this process automatically. We could learn meta models
combining clinical factors and prognostic models using them as features
representing meta-genes, prognostic pathways, etc. We could see prog-
nostic models such as Gene70 (MammaPrint) [141], Gene76 [143], etc as
a biologically relevant feature extraction or dimensionality reduction.
To have a survival prediction that depends on subtypes or clinical
factors, meta models should be non-linear, such as in [143, 61]. While
the beneﬁts of multivariate non-linear survival models are yet unclear
on microarray, these non-linear models such as the one presented in
chapter 7 are more promising in this settings.
Chapter A
Supplementary hypoxia
signature
A.1 Cell lines
ID Cell line Organ Disease
1 MCF-7 Breast Adenocarcinoma
2 MDA-MB-231 Breast Adenocarcinoma
3 T47D Breast Ductal carcinoma
4 A549 Lung Carcinoma
5 Widr Colon Colorectal adenocarcinoma
6 HCT116 WTP53 Colon Colorectal carcinoma
7 HCT116 -/- P53 Colon Colorectal carcinoma
8 HT29 Colon Colorectal adenocarcinoma
9 Colo-205 Colon Colorectal adenocarcinoma
10 LoVo Colon Colorectal adenocarcinoma
11 HCT15 Colon Colorectal adenocarcinoma
12 SiHa Cervix Squamous cell carcinoma
13 PC3 Prostate Adenocarcinoma
14 U373 Brain Glioblastoma
15 HepG2 Liver Hepatocellular carcinoma
16 Hep3B Liver Hepatocellular carcinoma
17 PLC/PRF/5 Liver Hepatoma
18 SK-HEP-1 Liver Adenocarcinoma
19 A498 Kidney Carcinoma
20 HT1080 Connective tissue Fibrosarcoma
Table A.1: List of Human Tumor Cells used for Microarray Analysis.
Cancer cells were acquired from the ATCC where they are regularly
authenticated. Cells were stored according to the supplier’s instructions
and used within 6 months after resuscitation of frozen aliquots.
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A.2 Outlier detection on the cell lines data
To check for outlier in the cell lines data, we used the methodology
proposed by Boulesteix et al. [16]. The main idea to detect outliers
is to compare two rankings of the features r∗ and r, respectively with
and without a feature transformation. The two rankings are computed
with the same feature ranking method, here a t-test. The diﬀerence
comes from a feature transformation which is applied on the data before
computing the ranking r∗. The objective of this transformation is to
mitigate the inﬂuence of outliers. The transformation is applied after
the data normalization and can be computed as follows:
x∗ij =
�
log
�
φ(xij) + �
1− φ(xij) + �
�
+ �∗
�
/(2�∗) (A.1)
where φ stands for the standard normal cumulative distribution func-
tion, � is a parameter and �∗ = log((1 + �)/�). Royston and Sauerbrei
[109] who proposed this transformation recommend the value � = 0.01
which is the one used here. The shape of the transformation can be seen
on ﬁgure A.1. The function is nearly linear on the interval [−2.8, 2.8]
where most of the observations lie after the normalization. The eﬀect of
outliers is limited as the function is bounded between 0 and 1.
The two ranking r and r∗ are thus respectively the rankings be-
fore and after this transformation. These two rankings should be very
close when the data are not aﬀected with outliers or extreme values. Fig-
ure A.2 compare the rankings of the best features (rj < 100 or r
∗
j < 100)
on the cell lines data. The rankings are computed here with a t-test be-
tween the normoxia and cycling hypoxia samples. Similar results are
obtained with normoxia and continuous hypoxia. Having all features
close to the diagonal shows that there are almost no diﬀerences between
the ranking before and after the transformation.
To have a better idea of the ranks discrepancy, Boulesteix et al. [16]
proposed to computeΔrj =
(r∗j−rj)
min(r∗j ,rj)
for each feature j. A high absolute
value of Δrj is obtained for the features aﬀected by extreme values. For
these features, the rankings are much better with either the transformed
or the original data.
Figure A.3 shows the distribution of Δrj for all features. Most of the
Δrj are really close to 0 showing a good concordance between the two
ranking. None of the best features (rj < 100 or r
∗
j < 100) was observed
with |Δrj | > 1. Such very good Δrj were observed by Boulesteix et al.
[16] only in a few of the best datasets they reported. Those results
conﬁrms the very good quality of the cell lines data.
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Figure A.1: Shape of the function used for data transformation.
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Figure A.2: Comparison between the two rankings: on the original and
on the transformed features. The diﬀerences between the rankings are
very small showing that the data are not aﬀected by extreme values.
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Figure A.3: Distribution of the Δrj of all features in the data set.
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A.3 CycHyp signatures
A.3.1 CycHyp signature in Aﬀymetrix HGU1.0ST micro-
array platform
Probeset Entrez Id GenBank Symbol
1 8018860 332 NM 001168 BIRC5
2 8064156 84619 NM 032527 ZGPAT ∗
3 8138912 23658 NM 012322 LSM5 §
4 7921786 5202 NM 012394 PFDN2
5 8165011 2219 NM 002003 FCN1
6 7964262 4666 NM 001113201 NACA ∗
7 7949792 5790 NM 005608 PTPRCAP �
8 8034101 11018 NM 006858 TMED1
9 8168087 3476 NM 001551 IGBP1
10 7963575 1975 NM 001417 EIF4B §
11 8124397 3006 NM 005319 HIST1H1C �
12 7975989 81892 NM 031210 SLIRP §
13 8127692 3351 NM 000863 HTR1B
14 8127087 2940 NM 000847 GSTA3
15 7941122 29901 NM 013299 SAC3D1
16 7998692 4913 NM 002528 NTHL1
17 8073623 758 NM 001044370 MPPED1
18 8014865 4761 NM 006160 NEUROD2 ∗
19 8005726 3768 NM 021012 KCNJ12
20 7966631 64211 NM 022363 LHX5 ∗
21 8037853 54958 NM 017854 TMEM160
22 8104136 3166 NM 018942 HMX1 ∗
23 7948606 746 NM 014206 C11orf10 �
24 8044773 8685 NM 006770 MARCO
25 7947015 7251 NM 006292 TSG101
26 7931553 8433 NM 003577 UTF1 ∗
27 7956876 84298 NM 032338 LLPH
28 8117372 8334 NM 003512 HIST1H2AC �
29 8001329 869 NM 004352 CBLN1
30 8027205 51079 NM 015965 NDUFA13
31 8042896 3196 NM 016170 TLX2 ∗
32 7911532 54998 NM 017900 AURKAIP1
33 8039923 54998 NM 017900 AURKAIP1
34 7992043 65990 BC001181 FAM173A
35 8063074 90204 NM 080603 ZSWIM1 ∗
36 7992191 23430 NM 012217 TPSD1
37 8108435 7322 NM 181838 UBE2D2
38 8165309 8721 NM 003792 EDF1 ∗
39 7946267 63875 NM 022061 MRPL17
40 7945536 51286 NM 016564 CEND1
41 8159609 8636 NM 003731 SSNA1 �
42 8005471 6234 NM 001031 RPS28 �, §
43 8025395 6234 NM 001031 RPS28
44 7942824 6234 NM 001031 RPS28
45 8170753 26576 NM 014370 SRPK3
46 8032718 1613 NM 001348 DAPK3
47 7967067 8655 NM 001037495 DYNLL1
48 8159654 25920 NM 015456 COBRA1 ∗
49 8011212 6391 NM 003001 SDHC
50 8011968 51003 NM 016060 MED31 ∗
Continued on Next Page. . .
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Table A.2 – Continued
Probeset Entrez Id GenBank Symbol
51 7977440 9834 NR 026800 KIAA0125
52 8016508 11267 NM 007241 SNF8 ∗
53 8168567 5456 NM 000307 POU3F4 ∗
54 8086317 64689 NM 031899 GORASP1
55 8052834 54980 BC005079 C2orf42
56 8073334 9978 NM 014248 RBX1 �
57 7915846 8569 NM 003684 MKNK1
58 8071920 6634 NM 004175 SNRPD3 §
59 8032371 81926 NM 031213 FAM108A1
60 7924884 8290 NM 003493 HIST3H3
61 8006845 6143 NM 000981 RPL19 §
62 7946812 6207 NM 001017 RPS13 �, §
63 7949015 65998 NM 001144936 C11orf95 ∗
64 8009784 51081 NM 015971 MRPS7 §
65 8174509 2787 NM 005274 GNG5
66 7906235 5546 NM 005973 PRCC §
67 8020179 57132 NM 020412 CHMP1B
68 7947450 4005 NM 005574 LMO2
69 8064370 6939 NM 004609 TCF15 ∗
70 7955896 22818 NM 016057 COPZ1
71 8137805 8379 NM 003550 MAD1L1 �
72 8117334 8359 NM 003538 HIST1H4A �
73 8117368 8364 NM 003542 HIST1H4C �
74 7977507 85495 NR 002312 RPPH1 §
75 7949410 378938 BC018448 MALAT1
76 8150433 157848 NM 152568 NKX6-3 ∗
77 8071168 29797 NR 024583 POM121L8P
78 7989611 84191 NM 032231 FAM96A
79 7980859 NM 001080113
80 8032782 126259 NM 144615 TMIGD2
81 8110861 64979 NM 032479 MRPL36 §
82 7901687 199964 NM 182532 TMEM61
83 7916130 112970 NM 138417 KTI12
84 8048712 440934 BC033986 LOC440934
85 8018993 146713 NM 001082575 RBFOX3 §
86 8032601 84839 NM 032753 RAX2
87 8010719 201255 NM 144999 LRRC45
88 8036584 3963 NM 002307 LGALS7
89 8133209 441251 NR 003666 SPDYE7P
90 8159501 286256 NM 178536 LCN12
91 8028546 3963 NM 002307 LGALS7
92 8065013 ENST00000427835
93 8018502 201292 NM 173547 TRIM65 ∗
94 7903294 64645 NM 033055 HIAT1
95 7989473 388125 NM 001007595 C2CD4B
96 8054449 644903 AK095987 FLJ38668
97 8081867 51300 NM 016589 TIMMDC1
98 7934544 118881 NM 144589 COMTD1
99 7968260 219409 NM 145657 GSX1 ∗
100 8022952 56853 NM 020180 CELF4 §
Table A.2: CycHyp gene list in HGU1.0st
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A.3.2 CycHyp signature in Aﬀymetrix HGU133a micro-
array platform
Probe Symbol Gene.title
1 202095 s at BIRC5 baculoviral IAP repeat-containing 5
2 221848 at ZGPAT zinc ﬁnger, CCCH-type with G patch domain
3 202903 at LSM5 LSM5 homolog, U6 small nuclear RNA associ-
ated (S. cerevisiae)
4 218336 at PFDN2 prefoldin subunit 2
5 205237 at FCN1 ﬁcolin (collagen/ﬁbrinogen domain containing)
1
6 200735 x at NACA nascent polypeptide-associated complex alpha
subunit
7 204960 at PTPRCAP protein tyrosine phosphatase, receptor type, C-
associated protein
8 203679 at TMED1 transmembrane emp24 protein transport do-
main containing 1
9 202105 at IGBP1 immunoglobulin (CD79A) binding protein 1
10 211938 at EIF4B eukaryotic translation initiation factor 4B
11 208046 at HIST2H4B /
HIST4H4 /
HIST2H4A /
HIST1H4L /
HIST1H4E /
HIST1H4B /
HIST1H4H /
HIST1H4C /
HIST1H4J /
HIST1H4K /
HIST1H4F /
HIST1H4D /
HIST1H4A /
HIST1H4I
histone cluster 2, H4b / histone cluster 4, H4 / his-
tone cluster 2, H4a / histone cluster 1, H4l / histone
cluster 1, H4e / histone cluster 1, H4b / histone clus-
ter 1, H4h / histone cluster 1, H4c / histone cluster
1, H4j / histone cluster 1, H4k / histone cluster 1,
H4f / histone cluster 1, H4d / histone cluster 1, H4a
/ histone cluster 1, H4i
12 202094 at BIRC5 baculoviral IAP repeat-containing 5
13 209398 at HIST1H1C histone cluster 1, H1c
14 205967 at HIST2H4B /
HIST4H4 /
HIST2H4A /
HIST1H4L /
HIST1H4E /
HIST1H4B /
HIST1H4H /
HIST1H4C /
HIST1H4J /
HIST1H4K /
HIST1H4F /
HIST1H4D /
HIST1H4A /
HIST1H4I
histone cluster 2, H4b / histone cluster 4, H4 / his-
tone cluster 2, H4a / histone cluster 1, H4l / histone
cluster 1, H4e / histone cluster 1, H4b / histone clus-
ter 1, H4h / histone cluster 1, H4c / histone cluster
1, H4j / histone cluster 1, H4k / histone cluster 1,
H4f / histone cluster 1, H4d / histone cluster 1, H4a
/ histone cluster 1, H4i
15 221434 s at C14orf156 chromosome 14 open reading frame 156
16 210799 at HTR1B 5-hydroxytryptamine (serotonin) receptor 1B
17 222102 at GSTA3 glutathione S-transferase alpha 3
18 205449 at SAC3D1 SAC3 domain containing 1
19 210334 x at BIRC5 baculoviral IAP repeat-containing 5
20 209731 at NTHL1 nth endonuclease III-like 1 (E. coli)
21 206436 at MPPED1 metallophosphoesterase domain containing 1
22 210271 at NEUROD2 neurogenic diﬀerentiation 2
23 207110 at KCNJ12 potassium inwardly-rectifying channel, subfamily J,
member 12
24 208333 at LHX5 LIM homeobox 5
25 202904 s at LSM5 LSM5 homolog, U6 small nuclear RNA associated (S.
cerevisiae)
26 219219 at TMEM160 transmembrane protein 160
27 207353 s at HMX1 H6 family homeobox 1
28 214386 at HMX1 H6 family homeobox 1
29 218213 s at C11orf10 chromosome 11 open reading frame 10
30 205819 at MARCO macrophage receptor with collagenous structure
31 201758 at TSG101 tumor susceptibility gene 101
32 208275 x at UTF1 undiﬀerentiated embryonic cell transcription factor 1
33 211747 s at LSM5 LSM5 homolog, U6 small nuclear RNA associated (S.
cerevisiae)
34 209779 at LLPH LLP homolog, long-term synaptic facilitation
(Aplysia)
35 215071 s at HIST1H2AC histone cluster 1, H2ac
36 205747 at CBLN1 cerebellin 1 precursor
37 220864 s at NDUFA13 NADH dehydrogenase (ubiquinone) 1 alpha subcom-
plex, 13
Continued on Next Page. . .
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Table A.3 – Continued
Probe Symbol Gene.title
38 207410 s at TLX2 T-cell leukemia homeobox 2
39 218580 x at AURKAIP1 aurora kinase A interacting protein 1
40 219709 x at FAM173A family with sequence similarity 173, member A
41 217592 at ZSWIM1 zinc ﬁnger, SWIM-type containing 1
42 214568 at TPSD1 tryptase delta 1
43 201344 at UBE2D2 ubiquitin-conjugating enzyme E2D 2 (UBC4/5 ho-
molog, yeast)
44 209058 at EDF1 endothelial diﬀerentiation-related factor 1
45 222216 s at MRPL17 mitochondrial ribosomal protein L17
46 219591 at CEND1 cell cycle exit and neuronal diﬀerentiation 1
47 210378 s at SSNA1 Sjogren syndrome nuclear autoantigen 1
48 208904 s at RPS28 ribosomal protein S28
49 206216 at SRPK3 SRSF protein kinase 3
50 203891 s at DAPK3 death-associated protein kinase 3
51 200703 at DYNLL1 dynein, light chain, LC8-type 1
52 202757 at COBRA1 cofactor of BRCA1
53 210131 x at SDHC succinate dehydrogenase complex, subunit C, integral
membrane protein, 15kDa
54 219318 x at MED31 mediator complex subunit 31
55 206478 at KIAA0125 KIAA0125
56 218391 at SNF8 SNF8, ESCRT-II complex subunit, homolog (S. cere-
visiae)
57 207694 at POU3F4 POU class 3 homeobox 4
58 201345 s at UBE2D2 ubiquitin-conjugating enzyme E2D 2 (UBC4/5 ho-
molog, yeast)
59 211049 at TLX2 T-cell leukemia homeobox 2
60 208903 at RPS28 ribosomal protein S28
61 215749 s at GORASP1 golgi reassembly stacking protein 1, 65kDa
62 219128 at C2orf42 chromosome 2 open reading frame 42
63 218117 at RBX1 ring-box 1
64 209467 s at MKNK1 MAP kinase interacting serine/threonine kinase 1
65 202004 x at SDHC succinate dehydrogenase complex, subunit C, integral
membrane protein, 15kDa
66 208902 s at RPS28 ribosomal protein S28
67 202567 at SNRPD3 small nuclear ribonucleoprotein D3 polypeptide
18kDa
68 221267 s at FAM108A1 family with sequence similarity 108, member A1
69 208572 at HIST3H3 histone cluster 3, H3
70 200029 at RPL19 ribosomal protein L19
71 200018 at RPS13 ribosomal protein S13
72 218641 at C11orf95 chromosome 11 open reading frame 95
73 201343 at UBE2D2 ubiquitin-conjugating enzyme E2D 2 (UBC4/5 ho-
molog, yeast)
74 208635 x at NACA nascent polypeptide-associated complex alpha sub-
unit
75 217932 at MRPS7 mitochondrial ribosomal protein S7
76 207157 s at GNG5 guanine nucleotide binding protein (G protein),
gamma 5
77 208938 at PRCC papillary renal cell carcinoma (translocation-
associated)
78 218178 s at CHMP1B chromatin modifying protein 1B
79 204249 s at LMO2 LIM domain only 2 (rhombotin-like 1)
80 211937 at EIF4B eukaryotic translation initiation factor 4B
81 207306 at TCF15 transcription factor 15 (basic helix-loop-helix)
82 217726 at COPZ1 coatomer protein complex, subunit zeta 1
83 204857 at MAD1L1 MAD1 mitotic arrest deﬁcient-like 1 (yeast)
84 218177 at CHMP1B chromatin modifying protein 1B
85 209059 s at EDF1 endothelial diﬀerentiation-related factor 1
86 219599 at EIF4B eukaryotic translation initiation factor 4B
87 203890 s at DAPK3 death-associated protein kinase 3
Table A.3: CycHyp signature in Aﬀymetrix HGU133a microarray platform
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Probeset Entrez Id GenBank Symbol
1 7948606 746 NM 014206 C11orf10
2 8043283 55818 NM 018433 KDM3A
3 8025395 6234 NM 001031 RPS28
4 8139706 23480 NM 014302 SEC61G
5 7942824 6234 NM 001031 RPS28
6 8005471 6234 NM 001031 RPS28
7 8048489 55139 NM 018089 ANKZF1
8 7994737 226 NM 000034 ALDOA
9 7934278 5033 NM 000917 P4HA1
10 8102518 401152 NM 001170330 C4orf3
11 8117334 8359 NM 003538 HIST1H4A
12 8074969 1652 NM 001355 DDT
13 8044766 51141 NM 016133 INSIG2
14 7937476 6181 NM 001004 RPLP2
15 8086961 5210 NM 004567 PFKFB4
16 8145454 665 NM 004331 BNIP3L
17 8113981 8974 NM 004199 P4HA2
18 8162142 81689 NM 030940 ISCA1
19 8007992 3837 NM 002265 KPNB1
20 7928308 54541 NM 019058 DDIT4
21 8073334 9978 NM 014248 RBX1
22 8124397 3006 NM 005319 HIST1H1C
23 8153459 65263 NM 023078 PYCRL
24 7916568 AF263547
25 7955117 23519 NM 012404 ANP32D
26 8098604 353322 NM 181726 ANKRD37
27 8121076 10957 NM 006813 PNRC1
28 7921076 54865 NM 182679 GPATCH4
29 7908879 8497 NM 015053 PPFIA4
30 8103518 23520 NM 012403 ANP32C
31 8050591 91942 NM 174889 NDUFAF2
32 8172154 6187 NM 002952 RPS2
33 7984846 1198 NM 001130028 CLK3
34 7946812 6207 NM 001017 RPS13
35 7982531 8125 NM 006305 ANP32A
36 8119898 7422 NM 001025366 VEGFA
37 8004331 9744 NM 014716 ACAP1
38 8159441 29085 NM 001135861 PHPT1
39 8168500 5230 NM 000291 PGK1
40 7938890 10196 NM 005788 PRMT3
41 7930398 4601 NM 005962 MXI1
42 7997740 81631 NM 022818 MAP1LC3B
43 8004360 147040 NM 001002914 KCTD11
44 7909782 51018 NM 016052 RRP15
45 7949792 5790 NM 005608 PTPRCAP
46 8124385 8366 NM 003544 HIST1H4B
47 8117368 8364 NM 003542 HIST1H4C
48 8081241 84319 NM 032359 C3orf26
49 8050079 246243 NM 002936 RNASEH1
50 8005765 26118 NM 015626 WSB1
51 7924491 64853 NM 022831 AIDA
52 8133273 ENST00000455206
53 8124391 8335 NM 003513 HIST1H2AB
54 8159609 8636 NM 003731 SSNA1
55 7957890 27340 NM 014503 UTP20
56 7933582 100287932 NM 006327 TIMM23
57 8153002 10397 NM 001135242 NDRG1
58 7926037 5209 NM 004566 PFKFB3
Continued on Next Page. . .
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Probeset Entrez Id GenBank Symbol
59 8082066 26355 NM 014367 FAM162A
60 8042962 9801 NM 014763 MRPL19
61 8090678 11222 NM 007208 MRPL3
62 7977507 85495 NR 002312 RPPH1
63 8007397 10197 NM 176863 PSME3
64 7998902 54985 NM 017885 HCFC1R1
65 8117372 8334 NM 003512 HIST1H2AC
66 7997230 5713 NM 002811 PSMD7
67 7915485 10969 NM 006824 EBNA1BP2
68 8113873 3094 NM 005340 HINT1
69 7958152 5223 NM 002629 PGAM1
70 7947867 5702 NM 002804 PSMC3
71 7964460 1649 NM 004083 DDIT3
72 7928395 170384 NM 173540 FUT11
73 8163629 944 NM 001244 TNFSF8
74 7965486 51134 NM 016122 CCDC41
75 8136179 23008 AF277175 KLHDC10
76 8095870 901 NM 004354 CCNG2
77 8127526 6170 NM 001000 RPL39
78 8174710 6170 NM 001000 RPL39
79 8137517 3361 NM 024012 HTR5A
80 7929624 5223 NM 002629 PGAM1
81 8052331 87178 NM 033109 PNPT1
82 8015969 7343 NM 014233 UBTF
83 8069168 386685 NM 198699 KRTAP10-12
84 7941087 5526 NM 006244 PPP2R5B
85 8026875 26780 NR 000012 SNORA68
86 8027621 2821 NM 000175 GPI
87 8130539 117289 NM 054114 TAGAP
88 8004691 92162 NM 203411 TMEM88
89 7962183 205 NM 001005353 AK4
90 8137805 8379 NM 003550 MAD1L1
91 8124388 8358 NM 003537 HIST1H3B
92 8083223 205428 NM 173552 C3orf58
93 8113305 1105 NM 001270 CHD1
94 8169659 4694 NM 004541 NDUFA1
95 8046408 5163 NM 002610 PDK1
96 8053599 23559 NM 012477 WBP1
97 8043377 23559 NM 012477 WBP1
98 7960878 642559 GU480887 POU5F1P3
99 7959023 643246 NM 001085481 MAP1LC3B2
100 8073148 468 NM 001675 ATF4
Table A.4: ContHyp gene list in HGU1.0st
A.4.2 ContHyp signature in Aﬀymetrix HGU133a mi-
croarray platform
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Probe Symbol Gene.title
1 208576 s at HIST1H3F /
HIST1H3B /
HIST1H3H /
HIST1H3J /
HIST1H3G /
HIST1H3I /
HIST1H3E /
HIST1H3C /
HIST1H3D /
HIST1H3A /
HIST1H2AD
histone cluster 1, H3f / histone cluster 1, H3b /
histone cluster 1, H3h / histone cluster 1, H3j /
histone cluster 1, H3g / histone cluster 1, H3i /
histone cluster 1, H3e / histone cluster 1, H3c /
histone cluster 1, H3d / histone cluster 1, H3a
/ histone cluster 1, H2ad
2 218944 at PYCRL pyrroline-5-carboxylate reductase-like
3 202464 s at PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3
4 214978 s at PPFIA4 protein tyrosine phosphatase, receptor type,
f polypeptide (PTPRF), interacting protein
(liprin), alpha 4
5 219037 at RRP15 ribosomal RNA processing 15 homolog (S. cere-
visiae)
6 217670 at RPLP2 ribosomal protein, large, P2
7 220596 at GPATCH4 G patch domain containing 4
8 200738 s at PGK1 phosphoglycerate kinase 1
9 213507 s at KPNB1 karyopherin (importin) beta 1
10 200886 s at PGAM1 phosphoglycerate mutase 1 (brain)
11 201705 at PSMD7 proteasome (prosome, macropain) 26S subunit,
non-ATPase, 7
12 210512 s at VEGFA vascular endothelial growth factor A
13 214764 at RRP15 ribosomal RNA processing 15 homolog (S. cere-
visiae)
14 204258 at CHD1 chromodomain helicase DNA binding protein 1
15 203465 at MRPL19 mitochondrial ribosomal protein L19
16 202733 at P4HA2 prolyl 4-hydroxylase, alpha polypeptide II
17 218497 s at RNASEH1 ribonuclease H1
18 207543 s at P4HA1 prolyl 4-hydroxylase, alpha polypeptide I
19 209273 s at ISCA1 iron-sulfur cluster assembly 1 homolog (S. cere-
visiae)
20 200632 s at NDRG1 N-myc downstream regulated 1
21 635 s at PPP2R5B protein phosphatase 2, regulatory subunit B’,
beta
22 209725 at UTP20 UTP20, small subunit (SSU) processome com-
ponent, homolog (yeast)
23 208903 at RPS28 ribosomal protein S28
24 218274 s at ANKZF1 ankyrin repeat and zinc ﬁnger domain contain-
ing 1
25 202692 s at UBTF upstream binding transcription factor, RNA
polymerase I
26 218117 at RBX1 ring-box 1
27 204611 s at PPP2R5B protein phosphatase 2, regulatory subunit B’,
beta
28 210111 s at KLHDC10 kelch domain containing 10
29 200018 at RPS13 ribosomal protein S13
30 204960 at PTPRCAP protein tyrosine phosphatase, receptor type, C-
associated protein
31 200779 at ATF4 activating transcription factor 4 (tax-
responsive enhancer element B67)
32 210265 x at POU5F1P3 POU class 5 homeobox 1 pseudogene 3
33 220942 x at FAM162A family with sequence similarity 162, member A
34 213406 at WSB1 WD repeat and SOCS box-containing 1
35 202364 at MXI1 MAX interactor 1
36 201051 at ANP32A acidic (leucine-rich) nuclear phosphoprotein 32
family, member A
37 200909 s at RPLP2 ribosomal protein, large, P2
38 204857 at MAD1L1 MAD1 mitotic arrest deﬁcient-like 1 (yeast)
39 214881 s at UBTF upstream binding transcription factor, RNA
polymerase I
40 221478 at BNIP3L BCL2/adenovirus E1B 19kDa interacting pro-
tein 3-like
41 221479 s at BNIP3L BCL2/adenovirus E1B 19kDa interacting pro-
tein 3-like
42 211527 x at VEGFA vascular endothelial growth factor A
43 209034 at PNRC1 proline-rich nuclear receptor coactivator 1
44 201295 s at WSB1 WD repeat and SOCS box-containing 1
Continued on Next Page. . .
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45 208046 at HIST2H4B /
HIST4H4 /
HIST2H4A /
HIST1H4L /
HIST1H4E /
HIST1H4B /
HIST1H4H /
HIST1H4C /
HIST1H4J /
HIST1H4K /
HIST1H4F /
HIST1H4D /
HIST1H4A /
HIST1H4I
histone cluster 2, H4b / histone cluster 4, H4 / his-
tone cluster 2, H4a / histone cluster 1, H4l / histone
cluster 1, H4e / histone cluster 1, H4b / histone clus-
ter 1, H4h / histone cluster 1, H4c / histone cluster
1, H4j / histone cluster 1, H4k / histone cluster 1,
H4f / histone cluster 1, H4d / histone cluster 1, H4a
/ histone cluster 1, H4i
46 209398 at HIST1H1C histone cluster 1, H1c
47 205967 at HIST2H4B /
HIST4H4 /
HIST2H4A /
HIST1H4L /
HIST1H4E /
HIST1H4B /
HIST1H4H /
HIST1H4C /
HIST1H4J /
HIST1H4K /
HIST1H4F /
HIST1H4D /
HIST1H4A /
HIST1H4I
histone cluster 2, H4b / histone cluster 4, H4 / his-
tone cluster 2, H4a / histone cluster 1, H4l / histone
cluster 1, H4e / histone cluster 1, H4b / histone clus-
ter 1, H4h / histone cluster 1, H4c / histone cluster
1, H4j / histone cluster 1, H4k / histone cluster 1,
H4f / histone cluster 1, H4d / histone cluster 1, H4a
/ histone cluster 1, H4i
48 221733 s at GPATCH4 G patch domain containing 4
49 214516 at HIST2H4B /
HIST4H4 /
HIST2H4A /
HIST1H4L /
HIST1H4E /
HIST1H4B /
HIST1H4H /
HIST1H4C /
HIST1H4J /
HIST1H4K /
HIST1H4F /
HIST1H4D /
HIST1H4A /
HIST1H4I
histone cluster 2, H4b / histone cluster 4, H4 / his-
tone cluster 2, H4a / histone cluster 1, H4l / histone
cluster 1, H4e / histone cluster 1, H4b / histone clus-
ter 1, H4h / histone cluster 1, H4c / histone cluster
1, H4j / histone cluster 1, H4k / histone cluster 1,
H4f / histone cluster 1, H4d / histone cluster 1, H4a
/ histone cluster 1, H4i
50 200908 s at RPLP2 ribosomal protein, large, P2
51 217027 x at KPNB1 karyopherin (importin) beta 1
52 203484 at SEC61G Sec61 gamma subunit
53 219644 at CCDC41 coiled-coil domain containing 41
54 218213 s at C11orf10 chromosome 11 open reading frame 10
55 217383 at PGK1 phosphoglycerate kinase 1
56 220611 at DAB1 disabled homolog 1 (Drosophila)
57 215071 s at HIST1H2AC histone cluster 1, H2ac
58 200737 at PGK1 phosphoglycerate kinase 1
59 213320 at PRMT3 protein arginine methyltransferase 3
60 202887 s at DDIT4 DNA-damage-inducible transcript 4
61 210561 s at WSB1 WD repeat and SOCS box-containing 1
62 208826 x at HINT1 histidine triad nucleotide binding protein 1
63 209852 x at PSME3 proteasome (prosome, macropain) activator subunit 3
(PA28 gamma; Ki)
64 200988 s at PSME3 proteasome (prosome, macropain) activator subunit 3
(PA28 gamma; Ki)
65 201296 s at WSB1 WD repeat and SOCS box-containing 1
66 221798 x at RPS2 ribosomal protein S2
67 212171 x at VEGFA vascular endothelial growth factor A
68 210378 s at SSNA1 Sjogren syndrome nuclear autoantigen 1
69 202298 at NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcom-
plex, 1, 7.5kDa
70 201038 s at ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 fam-
ily, member A
71 206246 at PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
4
72 203107 x at RPS2 ribosomal protein S2
73 208904 s at RPS28 ribosomal protein S28
74 208974 x at KPNB1 karyopherin (importin) beta 1
75 200966 x at ALDOA aldolase A, fructose-bisphosphate
76 214687 x at ALDOA aldolase A, fructose-bisphosphate
77 202929 s at DDT D-dopachrome tautomerase
78 212433 x at RPS2 ribosomal protein S2
79 208695 s at RPL39 ribosomal protein L39
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Probe Symbol Gene.title
80 217466 x at RPS2 ribosomal protein S2
81 202140 s at CLK3 CDC-like kinase 3
82 208787 at MRPL3 mitochondrial ribosomal protein L3
83 208569 at HIST1H2AB histone cluster 1, H2ab
84 201323 at EBNA1BP2 EBNA1 binding protein 2
85 213574 s at KPNB1 karyopherin (importin) beta 1
86 202769 at CCNG2 cyclin G2
87 218496 at RNASEH1 ribonuclease H1
88 45714 at HCFC1R1 host cell factor C1 regulator 1 (XPO1 dependent)
89 207216 at TNFSF8 tumor necrosis factor (ligand) superfamily, member 8
90 200093 s at HINT1 histidine triad nucleotide binding protein 1
91 212689 s at KDM3A lysine (K)-speciﬁc demethylase 3A
92 208902 s at RPS28 ribosomal protein S28
93 209254 at KLHDC10 kelch domain containing 10
94 221533 at FAM162A family with sequence similarity 162, member A
95 218118 s at LOC10431 translocase of inner mitochondrial membrane 23 ho-
molog (yeast)-like
96 208975 s at KPNB1 karyopherin (importin) beta 1
97 221362 at HTR5A 5-hydroxytryptamine (serotonin) receptor 5A
98 208308 s at GPI glucose-6-phosphate isomerase
99 205213 at ACAP1 ArfGAP with coiled-coil, ankyrin repeat and PH do-
mains 1
100 209274 s at ISCA1 iron-sulfur cluster assembly 1 homolog (S. cerevisiae)
101 204348 s at AK3L2 / AK4 adenylate kinase 3-like 2 (pseudogene) / adenylate ki-
nase 4
102 207721 x at HINT1 histidine triad nucleotide binding protein 1
103 213573 at KPNB1 karyopherin (importin) beta 1
104 208538 at ANP32C acidic (leucine-rich) nuclear phosphoprotein 32 fam-
ily, member C
105 221425 s at ISCA1 iron-sulfur cluster assembly 1 homolog (S. cerevisiae)
106 209566 at INSIG2 insulin induced gene 2
107 209853 s at PSME3 proteasome (prosome, macropain) activator subunit 3
(PA28 gamma; Ki)
108 204347 at AK3L2 / AK4 adenylate kinase 3-like 2 (pseudogene) / adenylate ki-
nase 4
109 200987 x at PSME3 proteasome (prosome, macropain) activator subunit 3
(PA28 gamma; Ki)
110 210513 s at VEGFA vascular endothelial growth factor A
111 217356 s at PGK1 phosphoglycerate kinase 1
112 209255 at KLHDC10 kelch domain containing 10
113 208786 s at MAP1LC3B microtubule-associated protein 1 light chain 3 beta
114 213803 at KPNB1 karyopherin (importin) beta 1
115 201294 s at WSB1 WD repeat and SOCS box-containing 1
116 205212 s at ACAP1 ArfGAP with coiled-coil, ankyrin repeat and PH do-
mains 1
117 206686 at PDK1 pyruvate dehydrogenase kinase, isozyme 1
118 201267 s at PSMC3 proteasome (prosome, macropain) 26S subunit, AT-
Pase, 3
119 220199 s at AIDA axin interactor, dorsalization associated
120 218537 at HCFC1R1 host cell factor C1 regulator 1 (XPO1 dependent)
121 202770 s at CCNG2 cyclin G2
122 201043 s at ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 fam-
ily, member A
123 211559 s at CCNG2 cyclin G2
Table A.5: ContHyp signature in Aﬀymetrix HGU133a microarray platform
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Normoxia−3Normoxia−8
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Normoxia−17Normoxia−1
Normoxia−7Normoxia−2
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ContHyp Signature
Normoxia
ContHyp
Figure A.4: Heatmap depicting the transcripts from the ContHyp sig-
nature either underexpressed (light blue) or overexpressed (dark blue)
(centered to median values). Each column corresponds to a speciﬁc hu-
man Gene 1.0 ST probeset ; each line represents a speciﬁc cell line either
maintained under normoxia (green) or exposed to continuous hypoxia
(blue). The numbers (from 1 to 20) can be used to access information
about speciﬁc cell lines in table A.1 in appendix.
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Normoxia−17Normoxia−4
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Figure A.5: Heatmap depicting the transcripts from the ContHyp sig-
nature either underexpressed (light blue) or overexpressed (dark blue)
(centered to median values). Each column corresponds to a speciﬁc
human Gene 1.0 ST probeset ; each line represents a speciﬁc cell line ei-
ther maintained under normoxia (green), exposed to continuous hypoxia
(blue) or exposed to cycling hypoxia (purple). The numbers (from 1 to
20) can be used to access information about speciﬁc cell line in table A.1
in appendix.
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A.6 GSEA analysis on the CycHyp and Cont-
Hyp data
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Gene sets Size ES p-val FDR q-val FWER p-val
JISON SICKLE CELL DISEASE DN 26 0.442 0 0.011 0.012
ZWANG TRANSIENTLY UP BY 2ND EGF
PULSE ONLY
226 0.158 0 0.016 0.036
REACTOME TRANSLATION 40 0.275 0.006 0.44 0.771
PECE MAMMARY STEM CELL DN 29 0.303 0.008 0.501 0.894
KRIGE RESPONSE TO TOSEDOSTAT 24HR
DN
94 0.12 0.155 0.978 1
BURTON ADIPOGENESIS 5 15 0.282 0.168 0.986 1
HAMAI APOPTOSIS VIA TRAIL DN 17 0.269 0.151 0.99 1
HSIAO HOUSEKEEPING GENES 65 0.143 0.14 0.99 1
MULLIGHAN MLL SIGNATURE 2 DN 15 0.277 0.175 0.992 1
REACTOME RNA POL I TRANSCRIPTION 17 0.267 0.16 0.992 1
HUTTMANN B CLL POOR SURVIVAL UP 20 0.26 0.12 0.993 1
REACTOME PEPTIDE CHAIN ELONGATION 27 0.202 0.206 0.994 1
WANG TUMOR INVASIVENESS UP 46 0.182 0.094 0.999 1
BOUDOUKHA BOUND BY IGF2BP2 15 0.371 0.024 1 0.998
BURTON ADIPOGENESIS 6 16 0.304 0.094 1 1
LI INDUCED T TO NATURAL KILLER UP 15 0.301 0.111 1 1
KEGG UBIQUITIN MEDIATED PROTEOLY-
SIS
22 0.29 0.045 1 1
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS 16 0.289 0.118 1 1
GOLDRATH ANTIGEN RESPONSE 19 0.286 0.078 1 1
WIERENGA STAT5A TARGETS DN 18 0.285 0.082 1 1
YAO TEMPORAL RESPONSE TO PROGES-
TERONE CLUSTER 17
21 0.281 0.064 1 1
LINDGREN BLADDER CANCER CLUSTER 3
UP
16 0.271 0.163 1 1
MALONEY RESPONSE TO 17AAG DN 18 0.264 0.144 1 1
UDAYAKUMAR MED1 TARGETS UP 19 0.26 0.145 1 1
AFFAR YY1 TARGETS UP 20 0.259 0.137 1 1
KEGG PATHWAYS IN CANCER 28 0.252 0.054 1 1
SWEET LUNG CANCER KRAS DN 26 0.25 0.076 1 1
REACTOME 3 UTR MEDIATED TRANSLA-
TIONAL REGULATION
32 0.249 0.033 1 1
YAGI AML WITH T 8 21 TRANSLOCATION 20 0.249 0.147 1 1
KEGG WNT SIGNALING PATHWAY 19 0.239 0.208 1 1
GARY CD5 TARGETS UP 31 0.228 0.073 1 1
REACTOME SRP DEPENDENT COTRANS-
LATIONAL PROTEIN TARGETING TO MEM-
BRANE
33 0.227 0.064 1 1
NIKOLSKY BREAST CANCER 16P13 AMPLI-
CON
26 0.227 0.118 1 1
MOHANKUMAR TLX1 TARGETS UP 27 0.224 0.122 1 1
NIKOLSKY BREAST CANCER 17Q21 Q25 AM-
PLICON
36 0.217 0.068 1 1
WONG EMBRYONIC STEM CELL CORE 46 0.196 0.062 1 1
YAGI AML WITH INV 16 TRANSLOCATION 34 0.186 0.197 1 1
MIKKELSEN ES ICP WITH H3K4ME3 54 0.175 0.076 1 1
KRIGE RESPONSE TO TOSEDOSTAT 6HR
UP
42 0.167 0.192 1 1
STARK PREFRONTAL CORTEX 22Q11 DELE-
TION DN
71 0.166 0.047 1 1
DELACROIX RAR BOUND ES 45 0.164 0.178 1 1
MOOTHA MITOCHONDRIA 65 0.152 0.099 1 1
MEISSNER BRAIN HCP WITH H3K27ME3 55 0.151 0.176 1 1
MARTENS TRETINOIN RESPONSE DN 108 0.148 0.028 1 0.999
KRIGE RESPONSE TO TOSEDOSTAT 6HR
DN
87 0.141 0.073 1 1
REACTOME METABOLISM OF PROTEINS 75 0.141 0.113 1 1
MIKKELSEN MEF HCP WITH H3K27ME3 89 0.137 0.085 1 1
ACEVEDO LIVER TUMOR VS NORMAL AD-
JACENT TISSUE UP
94 0.129 0.103 1 1
BENPORATH EED TARGETS 115 0.104 0.196 1 1
DANG BOUND BY MYC 127 0.102 0.174 1 1
Table A.6: GSEA preranked analysis on the CycHyp signature extended
to 2118 diﬀerentially expressed genes between normoxia and cycling hy-
poxia. The table contains the signature sizes, primary and normal-
ized enrichment scores (ES and NES, respectively), the nominal pval-
ues, the false discovery rates (FDR) qvalues and the familywise error
rate (FWER) for the top 50 gene sets enriched in this CycHyp signa-
ture. Only the two ﬁrst gene sets are signiﬁcantly enriched with a FDR
qvalue < 0.1.
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Gene sets Size ES p-val FDR q-val FWER p-val
FARDIN HYPOXIA 11 17 0.712 0 0 0
LEONARD HYPOXIA 21 0.524 0 0 0.002
MENSE HYPOXIA UP 39 0.477 0 0 0
ELVIDGE HYPOXIA BY DMOG UP 46 0.459 0 0 0
ELVIDGE HIF1A AND HIF2A TARGETS
DN
44 0.445 0 0 0
WINTER HYPOXIA METAGENE 46 0.443 0 0 0
QI HYPOXIA 36 0.421 0 0 0
ELVIDGE HIF1A TARGETS DN 43 0.39 0 0 0
ELVIDGE HYPOXIA UP 56 0.386 0 0 0
KRIEG HYPOXIA NOT VIA KDM3A 113 0.295 0 0 0
NAKAMURA TUMOR ZONE PERIPHERAL
VS CENTRAL DN
76 0.27 0 0.002 0.015
PRAMOONJAGO SOX4 TARGETS UP 15 0.551 0 0.003 0.029
WINTER HYPOXIA UP 20 0.491 0 0.003 0.024
GROSS HYPOXIA VIA HIF1A DN 23 0.432 0 0.007 0.083
GROSS HYPOXIA VIA ELK3 AND
HIF1A UP
29 0.392 0 0.007 0.079
BASAKI YBX1 TARGETS DN 35 0.359 0 0.007 0.07
MARTORIATI MDM4 TARGETS NEUROEP-
ITHELIUM UP
23 0.432 0 0.008 0.091
MARKEY RB1 ACUTE LOF UP 24 0.419 0 0.008 0.103
SCHLOSSER MYC TARGETS AND SERUM
RESPONSE DN
18 0.48 0 0.009 0.117
MANALO HYPOXIA UP 35 0.35 0 0.009 0.113
HARRIS HYPOXIA 17 0.488 0.002 0.01 0.143
REACTOME METABOLISM OF RNA 60 0.264 0.001 0.012 0.177
BOYAULT LIVER CANCER SUBCLASS G3 UP 44 0.301 0.001 0.014 0.22
BLALOCK ALZHEIMERS DISEASE DN 169 0.163 0 0.014 0.208
DANG BOUND BY MYC 170 0.162 0.002 0.016 0.253
PID HIF1 TFPATHWAY 16 0.477 0.002 0.017 0.283
DANG MYC TARGETS UP 44 0.3 0.001 0.017 0.278
SHAFFER IRF4 TARGETS IN MYELOMA VS
MATURE B LYMPHOCYTE
15 0.488 0 0.018 0.304
WEI MYCN TARGETS WITH E BOX 194 0.149 0.001 0.022 0.372
KRIGE RESPONSE TO TOSEDOSTAT 24HR
DN
220 0.139 0.001 0.024 0.408
REACTOME INFLUENZA LIFE CYCLE 33 0.322 0.002 0.03 0.492
NUYTTEN EZH2 TARGETS UP 78 0.217 0.002 0.03 0.501
GROSS HYPOXIA VIA ELK3 DN 29 0.339 0.002 0.031 0.535
BENPORATH MYC MAX TARGETS 120 0.176 0.001 0.032 0.558
CAIRO HEPATOBLASTOMA CLASSES UP 139 0.167 0.003 0.032 0.53
PODAR RESPONSE TO ADAPHOSTIN UP 25 0.352 0.003 0.049 0.725
KIM MYC AMPLIFICATION TARGETS UP 33 0.306 0.004 0.053 0.762
YAMAZAKI TCEB3 TARGETS DN 25 0.349 0.005 0.055 0.786
RODRIGUES THYROID CARCINOMA
POORLY DIFFERENTIATED UP
113 0.168 0.005 0.064 0.845
REACTOME RNA POL I PROMOTER OPEN-
ING
16 0.415 0.006 0.069 0.87
HSIAO HOUSEKEEPING GENES 72 0.208 0.004 0.071 0.88
GARY CD5 TARGETS DN 109 0.17 0.005 0.073 0.903
DODD NASOPHARYNGEAL CARCINOMA
DN
233 0.122 0.002 0.074 0.9
GRAESSMANN APOPTOSIS BY SERUM DE-
PRIVATION DN
28 0.322 0.006 0.075 0.899
YAO TEMPORAL RESPONSE TO PROGES-
TERONE CLUSTER 11
31 0.301 0.006 0.078 0.924
KRIGE RESPONSE TO TOSEDOSTAT 6HR
DN
188 0.131 0.007 0.083 0.941
GRAESSMANN RESPONSE TO MC AND
DOXORUBICIN DN
123 0.158 0.004 0.084 0.94
LEE BMP2 TARGETS DN 214 0.125 0.008 0.084 0.946
REACTOME RNA POL I TRANSCRIPTION 20 0.363 0.006 0.085 0.951
WANG CISPLATIN RESPONSE AND XPC DN 24 0.329 0.007 0.087 0.96
LOCKWOOD AMPLIFIED IN LUNG CANCER 27 0.312 0.009 0.098 0.975
PECE MAMMARY STEM CELL DN 29 0.297 0.011 0.099 0.978
Table A.7: GSEA preranked analysis on the ContHyp signature ex-
tended to 2065 diﬀerentially expressed genes between normoxia and con-
tinuous hypoxia. The table contains the signature sizes, primary and
normalized enrichment scores (ES and NES, respectively), the nominal
pvalues, the false discovery rates (FDR) qvalues and the familywise error
rate (FWER). 17 gene sets (bold) were previously identiﬁed as related
to hypoxia.
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A.7 Overlap with other hypoxia-related gene
signatures
Hypoxia Gene Set ps in common
1 PID HIF1APATHWAY 1
2 REACTOME REGULATION OF HYPOXIA INDUCIBLE FACTOR
HIF BY OXYGEN
2
3 GROSS HYPOXIA VIA ELK3 AND HIF1A DN 1
4 REACTOME OXYGEN DEPENDENT PROLINE HYDROXYLATION
OF HYPOXIA INDUCIBLE FACTOR ALPHA
2
5 WINTER HYPOXIA UP 1
6 WINTER HYPOXIA DN 1
7 ELVIDGE HYPOXIA BY DMOG DN 1
8 GROSS HYPOXIA VIA ELK3 UP 2
9 GROSS HYPOXIA VIA ELK3 ONLY DN 1
10 MANALO HYPOXIA DN 1
11 JIANG HYPOXIA NORMAL 1
12 JIANG HYPOXIA CANCER 1
13 KRIEG HYPOXIA NOT VIA KDM3A 4
Table A.8: Overlap, in terms of number of common genes, between the
CycHyp signature and gene sets from the MsigDB identiﬁed as being
related to hypoxia or HIF.
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Hypoxia Gene Set ps in common
1 BIOCARTA HIF PATHWAY 1
2 PID HIF2PATHWAY 2
3 PID HIF1APATHWAY 1
4 PID HIF1 TFPATHWAY 5
5 REACTOME REGULATION OF HYPOXIA INDUCIBLE FACTOR
HIF BY OXYGEN
2
6 ELVIDGE HIF1A TARGETS UP 2
7 ELVIDGE HIF1A TARGETS DN 15
8 ELVIDGE HIF1A AND HIF2A TARGETS DN 16
9 GROSS HYPOXIA VIA HIF1A ONLY 1
10 GROSS HIF1A TARGETS DN 3
11 GROSS HYPOXIA VIA HIF1A DN 4
12 GROSS HYPOXIA VIA ELK3 AND HIF1A UP 14
13 RANKIN ANGIOGENIC TARGETS OF VHL HIF2A DN 1
14 SEMENZA HIF1 TARGETS 4
15 QI HYPOXIA TARGETS OF HIF1A AND FOXA2 1
16 REACTOME OXYGEN DEPENDENT PROLINE HYDROXYLATION
OF HYPOXIA INDUCIBLE FACTOR ALPHA
1
17 WINTER HYPOXIA UP 11
18 ELVIDGE HYPOXIA UP 19
19 ELVIDGE HYPOXIA DN 4
20 ELVIDGE HYPOXIA BY DMOG UP 17
21 ELVIDGE HYPOXIA BY DMOG DN 2
22 WEINMANN ADAPTATION TO HYPOXIA UP 1
23 WEINMANN ADAPTATION TO HYPOXIA DN 1
24 KONDO HYPOXIA 1
25 GROSS HYPOXIA VIA ELK3 UP 4
26 GROSS HYPOXIA VIA ELK3 DN 6
27 GROSS HYPOXIA VIA ELK3 ONLY UP 1
28 MANALO HYPOXIA DN 5
29 MANALO HYPOXIA UP 10
30 MENSE HYPOXIA UP 19
31 KIM HYPOXIA 4
32 HARRIS HYPOXIA 7
33 LEONARD HYPOXIA 12
34 JIANG HYPOXIA NORMAL 9
35 JIANG HYPOXIA CANCER 2
36 JIANG AGING HYPOTHALAMUS UP 1
37 WINTER HYPOXIA METAGENE 16
38 MIZUKAMI HYPOXIA UP 1
39 QI HYPOXIA 14
40 FARDIN HYPOXIA 9 5
41 FARDIN HYPOXIA 11 14
42 WACKER HYPOXIA TARGETS OF VHL 3
43 KRIEG HYPOXIA VIA KDM3A 1
44 KRIEG HYPOXIA NOT VIA KDM3A 27
Table A.9: Overlap, in terms of number of common genes, between the
ContHyp signature and gene sets from the MsigDB identiﬁed as being
related to hypoxia or HIF.
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Size CycHyp ContHyp
Seigneuric et al. [114] Early 0% 72 0 0
Late 0% 71 1 7
Early 2% 34 1 0
Late 2% 32 0 3
Starmans et al. [126] Cluster 1 69 0 5
Cluster 2 246 1 20
Cluster 3 157 0 4
Cluster 4 95 1 1
Cluster 5 162 0 0
Cluster 6 14 0 0
Cluster 7 28 1 0
Upregulated 780 2 32
Downregulated 656 6 6
Table A.10: Overlap, in terms of number of common genes, between
the CycHyp or ContHyp signatures and the conventional hypoxiarelated
signatures described by Seigneuric et al. [114] and Starmans et al. [126].
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A.8 Hypoxia signatures on diﬀerent breast can-
cer subpopulations
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Figure A.6: Kaplan-Meier survival curves of patients with primary
breast cancer, as determined by using the CycHyp signature. The vali-
dation set is reduced here to node-negative patients.
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Figure A.7: Kaplan-Meier survival curves of patients with primary
breast cancer, as determined by using the CycHyp signature. The vali-
dation set is reduced here to node-negative and untreated patients.
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Figure A.8: Kaplan-Meier survival curves of patients with primary
breast cancer, as determined by using the CycHyp signature. The val-
idation set is deﬁned here as all patients minus the best population of
ER+/HER2-, node-negative and untreated patients.
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A.9 The CycHyp signature in association with
NPI
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Figure A.9: Kaplan-Meier survival curves of patients with primary
breast cancer stratiﬁed at low or high risk according to the CycHyp
signature and the NPI nomenclature.
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Figure A.10: Kaplan-Meier survival curves of patients with primary
breast cancer stratiﬁed at low or high risk according to the CycHyp
signature and the NPI nomenclature.
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Figure A.11: Kaplan-Meier survival curves of patients with primary
breast cancer stratiﬁed at low or high risk according to the CycHyp
signature and the NPI nomenclature.
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A.10 The CycHyp signature in association with
NPI with 6 groups
Blamey et al. [13] proposed to divided the Nottingham Prognostic Index
(NPI) in six groups:
• Excellent Prognostic Group:
NPI ≤ 2.4
• Good Prognostic Group:
2.4 < NPI ≤ 3.4
• Moderate Prognostic Group 1:
3.4 < NPI ≤ 4.4
• Moderate Prognostic Group 2:
4.4 < NPI ≤ 5.4
• Poor Prognostic Group:
5.4 < NPI ≤ 6.4
• Very poor Prognostic Group:
6.4 < NPI
We report in ﬁgures A.12, A.13 and A.14 the performances of the
CycHyp signature in each of these six NPI-subgroups on the 8 validation
data sets. The performances of the CycHyp signature are diﬃcult to
interpret in the 1st, 5th and 6th groups due to the small numbers of
events. Very interesting results are obtained in the good prognostic
group (GPG) with a BHR of 2.93 (p-values=3.25e-9). In this group,
the CycHyp model is able to identify almost every patients with distant
metastasis. Good performances are also obtained in moderate prognostic
group 1 (MPG1) with a BHR of 1.61 (p-values=4.21e-5).
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Figure A.12: Kaplan-Meier survival curves of patients with primary
breast cancer stratiﬁed at low or high risk according to the CycHyp
signature and the NPI nomenclature.
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Figure A.13: Kaplan-Meier survival curves of patients with primary
breast cancer stratiﬁed at low or high risk according to the CycHyp
signature and the NPI nomenclature.
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Figure A.14: Kaplan-Meier survival curves of patients with primary
breast cancer stratiﬁed at low or high risk according to the CycHyp
signature and the NPI nomenclature.

Chapter B
Supplementary Coxlogit
In this appendix, we describe the optimization procedure used in the es-
timation of the regularized Coxlogit model. First, we present the deriva-
tives of the log-likelihoods of the Cox, logistic and Coxlogit models in
respectively sections B.1, B.2 and B.3. Those derivatives are essential
in the optimization algorithm presented in section B.4.
B.1 Cox partial log-likelihood and derivatives
For the sake of simplicity, we deﬁne two ensembles R(ti) and C(ti) that
are used in the computation of the Cox partial log-likelihood:
R(ti) = {j|tj ≥ ti} (B.1)
C(ti) = {j|δj = 1, tj ≤ ti} (B.2)
The partial log-likelihood presented here is similar to the one pre-
sented in section 3.3.1. However, it is here written with respect to the
risk scores z.
lcox(z) =
n�
i=1
δi
zi − log �
k∈R(ti)
exp(zk)
 (B.3)
l�cox(z)j = δj −
�
i∈C(tj)
exp(zj)�
k∈R(ti) exp(zk)
(B.4)
l��cox(z)jj = −
�
i∈C(tj)
exp(zj)
�
k∈R(ti) exp(zk)− (exp(zj))
2��
k∈R(ti) exp(zk)
�2 (B.5)
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B.2 Logistic model log-likelihood and deriva-
tives
Similarly to the Cox model, we give here the logistic log-likelihood and
its derivatives with respect to the risk scores z:
llogi(z) =
n�
i=1
log(1 + exp(−gizi)) (B.6)
l�logi(z)j =
−gi exp(−gizi)
1 + exp(−gizi) (B.7)
l��logi(z)jj =
exp(−gizi)
(1 + exp(−gizi))2
(B.8)
B.3 Coxlogit model log-likelihood and deriva-
tives
As presented in section 6.2.1, the Coxlogit model can be described as
a mixture of the Cox and logistic model. The log-likelihood and its
derivatives are thus also a mixture of the Cox and logistic ones presented
in the previous sections.
l(z) = (1− γ) lcox(z) + γ llogi(z) (B.9)
l�(z)j = (1− γ) l�cox(z)j + γ l�logi(z)j (B.10)
l��(z)jj = (1− γ) l��cox(z)jj + γ l��logi(z)jj (B.11)
B.4 Regularization path for generalized linear
models
The Coxlogit model can be seen as generalized linear model similarly
as the Cox and logistic regression. In this thesis, we implemented in R
the algorithm for estimation of generalized linear models described in
[52, 117] to ﬁt the model parameters represented here by a vector λ.
The general principle of the algorithm B.1 is to follow the regulariza-
tion path. The algorithm starts with a very high regularization constant
λ such that the optimal solution is trivial (β = 0n×1). The λ constant is
then slowly decreased to allows more and more non-zeros βj (the model
parameters).
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Algorithm B.1: Iteratively reweighted least squares algorithm
Data: The normalized data matrix X ∈ Rn×p.
Result: A sparse solution βˆ = argmaxβ
1
n l(β)− λR(β).
Initialize β = 0n×1 and set η = Xβ;
Initialize λ suﬃciently high such that the trivial solution is
optimal;
while the number of non-zero βˆj < threshold do
Decrease λ;
repeat
Compute l�(η) and l��(η);
w = diag(l��(η));
z = η −w−1l�(η);
With a coordinate descent algorithm, ﬁnd βˆ minimizing:
1
n
n�
i=1
wi(zi − x�i β)2 + λR(β) (B.12)
Set β = βˆ and η = Xβˆ;
until convergence of βˆ;
end
For each λ along the regularization path, the algorithm performs an
iteratively reweighted least squares (IRLS). In these IRLS, the previ-
ous solution is used as warm start for the current λ. Exploiting these
warm start allows us to have very few iterations for each step in the
regularization path.
In the algorithm B.1, the optimization problem is thus reduced to
repeatedly solving a penalized least-square:
βˆ = argmin
β
1
n
n�
i=1
wi(zi − x�i β)2 + λR(β) (B.13)
This penalized least-square can be eﬃciently solved with a coordinate
descent, similarly as what is used in [52, 117]. This coordinate descent
algorithm was ﬁrst proposed by [139] for penalized linear regression.

Chapter C
Supplementary results with the
balanced hazard ratio
This section reports additional results and comparisons to chapter 8.
In particular we extend ﬁgure 8.7 while comparing the hazard ratio,
D-index [108], SEP [112] and the BHR [17]. We decide to represent
the BHR and SEP to the square to have the four metrics on the same
scale. With respect to the hazard ratio, the D-index slightly corrects
the performance with unbalanced risk groups. This correction is much
stronger with the BHR and SEP. These two metrics tend to zero when
all patients are in the same risk group. Figure C.2 compares the D-index
and BHR2 with their 95% conﬁdence intervals. The conﬁdence intervals
of the D-index is much wider than the BHR2 one.
To further compare the four metrics, we can repeat the experiment
presented is section 8.8. In these experiments, we generate survival data
for which an underlying threshold between risk groups is a priori ﬁxed
according to a prescribed proportion between a high or low risk proﬁle.
Figure C.3 oﬀers a closer look at the distribution over 500 runs of
the proportions between risk groups for which respectively the HR, D-
index, BHR and SEP, is maximum. The true proportion ρ in the low
risk group was here ﬁxed to 80%. The maximal BHR is clearly more
concentrated around the true underlying proportion while the maximum
HR distribution is much more dispersed and skewed towards an exces-
sively large value. The maximum D-index distribution is very similar to
what is observed with the hazard ratio. At the opposite, the maximum
SEP distribution is skewed toward a proportion of 0.5. These results
tend to show that the balanced hazard ratio is better at ﬁnding the true
proportion between risk groups.
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Figure C.1: Performance metrics on the VDX dataset while varying the
proportions in each risk group.
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Figure C.2: D-index, squared balanced hazard ratio and their conﬁdence
intervals on the VDX dataset while varying the proportions in each risk
group. The balanced hazard ratio is squared to be on the same scale as
the hazard ratio and the D-index.
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Figure C.3: Distribution over 500 runs of the low risk group proportion
for which respectively the BHR (c), HR (a), SEP (d) and D-index (b),
is maximum. The experiments are conducted with n = 200 patients,
the shape parameter k = 1 and the true group hazard ratio exp(µ) = 3.
The true underlying proportion of patients in the low risk group was set
to 80%.
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